Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010
DateTitle 
October 17, 2017BioTime, Inc. Announces Closing of Public Offering and Underwriters’ Full Exercise of Over-Allotment Option
ALAMEDA, Calif.--(BUSINESS WIRE)--Oct. 17, 2017-- BioTime, Inc. (“BioTime”) (NYSE American and TASE: BTX), a late stage clinical biotechnology company focused on developing and commercializing products addressing degenerative diseases, today announced the closing of its previously announced public offering of 9,615,385 shares of common stock, including 1,442,308 shares sold pursuant to the underwriters’ exercise in full of their option to purchase additi... 
Printer Friendly Version
October 13, 2017BioTime, Inc. Announces Pricing of $25.0 Million Public Offering of Common Stock
ALAMEDA, Calif.--(BUSINESS WIRE)--Oct. 13, 2017-- BioTime, Inc. (“BioTime”) (NYSE American and TASE: BTX), a late stage clinical biotechnology company focused on developing and commercializing products addressing degenerative diseases, today announced the pricing of an underwritten public offering of 9,615,385 shares of its common stock at a public offering price of $2.60 per share. The gross proceeds to BioTime from this offering are expected to be appr... 
Printer Friendly Version
October 12, 2017BioTime, Inc. Announces Proposed Public Offering of Common Stock
ALAMEDA, Calif.--(BUSINESS WIRE)--Oct. 12, 2017-- BioTime, Inc. (“BioTime”) (NYSE American and TASE: BTX), a late stage clinical biotechnology company focused on developing and commercializing products addressing degenerative diseases, today announced its intent to offer to sell shares of its common stock in an underwritten public offering. BioTime intends to grant the underwriters a 30-day option to purchase up to an aggregate of an additional 15% of th... 
Printer Friendly Version
October 11, 2017BioTime Announces First Patient in U.S. Clinical Trial Treated for Facial Volume Deficit
First investigator-led trial of Premvia in U.S. for cosmetic use Clinical trial being conducted by Dr. Aronowitz, a leading Beverly Hills-based Plastic Surgeon ALAMEDA, Calif.--(BUSINESS WIRE)--Oct. 11, 2017-- BioTime, Inc. (NYSE American: BTX), a late stage clinical biotechnology company focused on developing and commercializing products addressing degenerative diseases, today reported that an investigator-led clinical ... 
Printer Friendly Version
October 11, 2017BioTime and Processa Announce Their Intention to Enter into a HyStem® Sublicense for Drug Delivery
Processa is led by a management team with a proven track record in drug development and drug delivery ALAMEDA, Calif.--(BUSINESS WIRE)--Oct. 11, 2017-- BioTime, Inc. (NYSE American: BTX), a late stage clinical biotechnology company focused on developing and commercializing products addressing degenerative diseases, today reached agreement on terms to sublicense certain HyStem® rights to Processa Pharmaceuticals, Inc. (“Processa”) for... 
Printer Friendly Version
October 03, 2017BioTime to Present at the Cell and Gene Meeting on the Mesa
ALAMEDA, Calif.--(BUSINESS WIRE)--Oct. 3, 2017-- BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on developing and commercializing products addressing degenerative diseases, today announced that Jim Knight, SVP, Head of Corporate Development, will present at the Cell & Gene Therapy Meeting on the Mesa. Mr. Knight will provide an overview of the Company in his presentation on Thursday, October 5, 2017 at 4:45 pm PT/7... 
Printer Friendly Version
September 26, 2017BioTime Announces Positive Secondary and Additional Positive Long-Term Data from the Renevia® Pivotal Trial
Filing for Renevia® CE mark by the end of 2017 Positive long-term data in HIV-associated lipoatrophy reinforces Renevia’s® potential in multibillion-dollar global facial aesthetics market ALAMEDA, Calif.--(BUSINESS WIRE)--Sep. 26, 2017-- BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on developing and commercializing products addressing degenerative diseases, today annou... 
Printer Friendly Version
September 25, 2017BioTime Board of Directors Approves Distribution of AgeX Therapeutics Shares to BioTime Shareholders
ALAMEDA, Calif.--(BUSINESS WIRE)--Sep. 25, 2017-- BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on developing and commercializing products addressing degenerative diseases, announced today that its Board of Directors has approved a distribution of some or all of the shares of AgeX Therapeutics, Inc. owned by BioTime to BioTime’s shareholders. The Board also authorized management to work with investment banks and other... 
Printer Friendly Version
September 21, 2017BioTime Co-CEO Adi Mohanty to Participate in Panel Discussion at the Cell & Gene Therapy CEO Forum
ALAMEDA, Calif.--(BUSINESS WIRE)--Sep. 21, 2017-- BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on developing and commercializing products addressing degenerative diseases, today announced that Co-Chief Executive Officer Adi Mohanty will participate in a panel discussion at Cell & Gene Therapy CEO on Monday, September 25, 2017 in Boston. The panel, titled “Financing Innovation: Attracting Investment... 
Printer Friendly Version
September 21, 2017AgeX Therapeutics CEO Michael D. West to Participate in Fireside Chat with J. Craig Venter at the Cell & Gene Therapy CEO Forum
ALAMEDA, CA – September 21, 2017---AgeX Therapeutics, Inc. (AgeX), a subsidiary of BioTime, Inc. (NYSE American: BTX), announces that Chief Executive Officer Michael D. West, Ph.D., who also serves as Co-CEO of BioTime, is participating in a fireside chat at Cell & Gene Therapy CEO on Monday, September 25, 2017 in Boston.Dr. West’s fireside chat will be at 3:00pm ET/12:00pm PT with J. Craig Venter, Ph.D., Co-Founder and Executive Chairman of Human Longevity, Inc. and founder of Celera G... 
Printer Friendly Version
September 20, 2017BioTime to Present at the Ladenburg Thalmann 2017 Healthcare Conference
ALAMEDA, Calif.--(BUSINESS WIRE)--Sep. 20, 2017-- BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on developing and commercializing products addressing degenerative diseases, today announced that Adi Mohanty, Co-Chief Executive Officer, and Russell Skibsted, Chief Financial Officer, will present at the Ladenburg Thalmann 2017 Healthcare Conference in New York. Mr. Mohanty will provide an overview of the Company in his ... 
Printer Friendly Version
September 20, 2017BioTime to Present at the Cantor Fitzgerald Global Healthcare Conference
ALAMEDA, Calif.--(BUSINESS WIRE)--Sep. 20, 2017-- BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on developing and commercializing products addressing degenerative diseases, today announced that Adi Mohanty, Co-Chief Executive Officer, and Russell Skibsted, Chief Financial Officer, will present at the Cantor Fitzgerald Global Healthcare Conference in New York. Mr. Mohanty will provide an overview of the Company in his ... 
Printer Friendly Version
September 18, 2017BioTime Awarded Grant from the NIH
$1.56 Million Award Accelerates Retinal Restoration Program ALAMEDA, Calif.--(BUSINESS WIRE)--Sep. 18, 2017-- BioTime, Inc. (NYSE American:BTX), a clinical-stage biotechnology company focused on developing and commercializing products addressing degenerative diseases, today announced that it has been awarded a grant of up to $1.56 million from the Small Business Innovation Research program of the National Institutes o... 
Printer Friendly Version
September 14, 2017Two Key BioTime Patents Providing Protection to OpRegen® Remain Upheld
ALAMEDA, Calif.--(BUSINESS WIRE)--Sep. 14, 2017-- BioTime, Inc. (NYSE American: BTX), a clinical stage biotechnology company focused on developing and commercializing products addressing degenerative diseases, and its subsidiaries, today announced the successful conclusion of the challenge to two key patents before the European Patent Office Opposition division. As previously announced on March 28, 2017, the patents were upheld during the opposition proc... 
Printer Friendly Version
September 08, 2017BioTime to Present at the Rodman & Renshaw Annual Global Investment Conference
ALAMEDA, Calif.--(BUSINESS WIRE)--Sep. 8, 2017-- BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on developing and commercializing products addressing degenerative diseases, today announced that Adi Mohanty, Co-Chief Executive Officer, and Russell Skibsted, Chief Financial Officer, will present at the Rodman & Renshaw 19th Annual Global Investment Conference in New York. Mr. Mohanty will provide an overview o... 
Printer Friendly Version
September 05, 2017BioTime to Present at the LD Micro San Francisco Summit
ALAMEDA, Calif.--(BUSINESS WIRE)--Sep. 5, 2017-- BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on developing and commercializing products addressing degenerative diseases, today announced that Jim Knight, Senior Vice President, Head of Corporate Development, will present at the LD Micro San Francisco Summit at the Sir Francis Drake Hotel in San Francisco. Mr. Knight will provide an overview of the Company in his prese... 
Printer Friendly Version
August 28, 2017BioTime to Present Data at the Military Health System Research Symposium
ALAMEDA, Calif.--(BUSINESS WIRE)--Aug. 28, 2017-- BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on developing and commercializing products addressing degenerative diseases, today announced that it will be presenting one podium presentation and two abstracts at the Military Health System Research Symposium (MHSRS) August 27-30, 2017 in Washington, D.C. BioTime has recently released data from its two lead programs in me... 
Printer Friendly Version
August 17, 2017AgeX Therapeutics Closes $10 Million Capital Raise
• BioTime saving approximately $5 million annually on programs now in AgeXALAMEDA, Calif.--(BUSINESS WIRE)-- AgeX Therapeutics, Inc. (AgeX), a subsidiary of BioTime, Inc. (NYSE American: BTX), announced today that it has closed its round of equity financing, raising net proceeds of $10 million, valuing AgeX at approximately $68 million post-money. Post-closing, BioTime owns approximately 85% of the outstanding shares of AgeX. The financing, first announced on August 2, 2017, is expected to fund ... 
Printer Friendly Version
August 14, 2017BioTime Announces $2 Million Grant for Further Development of OpRegen® for Dry-AMD
ALAMEDA, Calif.--(BUSINESS WIRE)--Aug. 14, 2017-- BioTime, Inc. (NYSE MKT:BTX), a clinical-stage biotechnology company focused on developing and commercializing products addressing degenerative diseases, has been awarded a new grant for 2017 of up to 7.2 million Israeli New Shekels (approximately $2 million) from the Israel Innovation Authority (the “IIA”). The grant provides funding for the continued development of OpRegen®, and to date the IIA has prov... 
Printer Friendly Version
August 09, 2017AgeX Therapeutics CEO Michael D. West, Ph.D. to Deliver Keynote Address on Biotechnology and Aging at RAAD Festival
ALAMEDA, Calif.--(BUSINESS WIRE)--Aug. 9, 2017-- AgeX Therapeutics, Inc. (AgeX), a subsidiary of BioTime, Inc. (NYSE MKT:BTX), announced today that CEO Michael D. West, Ph.D., will deliver the keynote presentation at the RAAD Festival 2017 (RAADfest), a large annual gathering of life extension experts, August 9-13, at the Town and Country Resort & Convention Center in San Diego, California. Dr. West will deliver the presentation titled “Telome... 
Printer Friendly Version
August 02, 2017BioTime Reports Second Quarter Results and Recent Corporate Accomplishments
Conference Call and Live Webcast 4.30pm Eastern Time Today ALAMEDA, Calif.--(BUSINESS WIRE)--Aug. 2, 2017-- BioTime, Inc. (NYSE MKT: BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today reported financial results for the second quarter ended June 30, 2017. “The second quarter of 2017 was very productive for BioTime, with numerous significant clinical, financial and... 
Printer Friendly Version
August 02, 2017AgeX Therapeutics Obtains $10 Million in Capital and Commences Operations
Leverages Intellectual Property Assets from the BioTime Group of Companies Relating to Cellular Immortality and Regenerative Biology Funding to Advance the Development of Products Targeting Large Markets Associated with Age-Related Disease ALAMEDA, Calif. --(BUSINESS WIRE)--Aug. 2, 2017-- AgeX Therapeutics, Inc. (AgeX), a subsidiary of BioTime, Inc. (NYSE MKT: BTX), today reported that it has successfully raised $10 million in equity financing to fund its operations. Following... 
Printer Friendly Version
July 25, 2017BioTime Receives DSMB Approval to Start Third Patient Cohort in Clinical Trial for Dry-AMD; Commences Patient Enrollment in the US
ALAMEDA, Calif.--(BUSINESS WIRE)--Jul. 25, 2017-- BioTime, Inc. (NYSE MKT: BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced that the Data Safety Monitoring Board (DSMB) has authorized the Company to move forward with enrollment for cohort 3. The DSMB is an independent group of medical experts closely monitoring the Phase I/IIa OpRegen® clinical trial. In cohort 3 BioTim... 
Printer Friendly Version
July 20, 2017BioTime, Inc. to Announce Second Quarter 2017 Results on August 2, 2017
Conference Call and Webcast on Wednesday, August 2, 2017, at 4:30 p.m. ET / 1:30 p.m. PT ALAMEDA, Calif.--(BUSINESS WIRE)--Jul. 20, 2017-- BioTime, Inc. (NYSE MKT: BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced that it will release second quarter financial and operating results on Wednesday, August 2, 2017, after the close of the U.S. financial markets. The... 
Printer Friendly Version
July 19, 2017Data From BioTime’s Phase I/IIa OpRegen® Trial to be Presented at the 2017 American Academy of Ophthalmology (AAO) Annual Meeting
ALAMEDA, Calif.--(BUSINESS WIRE)--Jul. 19, 2017-- BioTime, Inc. (NYSE MKT: BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced that an abstract related to the Company’s retinal tissue implant has been accepted for a paper presentation at the American Academy of Ophthalmology (AAO) annual meeting being held in New Orleans, Louisiana, November 11-14. The abstr... 
Printer Friendly Version
July 18, 2017BioTime to Host Key Opinion Leader Event on the Topic of Dry AMD in New York City
Live Webcast at 12 noon EDT on Tuesday, July 25 ALAMEDA, Calif.--(BUSINESS WIRE)--Jul. 18, 2017-- BioTime, Inc. (NYSE MKT: BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, announced today that it will host a Key Opinion Leader event on the topic of dry age-related macular degeneration (AMD) in New York City on Tuesday, July 25. The meeting will feature a presentation by key ... 
Printer Friendly Version
July 13, 2017BioTime Subsidiary AgeX Therapeutics Appoints Aubrey de Grey, Ph.D. as VP of New Technology Discovery
World-Renowned Aging Researcher and Biomedical Gerontologist to Lead AgeX’s Research ALAMEDA, Calif. & MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Jul. 13, 2017-- AgeX Therapeutics (“AgeX”), a subsidiary of BioTime, Inc. (NYSE MKT:BTX) with a focus on developing new therapies in the field of biomedical gerontology, today announced the appointment of distinguished researcher and advocate Aubrey de Grey, Ph.D. as Vice-President of New Technology ... 
Printer Friendly Version
June 19, 2017Hadasit Bio-Holdings (HBL) and BioTime Complete Shares Swap Transaction in Cellcure Neurosciences
As part of the transaction, HBL, which owns 21% of Cellcure's share capital, will sell its entire holdings to BioTime, Inc., In exchange, BioTime will pay $12.75 million in Biotime shares to HBL JERUSALEM, June 19, 2017 /PRNewswire/ -- Hadasit Bio-Holdings Ltd. ("HBL") (TASE: HDST) announced that it has completed a share swap transaction with BioTime, Inc., ("BioTime") (TASE: BTX.TA) in their joint portfolio company Cell Cure Neurosciences ("Cell Cure"). The transaction is the first exi... 
Printer Friendly Version
June 19, 2017BioTime Expands & Advances Ophthalmology Portfolio
Expanded Exclusive, Global License to RPE and Photoreceptor Cells for Use in All Eye Disorders Data Presented at International Society for Stem Cell Research (ISSCR) Conference Translational Vision Sciences & Technology (TVST) Journal Publishes OpRegen® Data ALAMEDA, Calif.--(BUSINESS WIRE)--Jun. 19, 2017-- BioTime, Inc. (NYSE MKT: BTX), a clinical-stage biotechnology company developing ... 
Printer Friendly Version
June 14, 2017BioTime’s Renevia® Achieves Primary Endpoint in European Pivotal Trial
• Data Reinforce Renevia’s Potential in Multi-Billion Dollar Facial Aesthetics Market • BioTime on Track to File for Renevia CE Mark by End of 2017 • Conference Call Today with Lead Investigator at 4:30 p.m. ET ALAMEDA, Calif.--(BUSINESS WIRE)--Jun. 14, 2017-- BioTime, Inc. (NYSE MKT:BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today reported that... 
Printer Friendly Version
June 08, 2017BioTime to Announce Top Line Data From the Company’s Renevia European Pivotal trial
Schedules Conference Call for 4:30pm ET on June 14, 2017 ALAMEDA, Calif.--(BUSINESS WIRE)--Jun. 8, 2017-- BioTime, Inc. (NYSE MKT: BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced that it will report the top line data from the Company’s Renevia European pivotal trial, before the US market open on Wednesday, June 14, 2017. The Company will host a conference call and ... 
Printer Friendly Version
May 23, 2017BioTime Co-CEO Dr. Michael West to Deliver Presentation as Part of Biotech Panel at Mauldin Economics’ Strategic Investment Conference on May 24
ALAMEDA, Calif.--(BUSINESS WIRE)--May 23, 2017-- BioTime, Inc. (NYSE MKT: BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced that Co-Chief Executive Officer Michael D. West, Ph.D., is delivering a presentation as part of a panel on biotechnology at the Mauldin Economics’ Strategic Investment Conference on Wednesday, May 24 at 3:20pm EDT at the Omni Orlando Resort i... 
Printer Friendly Version
May 23, 2017BioTime to Present at 16th National Life Sciences and Biotechnology Week (MIXiii BIOMED)
ALAMEDA, Calif.--(BUSINESS WIRE)--May 23, 2017-- BioTime, Inc. (NYSE MKT: BTX and TASE: BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced that BioTime, and its subsidiary Cell Cure Neurosciences Ltd., will be featured in two presentations at the 16th National Life Sciences and Biotechnology Week (MIXiii BIOMED) on Wednesday, May 24, 2017 as part of the Regenerative ... 
Printer Friendly Version
May 11, 2017BioTime Presents Retinal Restoration Data at ARVO
Demonstrates Ability to Grow Full-Thickness, 3-D Retinal Tissue Tissue is Highly Similar to Natural Human Tissue ALAMEDA, Calif.--(BUSINESS WIRE)--May 11, 2017-- BioTime, Inc. (NYSE MKT: BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced that a poster related to the Company’s retinal restoration technology was presented at the Annual Meeting of the Asso... 
Printer Friendly Version
May 10, 2017BioTime, Inc. Reports First Quarter Results and Recent Corporate Accomplishments
Conference Call and Webcast Today at 4:30 p.m. Eastern Time ALAMEDA, Calif--(BUSINESS WIRE)--May 10, 2017-- BioTime, Inc. (NYSE MKT and TASE: BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today reported financial results for the first quarter ended March 31, 2017. “At BioTime we are continuing to make meaningful clinical progress with our core development programs... 
Printer Friendly Version
May 09, 2017BioTime Announces New Positive Data from OpRegen® Trial in Dry-AMD
Imaging Analysis Suggests Cell Engraftment and Likely Biological Response ALAMEDA, Calif.--(BUSINESS WIRE)--May 9, 2017-- BioTime, Inc. (NYSE MKT:BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced new data from the Phase I/IIa clinical trial of OpRegen® in the advanced form of dry age-related macular degeneration (dry-AMD). The interim data were presented on May ... 
Printer Friendly Version
May 08, 2017BioTime Co-CEO Dr. Michael D. West to Present at World Advanced Therapies & Regenerative Medicine Congress on May 17 and 19
Dr. West to Deliver Presentation on Applying AI to Stem Cell Biology and Participate in Roundtable Discussion ALAMEDA, Calif.--(BUSINESS WIRE)--May 8, 2017-- BioTime, Inc. (NYSE MKT: BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced that Co-Chief Executive Officer Michael D. West, Ph.D. will present at Terrapinn’s World Advanced Therapies & Regenerative Me... 
Printer Friendly Version
April 26, 2017BioTime, Inc. to Announce First Quarter 2017 Results on May 10, 2017
Conference Call and Webcast on Wednesday, May 10, 2017, at 4:30 p.m. ET / 1:30 p.m. PT ALAMEDA, Calif.--(BUSINESS WIRE)--Apr. 26, 2017-- BioTime, Inc. (NYSE MKT:BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced that it will release first quarter financial and operating results on Wednesday, May 10, 2017, after the close of the U.S. financial markets. The Compa... 
Printer Friendly Version
April 24, 2017BioTime to Present Additional Data at Upcoming ARVO
Retinal tissue regeneration presentation added OpRegen® presentation scheduled for May 8 ALAMEDA, Calif.--(BUSINESS WIRE)--Apr. 24, 2017-- BioTime, Inc. (NYSE MKT:BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced that an abstract related to the Company’s retinal tissue implant has been accepted for a paper presentation at the Annual Meeting of ... 
Printer Friendly Version
April 06, 2017BioTime Forms New Subsidiary AgeX Therapeutics, Inc. to Develop its Programs Focused on Human Aging
Objective is to quickly establish leadership in the emerging biotechnology field of Aging through pluripotency and iTR™ assets BioTime continues execution of corporate simplification strategy while remaining focused on Ophthalmology, Aesthetics and Therapeutics Delivery ALAMEDA, Calif.--(BUSINESS WIRE)--Apr. 6, 2017-- BioTime, Inc. (NYSE MKT:BTX), a clinical-stage biotechnology company developing and commercializing products addressing... 
Printer Friendly Version
April 04, 2017BioTime Co-CEO Dr. Michael West to Deliver Keynote Presentation at GTC Bio Stem Cell Summit on April 6
Will Present on the Promise of Pluripotent Cells in Advanced Therapeutics and the Company’s Plans to Develop Applications in Human Aging ALAMEDA, Calif.--(BUSINESS WIRE)--Apr. 4, 2017-- BioTime, Inc. (NYSE MKT:BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced that Co-Chief Executive Officer Michael D. West, Ph.D., is delivering a keynote presentation at the GT... 
Printer Friendly Version
March 28, 2017Key BioTime Patents Upheld by European Patent Office
EPO Rules Patents for OpRegen® are Valid and Remain in Force as Granted OpRegen® is in Development to Treat Dry-AMD ALAMEDA, Calif.--(BUSINESS WIRE)--Mar. 28, 2017-- BioTime, Inc. (NYSE MKT:BTX), a clinical stage biotechnology company developing and commercializing products addressing degenerative disease, today announced the successful defense of two key patents from challenge before the European Patent Office (EPO) Opposition divisio... 
Printer Friendly Version
March 20, 2017BioTime to Present at Oppenheimer 27th Annual Healthcare Conference
ALAMEDA, Calif.--(BUSINESS WIRE)--Mar. 20, 2017-- BioTime, Inc. (NYSE MKT: BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced that Russell Skibsted, Chief Financial Officer, will be presenting at the Oppenheimer 27th Annual Healthcare Conference at the Westin Grand Central in New York City on March 21, at 3:55 p.m. Eastern Time. A webcast of Mr. Skibsted’s ... 
Printer Friendly Version
March 16, 2017BioTime, Inc. Reports Fourth Quarter and Fiscal Year 2016 Financial Results and Recent Corporate Accomplishments
Conference Call and Webcast Today at 4:30 p.m. Eastern Time ALAMEDA, Calif.--(BUSINESS WIRE)--Mar. 16, 2017-- BioTime, Inc. (NYSE MKT and TASE: BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today reported financial results for the fourth quarter and year ended December 31, 2016. “I’m happy with the tremendous progress we made last year in all three of our strategi... 
Printer Friendly Version
March 15, 2017Data From BioTime’s OpRegen® Trial in Dry-AMD to be Presented at ARVO on May 8
ALAMEDA, Calif.--(BUSINESS WIRE)--Mar. 15, 2017-- BioTime, Inc. (NYSE MKT:BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced that a poster presentation based on data from its Phase I/IIa clinical trial of OpRegen® in the advanced form of dry age-related macular degeneration (dry-AMD) will be presented at the Annual Meeting of the Association for Research in Vision ... 
Printer Friendly Version
March 13, 2017BioTime Expands OpRegen® Clinical Trial in Dry-AMD With Opening of First US Sites
ALAMEDA, Calif.--(BUSINESS WIRE)--Mar. 13, 2017-- BioTime, Inc. (NYSE MKT:BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced the expansion of its ongoing Phase I/IIa clinical trial for OpRegen® in the advanced dry form age-related macular degeneration (dry-AMD) by naming the first two sites that will treat patients in the U.S. “The addition of U.S. clinical... 
Printer Friendly Version
February 23, 2017BioTime, Inc. to Announce Fourth Quarter and Fiscal 2016 Results on March 16, 2017
ALAMEDA, Calif.--(BUSINESS WIRE)--Feb. 23, 2017-- BioTime, Inc. (NYSE MKT:BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced that it will release fourth quarter and fiscal 2016 financial and operating results on Thursday, March 16, 2017, after the close of the U.S. financial markets. The Company will host a conference call and webcast on Thursday, March 16, 2017, at 4:30 ... 
Printer Friendly Version
February 21, 2017BioTime Reports Pro Forma Gain on Deconsolidation of OncoCyte Subsidiary
ALAMEDA, Calif.--(BUSINESS WIRE)--Feb. 21, 2017-- BioTime, Inc. (NYSE MKT:BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced the deconsolidation of OncoCyte Inc.’s financial statements from BioTime’s consolidated financial statements effective February 17, 2017. As a result of the deconsolidation, BioTime will report a pro forma, non-cash gain of approximately $56 million... 
Printer Friendly Version
February 15, 2017BioTime, Inc. Announces Closing of Public Offering of Common Stock
ALAMEDA, Calif. & JERUSALEM--(BUSINESS WIRE)--Feb. 15, 2017-- BioTime, Inc. (NYSE MKT and TASE:BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced the closing of its previously announced underwritten public offering. BioTime, Inc. sold 7,453,704, shares of its common stock in the offering, which includes 972,222 shares of its common stock issued in connection with the ... 
Printer Friendly Version
February 15, 2017CORRECTING and REPLACING BioTime Expands Ophthalmology Portfolio With Global In-Licensing Agreement for Next-Generation Retinal Disease Therapy From University of Pittsburgh
Advanced retinal regeneration program could lead to fully functional retinal tissue implants to restore vision in late stages of blindness ALAMEDA, Calif.--(BUSINESS WIRE)--Feb. 15, 2017-- Please replace the release dated February 6, 2017, with the following corrected version due to multiple revisions. The corrected release reads: BIOTIME EXPANDS OPHTHALMOLOGY PORTFOLIO WITH GLOBAL IN-LICENSING AGREEMENT FOR NEXT-GENERATION RET... 
Printer Friendly Version
February 13, 2017BioTime to Present at Two Upcoming Investor Conferences
ALAMEDA, Calif.--(BUSINESS WIRE)--Feb. 13, 2017-- BioTime, Inc. (NYSE MKT: BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced that Russell Skibsted, Chief Financial Officer, will be presenting at the BIO CEO & Investor Conference at the Waldorf-Astoria Hotel in New York City on Tuesday, February 14, at 2:30 p.m. Eastern Time, and at the Disruptive Growth Confer... 
Printer Friendly Version
February 10, 2017BioTime, Inc. Announces Pricing of Public Offering of Common Stock
ALAMEDA, Calif. & JERUSALEM--(BUSINESS WIRE)--Feb. 10, 2017-- BioTime, Inc. (NYSE MKT and TASE: BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced the pricing of an underwritten public offering of 6,481,482 shares of its common stock at a public offering price of $2.70 per share. The gross proceeds to BioTime, Inc. from this offering are expected to be approximately $... 
Printer Friendly Version
February 09, 2017BioTime, Inc. Announces Proposed Public Offering of Common Stock
ALAMEDA, Calif. & JERUSALEM--(BUSINESS WIRE)--Feb. 9, 2017-- BioTime, Inc. (NYSE MKT and TASE: BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced its intent to offer to sell shares of its common stock in an underwritten public offering. BioTime, Inc. also expects to grant to the underwriters for the offering a 30-day option to purchase up to an additional 15% of the n... 
Printer Friendly Version
February 07, 2017BioTime Appoints Industry Veteran, Stephana Patton, Ph.D., J.D., as General Counsel
Draws on a Deep Background at Leading Life Sciences Companies ALAMEDA, Calif.--(BUSINESS WIRE)--Feb. 7, 2017-- BioTime, Inc. (NYSE MKT:BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced the appointment of Stephana Patton, Ph.D., J.D., as General Counsel, a newly created position. Reporting in her new role to Adi Mohanty, Co-CEO, Dr. Patton will oversee ... 
Printer Friendly Version
February 06, 2017BioTime Expands Ophthalmology Portfolio With Global In-Licensing Agreement for Next-Generation Retinal Disease Therapy From University of Pittsburgh Medical Center
Advanced retinal regeneration program could lead to fully functional retinal tissue implants to restore vision in late stages of blindness ALAMEDA, Calif.--(BUSINESS WIRE)--Feb. 6, 2017-- BioTime, Inc. (NYSE MKT:BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced the acquisition of global rights to ophthalmology-related intellectual property (IP) assets from the Univer... 
Printer Friendly Version
January 26, 2017BioTime to Present at Noble Capital Markets’ Thirteenth Annual Investor Conference
ALAMEDA, Calif.--(BUSINESS WIRE)--Jan. 26, 2017-- BioTime, Inc. (NYSE MKT: BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced that management will present a corporate overview at the NobleCon13 - Noble Capital Markets’ Thirteenth Annual Investor Conference at the Boca Raton Resort & Club in Boca Raton, Florida, on Monday, January 30, at 11:00 a.m. Eastern Standard Tim... 
Printer Friendly Version
January 19, 2017Additional Data From BioTime’s OpRegen® Clinical Trial in Dry-AMD to be Presented at ARVO 2017
-Data from patients in Cohort 1 and Cohort 2 to be presented- ALAMEDA, Calif.--(BUSINESS WIRE)--Jan. 19, 2017-- BioTime, Inc. (NYSE MKT:BTX), a clinical stage biotechnology company with a focus on pluripotent stem cell technologies, and its subsidiary, Cell Cure Neurosciences, Ltd., today announced that an abstract evaluating OpRegen® in patients with advanced dry Age-Related Macular Degeneration (dry-AMD) based on the ongoing Phase I/IIa clinical tr... 
Printer Friendly Version
January 03, 2017BioTime and Subsidiary Cell Cure Neurosciences Establish Innovative Cell Therapy Manufacturing Center in Jerusalem, Israel
-Supplying OpRegen® for the Ongoing Clinical Trial for the Treatment of Dry Age-Related Macular Degeneration- -Center has Capability to Manufacture Additional BioTime Products- ALAMEDA, Calif. & JERUSALEM--(BUSINESS WIRE)--Jan. 3, 2017-- BioTime, Inc. (NYSE MKT: BTX and TASE: BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, and its majority-owned subsidiary, Cel... 
Printer Friendly Version
December 14, 2016BioTime Achieves Patient Recruitment Milestone in Renevia Pivotal Trial
Crosses Milestone of 50 Patients Randomized in Pivotal Trial Remains on Track for Top-Line Data by Middle of 2017 ALAMEDA, Calif.--(BUSINESS WIRE)--Dec. 14, 2016-- BioTime, Inc. (NYSE MKT:BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, announced that it has achieved an important patient enrollment milestone in its Renevia® pivotal trial in Europe. The company now ha... 
Printer Friendly Version
December 12, 2016BioTime to Present at Global Bioproduction Summit
Co-CEO Dr. Michael West to Discuss Human Cell Manufacturing for Regenerative Medicine ALAMEDA, Calif.--(BUSINESS WIRE)--Dec. 12, 2016-- BioTime, Inc. (NYSE MKT: BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced that Co-Chief Executive Officer Michael D. West, Ph.D., is delivering a presentation at the Global Bioproduction Summit, December 12-13, at the Hilton ... 
Printer Friendly Version
December 08, 2016BioTime Co-CEO Dr. Michael D. West to Deliver Plenary Presentation on the Field of Induced Tissue Regeneration at World Stem Cell Summit
Presentation Will Describe the Future of Aging Research and iTRTM, an Emerging Area of Research from BioTime Dr. West to also Serve on Panel: “Unleashing Regenerative Medicine to Extend the Healthy Lifespan” ALAMEDA, Calif.--(BUSINESS WIRE)--Dec. 8, 2016-- BioTime, Inc. (NYSE MKT: BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced that Co-Chief Executiv... 
Printer Friendly Version
November 18, 2016Positive Early Data From BioTime’s Renevia Pivotal Trial Presented at IFATS Meeting
-3D-imaging Suggests Grafts Retained Volume Over the Assessment Period- -Cells Remained Viable and Proliferated in Renevia Hydrogel- ALAMEDA, Calif.--(BUSINESS WIRE)--Nov. 18, 2016-- BioTime, Inc. (NYSE MKT: BTX), a clinical-stage biotechnology company with a focus on pluripotent cell-based technologies, announced details of positive data from its Renevia® pivotal trial, reported via a presentation at the 14th annual International Fede... 
Printer Friendly Version
November 10, 2016BioTime Co-CEO Dr. Michael D. West to Chair Cell Therapy Track at World Precision Medicine Congress USA 2016
-Will Also Present at Young Jewish Professionals Life Sciences & Pharmaceuticals CEO Symposium- ALAMEDA, Calif.--(BUSINESS WIRE)--Nov. 10, 2016-- BioTime, Inc. (NYSE MKT:BTX), a clinical-stage biotechnology company with a focus on pluripotent stem cell technologies, today announced that Co-Chief Executive Officer Michael D. West, Ph.D., is participating at two conferences during the week of November 14. On Monday, November 14, Dr. ... 
Printer Friendly Version
November 03, 2016BioTime, Inc. Reports Third Quarter Results and Recent Clinical Progress
Initial data from OpRegen® trial suggest cells able to engraft and survive at least 12 months Initial 3-D Imaging data from Renevia® trial run-in patients suggest volumetric improvements are sustained at least 12 months ALAMEDA, Calif.--(BUSINESS WIRE)--Nov. 3, 2016-- BioTime, Inc. (NYSE MKT and TASE: BTX), a clinical stage biotechnology company with a focus on pluripotent cell-based technologies, today re... 
Printer Friendly Version
November 01, 2016Data From BioTime’s Renevia Pivotal Trial in HIV-Associated Facial Liopatrophy to be Presented at the 14th Annual IFATS Meeting on November 17
ALAMEDA, Calif.--(BUSINESS WIRE)--Nov. 1, 2016-- BioTime, Inc. (NYSE MKT:BTX), a clinical stage biotechnology company with a focus on pluripotent stem cell technologies, today announced that an abstract evaluating Renevia® in ‘run-in’ patients with HIV-associated facial lipoatrophy from the Renevia-02 trial will be presented at the 14th annual International Federation for Adipose Therapeutics and Science meeting (IFATS) taking place from November ... 
Printer Friendly Version
October 31, 2016BioTime Appoints Industry Veteran Jim Knight as Senior Vice President, Head of Corporate Development
Brings Wealth of Value Creation Experience to BioTime ALAMEDA, Calif.--(BUSINESS WIRE)--Oct. 31, 2016-- BioTime, Inc. (NYSE MKT:BTX), a clinical-stage biotechnology company with a focus on pluripotent stem cell technologies, today announced that the company has appointed Jim Knight as Senior Vice President, Head of Corporate Development. He reports to Adi Mohanty, Co-Chief Executive Officer. In his new role, Mr. Knight will oversee bus... 
Printer Friendly Version
October 24, 2016BioTime, Inc. to Announce Third Quarter Results on November 3, 2016
ALAMEDA, Calif.--(BUSINESS WIRE)--Oct. 24, 2016-- BioTime, Inc. (NYSE MKT:BTX), a clinical-stage biotechnology company with a focus on pluripotent stem cell technologies, today announced that it will release third quarter financial and operating results on Thursday, November 3, 2016, after the close of the U.S. financial markets. The Company will host a conference call and webcast on Thursday, November 3, 2016, at 4:30 p.m. Eastern Time / 1:30 p.m. ... 
Printer Friendly Version
October 20, 2016First Patient Cohort Data From BioTime’s OpRegen® Clinical Trial in Dry-AMD to Be Presented at ISOPT Clinical Symposium on December 2, 2016
- OpRegen at the first dose caused no serious adverse events in the first patient cohort - - Retinal imaging suggests presence and survival of the transplanted cells in the subretinal space for up to one year - ALAMEDA, Calif.--(BUSINESS WIRE)--Oct. 20, 2016-- BioTime, Inc. (NYSE MKT and TASE: BTX), a clinical stage biotechnology company with a focus on pluripotent stem cell technologies, today reported that data from the first patient... 
Printer Friendly Version
October 13, 2016BioTime to Present at the BIO Investor Forum
ALAMEDA, Calif.--(BUSINESS WIRE)--Oct. 13, 2016-- BioTime, Inc. (NYSE MKT: BTX), a clinical stage biotechnology company with a focus on pluripotent stem cell technology, today announced that Adi Mohanty, Co-Chief Executive Officer, will be presenting at the BIO Investor Forum on Wednesday, October 19, 2016, at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time. The BIO Investor Forum is being held at the Westin St. Francis Hotel in San Francisco. ... 
Printer Friendly Version
September 23, 2016BioTime to Webcast Presentation at the Ladenburg Thalmann 2016 Healthcare Conference
ALAMEDA, Calif.--(BUSINESS WIRE)--Sep. 23, 2016-- BioTime, Inc. (NYSE MKT:BTX), a clinical stage regenerative medicine company with a focus on pluripotent stem cell technology, today announced that it will be presenting at the Ladenburg Thalmann 2016 Healthcare Conference in New York City on Tuesday, September 27, 2016, at 1:00 p.m. Eastern Time / 10:00 a.m. Pacific Time. The Ladenburg Thalmann Healthcare Conference is a well-respected event ... 
Printer Friendly Version
September 06, 2016BioTime to Present at Two Upcoming Investor Conferences
ALAMEDA, Calif.--(BUSINESS WIRE)--Sep. 6, 2016-- BioTime, Inc. (NYSE MKT: BTX), a clinical stage biotechnology company with a focus on pluripotent stem cell technology, today announced that it will be presenting at the following investor conferences: 2016 Gateway Conference at the Four Seasons Hotel, San Francisco, Wednesday, September 7, 2016, at 11:00am ET (8:00am PT) 18th Annual Rodman & Renshaw Globa... 
Printer Friendly Version
August 15, 2016BioTime Announces Issuance of 31 New Patents to Strengthen its Patent Portfolio in Regenerative Medicine
New Patents Supplement Existing Portfolio of More Than 700 Patents and Patent Applications Owned or Licensed by BioTime Family of Companies Worldwide ALAMEDA, Calif.--(BUSINESS WIRE)--Aug. 15, 2016-- BioTime, Inc. (NYSE MKT:BTX) today announced the issuance of 31 new patents between July 3, 2015 and August 3, 2016 that are owned by or licensed to BioTime, or its family of companies. The new patents add to the over 700 issued and pending patent... 
Printer Friendly Version
August 09, 2016BioTime, Inc. Reports Second Quarter Results and Recent Corporate Accomplishments
Therapeutic Candidates Continue Clinical Progress Deconsolidation Simplifies Financials Successful Public Equity Offering Strengthens Balance Sheet ALAMEDA, Calif.--(BUSINESS WIRE)--Aug. 9, 2016-- BioTime, Inc. (NYSE MKT:BTX), a clinical-stage regenerative medicine company with a focus on pluripotent stem cell technology, today reported financial results for the second quarter ended June 30, 2016 and ... 
Printer Friendly Version
July 27, 2016BioTime, Inc. to Report Second Quarter Results on August 9, 2016
ALAMEDA, Calif.--(BUSINESS WIRE)--Jul. 27, 2016-- BioTime, Inc. (NYSE MKT: BTX), a clinical-stage regenerative medicine company with a focus on pluripotent stem cell technology, today announced that it will release second quarter financial and operating results on Tuesday, August 9, 2016 after the close of the U.S. financial markets. The Company will host a conference call and webcast on Tuesday, August 9, 2016 at 4:30 p.m. Eastern / 1:30 p.m. Pacific to... 
Printer Friendly Version
July 13, 2016Landmark Stem Cell Clinical Trial Procedure Performed at Santa Clara Valley Medical Center
– July 13, 2016 /Press Release/ –Santa Clara County, CA. Last week, physicians at Santa Clara Valley Medical Center (SCVMC), in partnership with Stanford Medicine, successfully completed a surgery injecting stem cells into the spinal cord of a patient who had recently suffered a severe spinal cord injury. The patient became one of a handful of people in the world who have undergone this procedure as part of this clinical trial.Stem cells have the potential to regenerate new tissues and... 
Printer Friendly Version
July 05, 2016BioTime, Inc. Announces Full Exercise and Closing of Underwriters’ Over-Allotment Option
ALAMEDA, Calif.--(BUSINESS WIRE)--Jul. 5, 2016-- BioTime, Inc. (NYSE MKT: BTX), a clinical-stage biotechnology company focused on developing and commercializing novel therapies in the field of regenerative medicine, today announced that the underwriters of BioTime, Inc.’s previously announced public offering that initially closed on June 21, 2016, have purchased an additional 1,098,326 shares of BioTime, Inc.’s common stock at a price of $2.39 per share,... 
Printer Friendly Version
June 29, 2016BioTime Presents Online Resource for Applying Artificial Intelligence to Stem Cell Biology at Mensa 2016 Annual Gathering
- Deep Learning Algorithms have the potential to unlock mechanisms of tissue regeneration for applications in age-related disease - ALAMEDA, Calif.--(BUSINESS WIRE)--Jun. 29, 2016-- BioTime, Inc. (NYSE MKT: BTX), a clinical-stage regenerative medicine company with a focus on pluripotent stem cell technology, today announced that Co-CEO Dr. Michael D. West, will give a lecture at the Mensa Annual Gathering today titled, "Hayflick Rewound: Implications of Reversing the Aging of Human Cells." Dr.... 
Printer Friendly Version
June 21, 2016BioTime, Inc. Announces Closing of Public Offering of Common Stock
ALAMEDA, Calif.--(BUSINESS WIRE)--Jun. 21, 2016-- BioTime, Inc. (NYSE MKT:BTX), a clinical-stage biotechnology company focused on developing and commercializing novel therapies in the field of regenerative medicine, today announced the closing of its previously announced underwritten public offering. BioTime, Inc. sold 7,322,176 shares of its common stock in the offering. The offering price was $2.39 per share and gross proceeds to BioTime, Inc. are appr... 
Printer Friendly Version
June 16, 2016BioTime, Inc. Announces Pricing of Public Offering of Common Stock
ALAMEDA, Calif.--(BUSINESS WIRE)--Jun. 16, 2016-- BioTime, Inc. (NYSE MKT: BTX), a clinical-stage biotechnology company focused on developing and commercializing novel therapies in the field of regenerative medicine, today announced the pricing of an underwritten public offering of 7,322,176 shares of its common stock at a public offering price of $2.39 per share. The gross proceeds to BioTime, Inc. from this offering are expected to be approximately $17... 
Printer Friendly Version
June 15, 2016BioTime, Inc. Announces Proposed Public Offering of Common Stock
ALAMEDA, Calif.--(BUSINESS WIRE)--Jun. 15, 2016-- BioTime, Inc. (NYSE MKT:BTX), a clinical-stage biotechnology company focused on developing and commercializing novel therapies in the field of regenerative medicine, today announced its intent to offer to sell shares of its common stock in an underwritten public offering. The offering is subject to market, regulatory and other conditions and there can be no assurance as to whether or when the offering may... 
Printer Friendly Version
June 13, 2016BioTime’s Subsidiary Cell Cure Neurosciences Receives DSMB Approval to Start Second Patient Cohort in Clinical Trial for Dry-AMD
- Safety Confirmed with No Concerns Reported in Cohort 1 - - Approval to Immediately Proceed to Cohort 2 - ALAMEDA, Calif. & JERUSALEM--(BUSINESS WIRE)--Jun. 13, 2016-- BioTime, Inc. (NYSE MKT and TASE: BTX) and Cell Cure Neurosciences Ltd. (Cell Cure), a clinical-stage regenerative medicine company with a focus on pluripotent stem cell technology, today announced that the Data Safety Monitoring Board (DSMB), an independent group of medic... 
Printer Friendly Version
June 10, 2016BioTime Announces $2.2 Million Grant for Further Development of Dry-AMD Program
- Israel Innovation Authority awards a grant to Cell Cure Neurosciences, a BioTime Subsidiary, that will support ongoing development of OpRegen®, to address a leading cause of blindness, dry-AMD - This is the 10th year in receipt of an Israeli Government grant in support of Cell Cure ALAMEDA, Calif. & JERUSALEM--(BUSINESS WIRE)--Jun. 10, 2016-- BioTime, Inc. (NYSE MKT and TASE: BTX), a clinical-stage regenerative medicine co... 
Printer Friendly Version
June 09, 2016BioTime to Present at the Jefferies 2016 Global Healthcare Conference
ALAMEDA, Calif.--(BUSINESS WIRE)--Jun. 9, 2016-- BioTime, Inc. (NYSE MKT: BTX), a clinical-stage regenerative medicine company with a focus on pluripotent stem cell technology, today announced that the company will present at the Jefferies 2016 Global Healthcare Conference to be held in New York on June 7-10, 2016. Russell Skibsted, BioTime’s Chief Financial Officer, will provide an overview and an update on product development at 1:30 PM EDT on Friday, ... 
Printer Friendly Version
May 20, 2016BioTime to Present at Two Upcoming Investor Conferences
ALAMEDA, Calif.--(BUSINESS WIRE)--May 20, 2016-- BioTime, Inc. (NYSE MKT and TASE: BTX) announced that Co-Chief Executive Officer Michael D. West, Ph.D., will present at the 2016 Oppenheimer 17th Annual Israel Conference to be held at the David Intercontinental Hotel in Tel-Aviv on Sunday, May 22, 2016. Dr. West will also present at the Mauldin Economics 2016 Strategic Investment Conference, in Dallas, Texas on May 25, 2016. The conference ... 
Printer Friendly Version
May 10, 2016BioTime, Inc. Reports First Quarter Results and Recent Corporate Accomplishments
- First Cohort in OpRegen® Trial Completed - Management to Host Investor Conference Call on May 17, 2016 at 4:30 p.m. ET ALAMEDA, Calif.--(BUSINESS WIRE)--May 10, 2016-- BioTime, Inc. (NYSE MKT and TASE: BTX), a clinical-stage regenerative medicine company with a focus on pluripotent stem cell technology, today reported financial results for the first quarter ended March 31, 2016 and provided a corporate update. The Company also announ... 
Printer Friendly Version
April 26, 2016BioTime Co-CEO Dr. Michael West Presents at Biomedical Innovation for Healthy Longevity, International Conference
Presentation topics include: • BioTime’s Products in Development Addressing the Large and Growing Markets in Age-Related Degenerative Disease; and • New Insights into the Fundamental Biology of Human Aging ALAMEDA, Calif.--(BUSINESS WIRE)--Apr. 26, 2016-- BioTime, Inc. (NYSE MKT:BTX) announced that Co-Chief Executive Officer Michael D. West, Ph.D. delivered a presentation today at “Biomedical Innovation for Healthy Long... 
Printer Friendly Version
March 21, 2016BioTime, Inc. to Host Conference Call to Update Investors on Recent Accomplishments and Corporate Objectives for 2016
ALAMEDA, Calif.--(BUSINESS WIRE)--Mar. 21, 2016-- BioTime, Inc. (NYSE MKT:BTX) today announced that it will host a conference call on Thursday, March 31, to update investors on the Company’s recent accomplishments and objectives for the remainder of 2016. Among the highlights of the call will be an update on the clinical trials currently underway for Renevia® for lipoatrophy, and OpRegen® for dry age-related macular degeneration. In addition, management ... 
Printer Friendly Version
February 24, 2016BioTime Subsidiary Asterias Biotherapeutics Reports the Successful End-of-Phase II FDA Meeting for Immunotherapy in Acute Myeloid Leukemia
-- Provides Direction for Late-Stage Development of AST-VAC1 in Acute Myeloid Leukemia -- ALAMEDA, Calif.--(BUSINESS WIRE)--Feb. 24, 2016-- BioTime, Inc. (NYSE MKT:BTX), a clinical-stage regenerative medicine company with a focus on pluripotent stem cell technology, today announced that its subsidiary, Asterias Biotherapeutics (“Asterias”), has successfully completed an End-of-Phase II meeting with the U.S. Food and Drug Administration (FDA) f... 
Printer Friendly Version
February 16, 2016BioTime and Asterias Sign Share Transfer Agreement and Cross-License Agreement for Pluripotent Stem Cell Related Patents
FREMONT, Calif. & ALAMEDA, Calif.--(BUSINESS WIRE)--Feb. 16, 2016-- Asterias Biotherapeutics, Inc. (NYSE MKT:AST) and BioTime, Inc. (NYSE MKT and TASE:BTX), both clinical-stage regenerative medicine companies with a focus on pluripotent stem cell technology, and BioTime’s wholly owned subsidiary ES Cell International Pte Ltd (“ESI”), have entered into a Share Transfer Agreement through which BioTime will re-acquire from Asterias shares of capital sto... 
Printer Friendly Version
February 01, 2016BioTime, Inc. to Present at Three Investor Conferences in February
ALAMEDA, Calif.--(BUSINESS WIRE)--Feb. 1, 2016-- BioTime, Inc. (NYSE MKT: BTX), a clinical-stage regenerative medicine company with a focus on pluripotent stem cell technology, announced today that it will present at the following three investor conferences in February: 18th Annual BIO CEO & Investor Conference in New York City on Tuesday, February 9 at 2:00 p.m. ET Source Capital Group’s 2016 Disruptive G... 
Printer Friendly Version
January 12, 2016Adjustments Affecting BioTime, Inc. Common Share Purchase Warrants Expiring October 1, 2018
ALAMEDA, Calif.--(BUSINESS WIRE)--Jan. 12, 2016-- BioTime, Inc. (NYSE MKT and TASE: BTX) announced today that pursuant to Section 6.1(c) of the Warrant Agreement dated as of October 1, 2013, as amended September 19, 2014, between BioTime and American Stock Transfer & Trust Company LLC as Warrant Agent (the “Warrant Agreement”) governing the BioTime Common Share Purchase Warrants Expiring October 1, 2018 (the “Warrants”), the Board of Directors of Bio... 
Printer Friendly Version
December 31, 2015BioTime Completes Distribution of Approximately 4.75 Million Shares of OncoCyte Corporation Common Stock
Regular Way Trading of OncoCyte common stock on NYSE MKT to begin January 4, 2016 ALAMEDA, Calif.--(BUSINESS WIRE)--Dec. 31, 2015-- BioTime, Inc. (NYSE MKT: BTX), a clinical-stage regenerative medicine company with a focus on pluripotent stem cell technology, has completed its previously announced distribution of approximately 4.75 million shares of common stock of its subsidiary OncoCyte Corporation (“OncoCyte”) to BioTime shareholders. Regul... 
Printer Friendly Version
December 30, 2015BioTime Announces “When-Issued” Trading of Subsidiary OncoCyte Corporation in Connection With Planned Distribution
ALAMEDA, Calif.--(BUSINESS WIRE)--Dec. 30, 2015-- BioTime, Inc. (NYSE MKT: BTX), a clinical-stage regenerative medicine company with a focus on pluripotent stem cell technology, today announced that the common stock of its subsidiary OncoCyte Corporation (“OncoCyte”) will begin trading today on a “when-issued” basis on the NYSE MKT under the symbol OCX WI. “Regular-way” trading of OncoCyte common stock on the NYSE MKT is expected to begin on January 4, 2... 
Printer Friendly Version
December 11, 2015BioTime Co-Chief Executive Officer Michael D. West, PhD to Deliver Keynote Speech at the 2015 World Stem Cell Summit
ALAMEDA, Calif.--(BUSINESS WIRE)--Dec. 11, 2015-- BioTime, Inc. (NYSE MKT:BTX), a clinical-stage regenerative medicine company with a focus on pluripotent stem cell technology, today announced that its co-Chief Executive Officer Michael D. West, PhD will deliver a keynote presentation at the 2015 World Stem Cell Summit in Atlanta, Georgia on Saturday, December 12, 2015 from 11:30am to 12:30pm EST. Dr. West’s lecture is titled, “Emerging Trends in ... 
Printer Friendly Version
December 11, 2015BioTime, Inc. Announces Record Date, Distribution Ratio, and Distribution Date for Distribution of Shares of Subsidiary OncoCyte Corporation
ALAMEDA, Calif.--(BUSINESS WIRE)--Dec. 11, 2015-- BioTime, Inc. (NYSE MKT and TASE: BTX), a clinical-stage regenerative medicine company with a focus on pluripotent stem cell technology, today announced that its Board of Directors has set the record date, the distribution ratio, and expected distribution date for the distribution of a portion of the shares of common stock of BioTime’s subsidiary OncoCyte Corporation (“OncoCyte”) to BioTime shareholders. ... 
Printer Friendly Version
December 04, 2015BioTime, Inc. to Present at Oppenheimer Annual Healthcare Conference
ALAMEDA, Calif.--(BUSINESS WIRE)--Dec. 4, 2015-- BioTime, Inc. (NYSE MKT and TASE: BTX), a clinical-stage regenerative medicine company with a focus on pluripotent stem cell technology, today announced that Adi Mohanty, Co-Chief Executive Officer, is scheduled to present at the Oppenheimer 26th Annual Healthcare Conference in New York City to be held on December 8-9, 2015. Mr. Mohanty will provide an overview of the Company and an update on product devel... 
Printer Friendly Version
November 18, 2015BioTime, Inc. Announces the Appointment of Life Sciences Industry Veteran Russell Skibsted as Chief Financial Officer
ALAMEDA, Calif.--(BUSINESS WIRE)--Nov. 18, 2015-- BioTime, Inc. (NYSE MKT and TASE: BTX), a clinical-stage regenerative medicine company with a focus on pluripotent stem cell technology, today announced that the Company’s Board of Directors has appointed Russell Skibsted to the position of Chief Financial Officer, succeeding Robert Peabody. Mr. Russell Skibsted brings over 25 years of financial management and life sciences business experie... 
Printer Friendly Version
November 09, 2015BioTime, Inc. Reports Third Quarter 2015 Results and Recent Corporate Accomplishments
ALAMEDA, Calif.--(BUSINESS WIRE)--Nov. 9, 2015-- BioTime, Inc. (NYSE MKT and TASE:BTX) today reported financial results for the third quarter ended September 30, 2015 and provided an update on its recent accomplishments. “During the third quarter, BioTime and its family of companies achieved significant progress on multiple fronts,” said Adi Mohanty, BioTime’s co-Chief Executive Officer. “We are delivering on our commitment to reduce the c... 
Printer Friendly Version
November 06, 2015BioTime, Inc. and Hepregen Corporation Form Ascendance Biotechnology, Inc. to Address the In Vitro Cell Biology Market
Combination of BioTime’s ESI BIO Division and Hepregen to Focus on Next-Generation Metabolism and Safety Screening of New Drugs and Chemicals Provides Access to Hepregen’s Current Customer Base of Major Pharmaceutical and Chemical Companies BioTime Retains Cell Therapy Opportunities While Gaining Entry to Drug Screening Industry ALAMEDA, Calif. & MEDFORD, Mass.--(BUSINESS WIRE)--Nov. 6, 2... 
Printer Friendly Version
October 19, 2015Adi Mohanty Joins Michael D. West, PhD, as Co-CEO of BioTime, Inc.
ALAMEDA, Calif.--(BUSINESS WIRE)--Oct. 19, 2015-- BioTime, Inc. (NYSE MKT and TASE: BTX), a clinical-stage regenerative medicine company with a focus on pluripotent stem cell technology, reported today that its Board of Directors has appointed Adi Mohanty to serve with Michael D. West, PhD, as co-Chief Executive Officer. Mr. Mohanty has served as BioTime’s Chief Operating Officer since December 2014. Dr. West will lead BioTime’s science, technology devel... 
Printer Friendly Version
October 07, 2015BioTime’s Subsidiary OncoCyte Corporation Files Form 10 Registration Statement for Planned Distribution
BioTime Plans Distribution of Shares of Subsidiary OncoCyte Corporation to BioTime Shareholders Planned Distribution to Allow OncoCyte Greater Access to Capital Markets as a Publicly Traded Company ALAMEDA, Calif.--(BUSINESS WIRE)--Oct. 7, 2015-- BioTime, Inc. (NYSE MKT and TASE: BTX), a clinical-stage regenerative medicine company with a focus on pluripotent stem cell technology, and its subsidiary OncoCyte Corpo... 
Printer Friendly Version
October 02, 2015BioTime, Inc. Agrees to Sell $5.1 Million of Equity
ALAMEDA, Calif.--(BUSINESS WIRE)--Oct. 2, 2015-- BioTime, Inc. (NYSE MKT and TASE: BTX), a clinical-stage regenerative medicine company with a focus on pluripotent stem cell technology, today announced that it has agreed to sell 1,600,000 of its common shares, no par value, at an offering price of $3.19 per share to its largest shareholder, Broadwood Partners, L.P. (“Broadwood”). Neal Bradsher, a BioTime director, is the President of the investment manag... 
Printer Friendly Version
October 01, 2015BioTime Announces the Closing of a $20 Million Direct Registered Offering; Demand Exceeds NIS 80 Million Offered
- Offering Priced at $3.13 Per Share - Inclusion in Six Major Indexes of the Tel Aviv Stock Exchange ALAMEDA, Calif.--(BUSINESS WIRE)--Oct. 1, 2015-- BioTime, Inc. (NYSE MKT and TASE: BTX), a clinical-stage regenerative medicine company with a focus on pluripotent stem cell technology, today announced that BioTime completed a registered direct offering of 6,530,612 shares to a select group of TASE Indexes and mutual funds. The total p... 
Printer Friendly Version
September 28, 2015BioTime’s Subsidiary Cell Cure Neurosciences Ltd. Receives FDA Fast-Track Designation for OpRegen® for the Treatment of the Dry Form of Age-Related Macular Degeneration
ALAMEDA, Calif. & JERUSALEM--(BUSINESS WIRE)--Sep. 28, 2015-- BioTime, Inc. (NYSE MKT and TASE: BTX) and its subsidiary Cell Cure Neurosciences Ltd. (“Cell Cure”) today announced that the U.S. Food and Drug Administration (“FDA”) has granted Fast Track designation for OpRegen®, a cell-based therapeutic product consisting of retinal pigment epithelial (RPE) cells designed to block the progression of the severe dry-form of age-related macular degenerat... 
Printer Friendly Version
September 25, 2015BioTime, Inc. Agrees to Sell Up to $20.7 Million of Common Shares
Shares to be sold to TASE Index Funds in Israel ALAMEDA, Calif.--(BUSINESS WIRE)--Sep. 25, 2015-- BioTime, Inc. (NYSE MKT and TASE: BTX) today announced that it has agreed to sell up to $20.7 million of its common shares in a registered direct offering to select investment funds in Israel that hold shares of companies that are included within certain stock indexes of the Tel Aviv Stock Exchange (the “TASE”). The price per share will be determined wit... 
Printer Friendly Version
September 14, 2015BioTime, Inc. Agrees to Sell $8.58 Million of Common Shares
ALAMEDA, Calif.--(BUSINESS WIRE)--Sep. 14, 2015-- BioTime, Inc. (NYSE MKT and TASE: BTX) today announced that it has agreed to sell 2,607,401 of its common shares, no par value, at an offering price of $3.29 per share, for a gross purchase price of approximately $8.58 million, to selected investors, including a major shareholder, Broadwood Partners, L.P. (“Broadwood”), in a registered direct offering. The price per share was the closing price of BioTime ... 
Printer Friendly Version
September 04, 2015BioTime Announces Dual Listing on the Tel Aviv Stock Exchange
- Common shares are currently listed on NYSE MKT and will also be listed on the Tel Aviv Stock Exchange (TASE) beginning September 8, 2015 under ticker symbol BTX - Anticipated inclusion in the TASE: TA-75, TA-100, TA-BlueTech, TA-Tech-Elite and TA-Biomed Indexes ALAMEDA, Calif. & TEL AVIV, Israel--(BUSINESS WIRE)--Sep. 4, 2015-- BioTime, Inc. (NYSE MKT: BTX), a biotechnology company focused on the development and commercialization... 
Printer Friendly Version
September 02, 2015ESI BIO - A Division of BioTime, Inc. Launches New Research Technology Platform, VascuNet™ Pericyte Co-Culture Assay
Provides Researchers with In Vitro Assays with Greater Physiological Relevance and Accuracy ALAMEDA, Calif., September 2, 2015 – ESI BIO (esibio.com), the stem cell products division of BioTime, Inc., announced today the release of its most recent technology platform designed to give researchers new standardized in vitro assays with greater physiological relevance and accuracy. The VascuNet™ Pericyte Co-Culture Assay provides a stable, clinically relevant angiogenesis model not c... 
Printer Friendly Version
September 01, 2015BioTime Chief Executive Officer Dr. Michael D. West to be Keynote Speaker at Stem Cells & Regenerative Medicine Congress 2015
ALAMEDA, Calif.--(BUSINESS WIRE)--Sep. 1, 2015-- BioTime, Inc. (NYSE MKT:BTX) announced today that its Chief Executive Officer Michael D. West, Ph.D. will deliver a keynote presentation at the Stem Cells & Regenerative Medicine Congress in Washington, D.C. from 9:30 to 10:00 a.m. EDT on Wednesday, September 2, 2015. Dr. West’s lecture is titled, “The Replicative Immortality of the Germ-Line: Implications for the Application of Regenerative Medicine i... 
Printer Friendly Version
August 28, 2015BioTime Management to Present at Rodman & Renshaw 17th Annual Global Investment Conference
ALAMEDA, Calif.--(BUSINESS WIRE)--Aug. 28, 2015-- BioTime, Inc. (NYSE MKT:BTX) announced today that BioTime management will present at the Rodman & Renshaw 17th Annual Investment Conference in New York City from 3:00 to 3:25 p.m. EDT on Thursday, September 10, 2015. Investors will receive an update on BioTime and its subsidiaries. The investor presentation will also be available for a live webcast by clicking on the following link: http://www... 
Printer Friendly Version
August 10, 2015BioTime, Inc. Reports Second Quarter 2015 Results and Recent Developments
ALAMEDA, Calif.--(BUSINESS WIRE)--Aug. 10, 2015-- BioTime, Inc. (NYSE MKT:BTX) today reported financial results for the second quarter ended June 30, 2015 and provided a corporate update. “BioTime’s management team has sharpened its focus on our high priority programs,” said Dr. Michael D. West, BioTime’s Chief Executive Officer. “Our strategy for achieving the leadership role in regenerative medicine includes: continuing to advance the ongoing c... 
Printer Friendly Version
August 10, 2015BioTime Announces the Issuance of 27 New Patents Protecting Stem Cell-Based Product Development
New patents add to existing portfolio of over 700 issued and pending patents and patent applications world wide owned or licensed to BioTime or its subsidiaries ALAMEDA, Calif.--(BUSINESS WIRE)--Aug. 10, 2015-- BioTime, Inc. (NYSE MKT:BTX) today announced that 27 new patents have issued during the first half of 2015 that are owned or licensed to BioTime or its subsidiaries. These new patents add to the portfolio of over 700 issued ... 
Printer Friendly Version
May 20, 2015BioTime to Present at the Jefferies 2015 Global Healthcare Conference
ALAMEDA, Calif.--(BUSINESS WIRE)--May 20, 2015-- BioTime, Inc. (NYSE MKT: BTX) today announced that Chief Executive Officer Michael D. West, PhD will present at the Jefferies 2015 Global Healthcare Conference to be held in New York on June 1-4, 2015. Dr. West will provide an overview of the company and an update on product development in his presentation at 3:00 PM EDT on Wednesday, June 3, 2015. Attendance at the conference is by invitati... 
Printer Friendly Version
May 13, 2015BioTime’s Subsidiary Cell Cure Neurosciences Ltd. Awarded $1.6 Million Grant From Israel’s Office of the Chief Scientist
ALAMEDA, Calif. & JERUSALEM--(BUSINESS WIRE)--May 13, 2015-- BioTime, Inc. (NYSE MKT: BTX) and its subsidiary Cell Cure Neurosciences Ltd. (Cell Cure) today announced that Cell Cure has been awarded a grant for 2015 of 6.24 million shekels (approximately $1.61 million) from Israel’s Office of the Chief Scientist (OCS) to help finance the development of OpRegen®, a cell-based therapeutic product that consists of animal product-free retinal pigm... 
Printer Friendly Version
May 11, 2015BioTime, Inc. Reports First Quarter 2015 Results and Recent Corporate Accomplishments
ALAMEDA, Calif.--(BUSINESS WIRE)--May 11, 2015-- BioTime, Inc. (NYSE MKT:BTX) today reported financial results for the first quarter ended March 31, 2015 and provided a corporate update. “BioTime continues to advance its strategic product development programs. We are currently enrolling patients in a pivotal trial of Renevia™ for the treatment of HIV-associated lipoatrophy,” said Dr. Michael D. West, BioTime’s Chief Executive Officer. “At this ye... 
Printer Friendly Version
May 04, 2015Cell Cure Neurosciences Announces Preclinical Efficacy Data Demonstrating OpRegen® Preserves Vision
Data to be Presented at Association for Research in Vision and Ophthalmology (ARVO) 2015 Annual Meeting ALAMEDA, Calif. & JERUSALEM--(BUSINESS WIRE)--May 4, 2015-- BioTime, Inc. (NYSE MKT: BTX) and its subsidiary Cell Cure Neurosciences Ltd. (Cell Cure) today announced that preclinical data demonstrating that Cell Cure’s product candidate, OpRegen®, preserved vision and retinal structure when transplanted into the leading animal model of r... 
Printer Friendly Version
April 27, 2015BioTime’s Clinical Grade Stem Cells From Subsidiary ES Cell International to Be Used in Planned CIRM-Funded Preclinical Studies of Huntington’s Disease
ALAMEDA, Calif.--(BUSINESS WIRE)--Apr. 27, 2015-- BioTime, Inc. (NYSE MKT:BTX) today announced that the clinical-grade human Embryonic Stem (hES) cell lines from BioTime’s wholly-owned subsidiary ES Cell International Pte Ltd (ESI, Singapore) will be used by UC Irvine scientist Dr. Leslie Thompson to continue her promising research in the use of stem cells to treat Huntington’s disease under a $5 million grant from the California Institute for Regenerati... 
Printer Friendly Version
April 22, 2015BioTime Licenses Beckman Research Institute of City of Hope to Manufacture Clinical Grade Stem Cells
ALAMEDA, Calif.--(BUSINESS WIRE)--Apr. 22, 2015-- BioTime, Inc. (NYSE MKT: BTX) today announced a nonexclusive License Agreement between BioTime’s subsidiary ES Cell International Pte Ltd (ESI) and Beckman Research Institute of the City of Hope (BRICOH, Duarte, CA) through which ESI’s clinical-grade human embryonic stem (hES) cells will be manufactured and provided to BRICOH’s clinical collaborators, including medical research organizations intent on usi... 
Printer Friendly Version
April 20, 2015Positive Clinical Results of OncoCyte’s PanC-Dx™ Diagnostic Test Demonstrate High Level of Sensitivity and Specificity in Non-Invasive Detection of Bladder Cancer
Data Presented at American Association for Cancer Research 2015 Annual Meeting ALAMEDA, Calif.--(BUSINESS WIRE)--Apr. 20, 2015-- BioTime, Inc. (NYSE MKT:BTX) and its subsidiary OncoCyte Corporation today announced positive clinical results of PanC-Dx™, OncoCyte’s class of proprietary, non-invasive cancer diagnostic tests, in detecting the most common type of bladder cancer, urothelial carcinoma (UC). Karen B. Chapman, PhD, Vice President of Re... 
Printer Friendly Version
March 11, 2015BioTime, Inc. Reports Fourth Quarter and Fiscal Year End 2014 Financial Results and Recent Corporate Accomplishments
ALAMEDA, Calif.--(BUSINESS WIRE)--Mar. 11, 2015-- BioTime, Inc. (NYSE MKT: BTX) today reported financial results for the quarter and year ended December 31, 2014, and highlighted its fourth quarter and recent corporate accomplishments. “In 2014, BioTime and its subsidiaries built strong momentum in advancing the development of therapeutic and diagnostic products that address unmet medical needs with large market potential,” said Dr. Michae... 
Printer Friendly Version
February 24, 2015BioTime Announces First Patient Treated in Pivotal Clinical Trial of Renevia™ for HIV-Associated Lipoatrophy
ALAMEDA, Calif.--(BUSINESS WIRE)--Feb. 24, 2015-- BioTime, Inc. (NYSE MKT: BTX) today announced that the first patient was successfully treated in the Company’s pivotal clinical trial in Europe assessing the efficacy of Renevia™ for the treatment of HIV-associated lipoatrophy. HIV-associated lipoatrophy is a disorder characterized by abnormal loss of body fat from under the skin that occurs in almost half of the approximately three million people on ... 
Printer Friendly Version
February 23, 2015ESI BIO – A Division of BioTime, Inc., Announces Alliance Agreement with Pivotal Scientific Ltd for Distribution of Stem Cell Products
ALAMEDA, Calif., February 23, 2015 – ESI BIO, the stem cell products division of BioTime, Inc., providing stem cells and stem cell research reagents world-wide, and Pivotal Scientific Ltd, a company specializing in developing the international growth of biotech enterprises, announced an alliance agreement to develop business opportunities and manage ESI BIO’s growing network of new international distributors. ESI BIO’s (esibio.com) research products are used by stem cell resear... 
Printer Friendly Version
February 17, 2015Cell Cure Neurosciences Ltd. Provides Update on its Product Development and Partnering Activities
ALAMEDA, Calif. & JERUSALEM--(BUSINESS WIRE)--Feb. 17, 2015-- BioTime, Inc. (NYSE MKT: BTX) and its subsidiary Cell Cure Neurosciences Ltd. (“Cell Cure”) today provided an update on Cell Cure’s product development and partnering activities. On February 16, 2015, Cell Cure opened the clinical trial of OpRegen® titled “Phase I/IIa Dose Escalation Safety and Efficacy Study of Human Embryonic Stem Cell-Derived Retinal Pigment Epithelium Cells ... 
Printer Friendly Version
January 27, 2015ESI BIO - A Division of BioTime, Inc. Announces New UK Distribution Agreement with 2BScientific
ALAMEDA, Calif., January 27, 2015 – ESI BIO, the stem cell products division of BioTime, Inc., announces that its cGMP and research grade stem cell lines, reagents and cell matrix products are now available in the UK and Ireland through 2BScientific Ltd. ESI BIO’s (esibio.com) research products are used by stem cell researchers around the world and include clinical and research grade human embryonic stem cells from ES Cell International (ESI) and HyStem® hyaluronan-based hydrogel ex... 
Printer Friendly Version
January 26, 2015BioTime Announces Issuance of 14 New Patents in the Fields of Regenerative Medicine, Stem Cell Technology, and Cancer Therapy
ALAMEDA, Calif.--(BUSINESS WIRE)--Jan. 26, 2015-- BioTime, Inc. (NYSE MKT: BTX) announced today the issuance of 14 new patents covering a wide range of the core technologies of BioTime and its subsidiaries Asterias Biotherapeutics, Inc. (NYSE MKT: AST), OrthoCyte Corporation, ES Cell International Pte Ltd, OncoCyte Corporation, and ReCyte Therapeutics, Inc. The new patents issued over Q3 and Q4 of 2014 add to the BioTime family of companies’ paten... 
Printer Friendly Version
December 29, 2014BioTime Appoints Adi Mohanty Chief Operating Officer
Executive Brings Proven Leadership in Biopharmaceutical Product Development and Commercialization to BioTime ALAMEDA, Calif.--(BUSINESS WIRE)--Dec. 29, 2014-- BioTime, Inc. (NYSE MKT:BTX), a leader in developing pluripotent stem-cell therapies and other technologies designed to address major unmet medical needs, today announced the appointment of Adi Mohanty to the position of Chief Operating Officer of the Company. Mr. Mohanty’s primary respo... 
Printer Friendly Version
December 15, 2014BioTime Subsidiary ES Cell International and GE Healthcare Cross-License patents in the Field of Cell Assays for Drug Testing
ALAMEDA, Calif.--(BUSINESS WIRE)--Dec. 15, 2014-- BioTime, Inc. (NYSE MKT: BTX) today announced that its subsidiary ES Cell International Pte. Ltd. (“ESI”) and GE Healthcare (GEHC) have signed a set of license agreements through which GEHC received rights to ESI’s stem cell patents and ESI received rights to stem cell patents controlled by GEHC, in both cases for the development of cellular assays and models derived from stem cells for use in drug discov... 
Printer Friendly Version
December 15, 2014BioTime, Inc. Subsidiary OncoCyte Corporation Completes Initial Enrollment of Clinical Study of Urine-Based Bladder Cancer Diagnostic
-OncoCyte’s Proprietary Diagnostic Markers Tested on Patient Samples Collected by Pathologists at Leading US Medical Institution- ALAMEDA, Calif.--(BUSINESS WIRE)--Dec. 15, 2014-- BioTime, Inc. (NYSE MKT: BTX) and its subsidiary OncoCyte Corporation today announced that OncoCyte has completed enrollment in the initial clinical study of its urine-based bladder cancer diagnostic test. The study, which involved 100 patients, was conducted in collaborati... 
Printer Friendly Version
December 15, 2014BioTime Appoints Angus C. Russell to Board of Directors
ALAMEDA, Calif.--(BUSINESS WIRE)--Dec. 15, 2014-- BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced that Angus C. Russell, former Chief Executive Officer of Shire plc, has been appointed to BioTime's Board of Directors. Shire is a leading global specialty biopharmaceutical company. During Mr. Russell's tenure as Chief Executive Officer of Shire from 200... 
Printer Friendly Version
December 12, 2014BioTime to Host Investor and Analyst Day on December 15, 2014
ALAMEDA, Calif.--(BUSINESS WIRE)--Dec. 12, 2014-- BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, announced today that it will host its Investor and Analyst Day meeting on Monday, December 15, 2014 at the Harvard Club of New York City. A live webcast of the presentations will begin at 1:15 pm ET and the webcast will conclude by 4:00 pm ET. Presentations will p... 
Printer Friendly Version
December 03, 2014BioTime to Present at the LD Micro VII Conference
ALAMEDA, Calif.--(BUSINESS WIRE)--Dec. 3, 2014-- BioTime, Inc. (NYSE MKT:BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced that Chief Executive Officer Michael D. West, PhD will present at the LD Micro VII Conference taking place December 2-4, 2014 in Los Angeles, California. Dr. West will provide a corporate update in his presentation on Thursday, December 4, 2014, 4:00... 
Printer Friendly Version
November 10, 2014BioTime Reports Third Quarter Results and Recent Progress
Asterias Biotherapeutics approved for listing on NYSE MKT Asterias’ AST-OPC1 cleared by FDA for Phase 1/2a dose escalation clinical trial for spinal cord injury Cell Cure Neuroscience’s OpRegen® cleared by FDA for Phase 1/2a dose escalation clinical trial for the dry form of age-related macular degeneration Renevia™ cleared for pivotal trial in Europe for treatment of HIV-related lipoat... 
Printer Friendly Version
November 04, 2014BioTime Receives Authorization to Begin Pivotal Human Clinical Trial of Renevia™ in Europe
Renevia™ to be utilized in the treatment of HIV-related lipoatrophy, a disorder estimated to afflict more than 3.5 million patients globally Patient enrollment initiated; expected to be completed in 2015 ALAMEDA, Calif.--(BUSINESS WIRE)--Nov. 4, 2014-- BioTime, Inc. (NYSE MKT:BTX) today reported that it has received authorization to begin its pivotal human clinical trial of Renevia™ in Europe. In the trial, Renevi... 
Printer Friendly Version
October 09, 2014BioTime, Inc. Closes $31 Million Financing
ALAMEDA, Calif.--(BUSINESS WIRE)--Oct. 9, 2014-- BioTime, Inc. (NYSE MKT: BTX) today announced that it has closed the equity financing it disclosed on October 3, 2014, through which BioTime received $29,425,961 and certain subsidiaries received approximately $1,558,905 from the sale of BioTime common shares. BioTime and the subsidiaries intend to use the net proceeds from their sales to finance clinical trials of products under development, to finance th... 
Printer Friendly Version
October 06, 2014Michael H. Mulroy and Stephen L. Cartt Joining BioTime Board of Directors
ALAMEDA, Calif.--(BUSINESS WIRE)--Oct. 6, 2014-- BioTime, Inc. (NYSE MKT:BTX) announced today that Michael H. Mulroy and Stephen L. Cartt are joining its Board of Directors. Mr. Mulroy has been appointed to the Board to fill a vacancy and Mr. Cartt has been nominated for election to the Board at the Company’s upcoming annual shareholders’ meeting, which will be held on November 4. Mr. Mulroy most recently served as Executive Vice President... 
Printer Friendly Version
October 06, 2014BioTime, Inc. and Subsidiaries to Raise $31 Million Through Sales of Common Shares
Shares to be sold at the October 2, 2014 closing market share price Funds to be used in part for clinical trials ALAMEDA, Calif.--(BUSINESS WIRE)--Oct. 6, 2014-- BioTime, Inc. (NYSE MKT:BTX) today announced that it has agreed to sell up to an aggregate of 9,431,398 common shares, in a registered direct offering at an offering price of $3.12 per share. The price per share was the closing price of our common shares on the NYSE... 
Printer Friendly Version
October 03, 2014BioTime’s Subsidiary OncoCyte Corporation Announces Completion of Multi-Site Clinical Study of Lung Cancer Diagnostic by Collaborators at The Wistar Institute
- Final Study Enrollment Exceeds 600 Patients - ALAMEDA, Calif.--(BUSINESS WIRE)--Oct. 3, 2014-- BioTime, Inc. (NYSE MKT: BTX), and its subsidiary OncoCyte Corporation today announced that OncoCyte’s collaborators at The Wistar Institute have completed enrollment of a large, multi-site study evaluating a blood-based lung cancer diagnostic test. OncoCyte previously entered into a Sponsored Research Agreement and a Material Transfer Agreement ... 
Printer Friendly Version
September 09, 2014BioTime CEO Dr. Michael D. West to Present at Rodman & Renshaw 16th Annual Healthcare Conference
ALAMEDA, Calif.--(BUSINESS WIRE)--Sep. 9, 2014-- BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced that Chief Executive Officer Michael D. West, Ph.D. will present at the Rodman & Renshaw 16th Annual Healthcare Conference at 9:35 a.m. EDT on Wednesday, September 10, 2014. The conference will be held at the New York Palace Hotel in New York City. Dr. West wi... 
Printer Friendly Version
August 28, 2014BioTime to Collaborate With the University of Wisconsin and Louvain University in Test of HyStem®-Based Hydrogel for Vocal Fold Scarring
Investigator-initiated clinical trial may follow preclinical studies ALAMEDA, Calif.--(BUSINESS WIRE)--Aug. 28, 2014-- BioTime, Inc. (NYSE MKT:BTX) today announced that it has entered into a collaboration with Susan Thibeault, Ph.D., of the University of Wisconsin and Marc Remacle, M.D. of Louvain University to evaluate BioTime’s proprietary HyStem®-based hydrogel for the treatment of vocal fold scarring. Preclinical studies published by Dr. T... 
Printer Friendly Version
August 12, 2014BioTime Receives FDA Premarket Notification Clearance for Premvia™ 510(k)
ALAMEDA, Calif.--(BUSINESS WIRE)--Aug. 12, 2014-- BioTime, Inc. (NYSE MKT: BTX) today announced that it has received notice from the FDA’s Center for Devices and Radiologic Health that Premvia™ has been cleared for marketing as a Class II medical device. Premvia™ is the first FDA-cleared member of BioTime’s HyStem® family of hydrogels, which are designed to mimic the natural structures of the human body’s extracellular matrix. According to the FDA ... 
Printer Friendly Version
August 12, 2014BioTime Announces Second Quarter 2014 Results and Recent Developments
Three cancer diagnostic products in clinical development IND amendment pending for expanded clinical trials of AST-OPC1 Asterias obtains over $12 million in financing and awarded a $14 million grant FDA provides 510(k) premarket clearance for Premvia™ ALAMEDA, Calif.--(BUSINESS WIRE)--Aug. 12, 2014-- BioTime, Inc. (NYSE MKT: BTX) today reported financial results for the first quar... 
Printer Friendly Version
July 14, 2014BioTime Announces Issuance of 14 Patents in the Fields of Regenerative Medicine, and Cancer Diagnosis and Therapy
- New issued patents add to existing estate of over 600 patents and patent applications worldwide in the emerging field of pluripotent stem cell technology - ALAMEDA, Calif.--(BUSINESS WIRE)--Jul. 14, 2014-- BioTime, Inc. (NYSE MKT:BTX) announced today the issuance of 14 new patents to BioTime and its subsidiary companies. The patents issued in Australia, Canada, China, Japan, and the United States, cover a wide range of core technologi... 
Printer Friendly Version
June 02, 2014BioTime to Present at the Jefferies 2014 Global Healthcare Conference
ALAMEDA, Calif.--(BUSINESS WIRE)--Jun. 2, 2014-- BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced that Chief Executive Officer Michael D. West, PhD will present at the Jefferies 2014 Global Healthcare Conference taking place June 2-5 in New York City. Dr. West will provide a corporate update in his presentation on Thursday, June 5, 2014, 9:00 AM EDT, at the Gr... 
Printer Friendly Version
May 28, 2014BioTime Receives ISO 13485 Certification for Medical Devices
ALAMEDA, Calif.--(BUSINESS WIRE)--May 28, 2014-- BioTime, Inc. (NYSE MKT: BTX) today announced that it has received ISO 13485:2003 certification from BSI (British Standards Institution) for design, development, manufacture, and distribution of BioTime HyStem® hydrogels for cell delivery applications. BSI is currently one of the world’s largest independent certification bodies for quality management systems and ISO 13485:2003 is the world’s ... 
Printer Friendly Version
May 12, 2014BioTime Announces First Quarter 2014 Results and Recent Developments
Four products currently in clinical development Three therapeutic products currently in late-stage preparation for clinical development Shares of Asterias subsidiary scheduled to trade publicly in near term LifeMap Solutions subsidiary launched to develop mobile health products ALAMEDA, Calif.--(BUSINESS WIRE)--May 12, 2014-- BioTime, Inc. (NYSE MKT: BTX) today reported... 
Printer Friendly Version
May 05, 2014BioTime Raises $6.4 Million in Equity Financing
ALAMEDA, Calif.--(BUSINESS WIRE)--May 5, 2014-- BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced that on May 1, 2014, the Company received approximately $6.4 million in equity financing. The funds were raised from current long-term investors in the Company and will be used for funding product development, including this year's anticipated pivotal Renevia™ clin... 
Printer Friendly Version
May 01, 2014BioTime Division ESI BIO Launches New Responsive Design Website to the Scientific Community
ESI BIO’s website has been designed to provide the ultimate user-friendly experience whether on a desktop, tablet or mobile device. Allowing customers access to detailed product information and videos with the option to share information across all major social networking sites. ALAMEDA, Calif., May 1, 2014 - BioTime, Inc. through its new research products division ESI BIO, today unveiled a new responsive design website, www.esibio.com, which enriches the online research reagent shoppin... 
Printer Friendly Version
April 24, 2014BioTime to Present at GTC Stem Cell Summit 2014
ALAMEDA, Calif.--(BUSINESS WIRE)--Apr. 24, 2014-- BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced that Chief Executive Officer Michael D. West, PhD will present at the GTC Stem Cell Summit 2014 taking place April 23-25, 2014 in Cambridge, MA. The following are specific details regarding BioTime’s presentation:   ... 
Printer Friendly Version
April 14, 2014BioTime, Inc. Announces Board Membership Changes and Management and Board Changes at Its Subsidiary Asterias Biotherapeutics, Inc.
ALAMEDA, Calif.--(BUSINESS WIRE)--Apr. 14, 2014-- BioTime, Inc. (NYSE MKT: BTX) announced that its Board of Directors has appointed Deborah Andrews and David Schlachet to the Board of Directors. David Schlachet serves as a director of several public and private companies. Mr. Schlachet is the former Chairman and Chief Executive Officer of Syneron Medical Ltd., an Israeli aesthetic medical device company, and he has served as a director of the Tel... 
Printer Friendly Version
April 07, 2014BioTime to Present at 13th Annual Needham Healthcare Conference
ALAMEDA, Calif.--(BUSINESS WIRE)--Apr. 7, 2014-- BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced that Chief Executive Officer Michael D. West, PhD will present at the 13th Annual Needham Healthcare Conference to be held April 8-9, 2014 in New York City. The following are specific details regarding BioTime’s presentation: ... 
Printer Friendly Version
March 25, 2014BioTime To Present at Regen Med Investor Day March 26 in New York
ALAMEDA, Calif.--(BUSINESS WIRE)--Mar. 25, 2014-- BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced that Chief Executive Officer Michael D. West, PhD will present at the 2nd Annual Regen Med Investor Day to be held Wednesday, March 26, 2014 in New York City. Organized by the Alliance for Regenerative Medicine (ARM) in partnership with leading fin... 
Printer Friendly Version
March 17, 2014BioTime Announces Fourth Quarter and Fiscal Year End 2013 Financial Results and Recent Corporate Accomplishments
ALAMEDA, Calif.--(BUSINESS WIRE)--Mar. 17, 2014-- BioTime, Inc. (NYSE MKT: BTX), today reported financial results for the fourth quarter and year ended December 31, 2013 and highlighted its fourth quarter and recent corporate accomplishments. Fourth Quarter and Recent Highlighted Corporate Accomplishments BioTime’s subsidiary Asterias Biotherapeutics, Inc. completed the acquisition of stem cell assets from Geron Corporation, i... 
Printer Friendly Version
March 05, 2014BioTime Raises $3.5 Million Through Preferred Stock Offering
ALAMEDA, Calif.--(BUSINESS WIRE)--Mar. 5, 2014-- BioTime, Inc. (NYSE MKT: BTX) today announced it has sold 70,000 shares of a newly authorized Series A Convertible Preferred Stock for $3.5 million. The Series A Preferred Stock carries a cumulative annual 3% preferred dividend or $1.50 per share, in preference to BioTime common shares. Each share of Series A Preferred Stock is convertible, at the election of the holder, into BioTime common shares at a con... 
Printer Friendly Version
March 03, 2014BioTime Provides Financing and Product Development Update
$12.6 Million Raised Since October 1, 2013 in At-the-Market Stock Sales Company is Awarded New NIH SBIR Grant Premvia™ 510(k) Premarket Notification Submitted to FDA for Review ALAMEDA, Calif.--(BUSINESS WIRE)--Mar. 3, 2014-- BioTime, Inc. (NYSE MKT: BTX) today announced the results of its capital raising activities since October 1, 2013 through its $25 million Controlled Equity Offering f... 
Printer Friendly Version
February 18, 2014BioTime CEO Dr. Michael West to Present at 9th Annual Stem Cell Summit
ALAMEDA, Calif.--(BUSINESS WIRE)--Feb. 18, 2014-- BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced that Chief Executive Officer Michael D. West, PhD will present at the 9th Annual Stem Cell Summit in New York. Dr. West will speak in the session “Disrupting the Pharma Model with Allogeneic Stem Cell Therapies” on February 18, 2014, starting at 9:05 a.m. EST. ... 
Printer Friendly Version
January 13, 2014BioTime Reports Results of Clinical Safety Trial of Renevia™
Renevia™ Appears Safe And Well Tolerated With No Serious Unexpected Adverse Events Observed During The Trial Period Manufacturing and Biocompatibility Information Submitted in a Device Master File to FDA ALAMEDA, Calif.--(BUSINESS WIRE)--Jan. 13, 2014-- BioTime, Inc. (NYSE MKT: BTX) today announced the completion of a safety trial evaluating Renevia™, a proprietary injectable matrix designed to facilitate the stab... 
Printer Friendly Version
December 20, 2013BioTime Reports Isolation of Novel Brain-Associated Cells From Human Embryonic Stem Cells
ALAMEDA, Calif.--(BUSINESS WIRE)--Dec. 20, 2013-- BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine reported today the publication of a peer-reviewed scientific paper on the successful generation of human cells with markers of particular cell types in the human brain, potentially useful in the treatment of neurological diseases such as Alzheimer’s disease. The paper publ... 
Printer Friendly Version
December 04, 2013BioTime’s CEO, Dr. Michael West to Moderate Session on Mapping the Cellular Basis of Life at the 2013 World Stem Cell Summit
ALAMEDA, Calif.--(BUSINESS WIRE)--Dec. 4, 2013-- BioTime, Inc. (NYSE MKT: BTX) and subsidiary, LifeMap Sciences, announced that BioTime’s CEO, Dr. Michael West will lead a session titled “From Mapping the Genome to Mapping the Embryome: The Urgent Need for an International Initiative” today at the 2013 World Stem Cell Summit in San Diego, California. The session will include world leaders in stem cell biology discussing how major advances in stem ... 
Printer Friendly Version
November 25, 2013BioTime CEO Dr. Michael West to Present at 11th Annual Commercial Translation of Regenerative Medicine Conference
ALAMEDA, Calif.--(BUSINESS WIRE)--Nov. 25, 2013-- BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced that Chief Executive Officer Michael D. West, PhD will present at the 11th Annual Commercial Translation of Regenerative Medicine conference in London on Monday, November 25, 2013. Dr. West’s presentation titled “Strategies for the Manufacture of Highly ... 
Printer Friendly Version
November 12, 2013BioTime Announces Third Quarter 2013 Financial Results and Recent Corporate Accomplishments
ALAMEDA, Calif.--(BUSINESS WIRE)--Nov. 12, 2013-- BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today reported financial results for the third quarter ended September 30, 2013 and highlighted recent corporate accomplishments. Third Quarter and Recent Corporate Accomplishments BioTime’s subsidiary, Asterias Biotherapeutics, Inc., completed its ... 
Printer Friendly Version
October 28, 2013BioTime Reports Interim Results on Renevia™ Clinical Safety Trial
- Enrollment completed in first safety study of Renevia™ for dermatological applications - - Two weeks following administration, Renevia™ appears safe and well tolerated with no serious unexpected adverse events observed to date - ALAMEDA, Calif.--(BUSINESS WIRE)--Oct. 28, 2013-- BioTime, Inc. (NYSE MKT: BTX), today announced that William Tew, Ph.D., BioTime’s Chief Commercial Officer will provide an update on the development of... 
Printer Friendly Version
October 28, 2013BioTime Organizes New ESI BIO Division to Develop, Manufacture and Market the Company’s Cell-Based Research Products
Appoints Jeffrey Janus as CEO of ES Cell International Pte Ltd. ALAMEDA, Calif.--(BUSINESS WIRE)--Oct. 28, 2013-- BioTime, Inc. (NYSE MKT: BTX) today announced changes to the organization and management of its research products business. The research products business will be consolidated into a new ESI BIO Division which shall be BioTime’s primary developer, manufacturer and distributor for its growing portfolio of stem-cell-based research pr... 
Printer Friendly Version
October 28, 2013BioTime, Inc. to Provide Company Updates During Investor Day, October 28, 2013
ALAMEDA, Calif.--(BUSINESS WIRE)--Oct. 28, 2013-- BioTime, Inc. (NYSE MKT: BTX) announced today that it will be holding its annual Investor Day providing company updates at the Harvard Club in New York City. The presentations will be available on the company website, www.biotimeinc.com. Thomas Okarma, M.D., Ph.D., President and CEO of Asterias Biotherapeutics Inc., will present a summary of Asterias, a new subsidiary of BioTime. Asterias r... 
Printer Friendly Version
October 04, 2013BioTime Announces Additional Products in Development Based on HyStem® Technology
ALAMEDA, Calif.--(BUSINESS WIRE)--Oct. 4, 2013-- BioTime, Inc. (NYSE MKT: BTX), today announced that it has initiated the development of two new products based on its HyStem® hydrogel technology platform. The first of these new products is ReGlydeTM, a cross-linked thiol-modified hyaluronan hydrogel for the management and protection of tendon injuries following surgical repair of the digital flexor or extensor tendons of the hand. The prod... 
Printer Friendly Version
September 19, 2013BioTime Signs Exclusive Agreement with Jade Therapeutics for Ophthalmic Drug Delivery Applications of HyStem® Technology
ALAMEDA, Calif.--(BUSINESS WIRE)--Sep. 19, 2013-- BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced the signing of an exclusive sublicense agreement with Jade Therapeutics, Inc., a Salt Lake City-based developer of ophthalmic sustained-release drug delivery platforms. This new agreement supersedes the previously announced sublicense and supply agreements and ex... 
Printer Friendly Version
August 28, 2013BioTime Receives Approval to Begin Human Clinical Trials of Renevia
ALAMEDA, Calif.--(BUSINESS WIRE)--Aug. 28, 2013-- BioTime, Inc. (NYSE MKT: BTX) today announced that it has received approval from The Spanish Agency of Medicines and Medical Devices (AEMPS) to begin human clinical trials of Renevia™, a unique biomaterial used as a delivery matrix for autologous adipose derived cells to treat the loss of subcutaneous adipose tissue (lipoatrophies) arising from trauma, surgical resection, and congenital defects and ... 
Printer Friendly Version
August 21, 2013BioTime Announces the Appointment of Lesley Stolz as Executive Vice President of Corporate Development
ALAMEDA, Calif.--(BUSINESS WIRE)--Aug. 21, 2013-- BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced the expansion of its senior management team with the appointment of Lesley Stolz, Ph.D. as Executive Vice President, Corporate Development. Dr. Stolz has more than 18 years of life science industry experience in corporate and business development. ... 
Printer Friendly Version
August 19, 2013BioTime CEO Dr. Michael West to Give Keynote Address at the MSC 2013 Adult Stem Cell Therapy & Regenerative Medicine Conference
ALAMEDA, Calif.--(BUSINESS WIRE)--Aug. 19, 2013-- BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, announced that Chief Executive Officer Michael D. West, PhD will give the keynote address at the MSC 2013 Adult Stem Cell Therapy & Regenerative Medicine conference on Monday, August 19, 2013, at 12:15 p.m. EDT in Cleveland, Ohio. Dr. West will discuss the potential u... 
Printer Friendly Version
August 09, 2013BioTime Announces Second Quarter 2013 Financial Results and Recent Corporate Accomplishments
ALAMEDA, Calif.--(BUSINESS WIRE)--Aug. 9, 2013-- BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today reported financial results for the second quarter ended June 30, 2013 and highlighted recent corporate accomplishments. Second Quarter and Recent Corporate Accomplishments BioTime’s shareholders approved the proposals related to the planned ... 
Printer Friendly Version
July 16, 2013BioTime CEO Dr. Michael West to Present at the Case Western Reserve University 6th Annual Regenerative Medicine Business Education Course
ALAMEDA, Calif.--(BUSINESS WIRE)--Jul. 16, 2013-- BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, announced that Chief Executive Officer Michael D. West, PhD will present today at the Case Western Reserve University in the meeting “The Business of Regenerative Medicine: From Stem Cells to the Market Place” in Cleveland, Ohio. Dr. West’s presentation titled “Embryomics: ... 
Printer Friendly Version
June 12, 2013BioTime Appoints Henry L. Nordhoff to Board of Directors
ALAMEDA, Calif.--(BUSINESS WIRE)--Jun. 12, 2013-- BioTime, Inc. (NYSE MKT: BTX) today announced that Henry L. Nordhoff, former CEO and Chairman of Gen-Probe Inc., has been appointed to its Board of Directors. “We are pleased to welcome an accomplished healthcare executive of Hank's caliber to BioTime's board,” said Alfred D. Kingsley, Chairman of the Board of BioTime. “Hank's 43 years of experience in the pharmaceutical business, including... 
Printer Friendly Version
June 07, 2013BioTime, Inc. Closes on $9 Million Financing
ALAMEDA, Calif.--(BUSINESS WIRE)--Jun. 7, 2013-- BioTime, Inc. (NYSE MKT: BTX) today announced that it has closed the equity financing it announced on June 3, 2013 and received gross proceeds of $9,057,966. BioTime intends to use the net proceeds from the sale of its common shares and warrants for working capital and other general corporate purposes, and may invest a portion of the proceeds in one or more of its subsidiaries, including fun... 
Printer Friendly Version
June 03, 2013BioTime, Inc. to Raise $9 Million in Registered Direct Offering
ALAMEDA, Calif.--(BUSINESS WIRE)--Jun. 3, 2013-- BioTime, Inc. (NYSE MKT: BTX) today announced that it has agreed to sell up to an aggregate of 2,180,016 common shares and 545,004 warrants to purchase common shares, in “units” with each unit consisting of one common share and one-quarter of a warrant, at an offering price of $4.155 per unit. BioTime expects to receive gross proceeds of $9,057,966.48 from the sale of the common shares and warrants. The pr... 
Printer Friendly Version
May 23, 2013BioTime Announces Results of Vote at Special Meeting of Shareholders
Shareholders approve proposals related to the planned acquisition of stem cell assets of Geron Corporation by BioTime subsidiary Asterias Biotherapeutics, Inc. ALAMEDA, Calif.--(BUSINESS WIRE)--May. 23, 2013-- BioTime, Inc. (NYSE MKT: BTX) today announced that at a Special Meeting held on May 21, 2013, its shareholders approved the proposals related to the planned acquisition of stem cell related assets from Geron Corporation by BioTime’s subs... 
Printer Friendly Version
May 20, 2013BioTime CEO Dr. Michael West to Present at USC Minisymposium: Musculoskeletal Development and Repair
ALAMEDA, Calif.--(BUSINESS WIRE)--May. 20, 2013-- BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced that Chief Executive Officer Michael D. West, PhD will present at the USC Minisymposium: Musculoskeletal Development and Repair conference at the Keck School of Medicine, the University of Southern California, on Monday, May 20, 2013. Dr. West’s presentation titl... 
Printer Friendly Version
May 14, 2013BioTime Appoints Franklin Berger to Board of Directors
ALAMEDA, Calif.--(BUSINESS WIRE)--May. 14, 2013-- BioTime, Inc. (NYSE MKT: BTX) today announced that Franklin M. Berger, CFA, 63, has been appointed to its Board of Directors. “We are pleased to welcome a recognized biotechnology industry expert of Franklin's caliber to BioTime's Board,” said Alfred D. Kingsley, Chairman of the Board of BioTime. “Franklin adds to our Board a great deal of experience as a director of biotechnology companies, as an... 
Printer Friendly Version
May 10, 2013BioTime Announces First Quarter 2013 Financial Results and Recent Corporate Accomplishments
ALAMEDA, Calif.--(BUSINESS WIRE)--May. 10, 2013-- BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today reported financial results for the first quarter ended March 31, 2013 and highlighted recent corporate accomplishments. First Quarter and Recent Corporate Accomplishments Entered into an Asset Contribution Agreement with Geron Corporation ... 
Printer Friendly Version
May 07, 2013BioTime and Subsidiary LifeMap Sciences Announce Release of Enhanced LifeMap BioReagents™ Portal Offering Additional PureStem™ Human Progenitor Cells Including Those for Diabetes Research
ALAMEDA, Calif.--(BUSINESS WIRE)--May. 7, 2013-- BioTime, Inc. (NYSE MKT: BTX) and subsidiary, LifeMap Sciences, today announced the release of the enhanced LifeMap BioReagents™ portal (http://bioreagents.lifemapsc.com/) featuring an improved user interface, product descriptions, and customer support options, as well as the addition of new PureStem™ progenitor cells to the site. These novel progenitors provide new and unique tools for researchers ... 
Printer Friendly Version
April 29, 2013BioTime Announces CFO Succession Plan
Robert W. Peabody to become CFO on May 10, 2013 ALAMEDA, Calif.--(BUSINESS WIRE)--Apr. 29, 2013-- BioTime, Inc. (NYSE MKT: BTX) announced today that its Senior Vice President and Chief Operating Officer, Robert W. Peabody, will reassume the additional role of Chief Financial Officer on May 10, 2013. BioTime’s current Chief Financial Officer, Peter S. Garcia, has resigned his position with BioTime and its subsidiaries effective May 10, 2013. Mr... 
Printer Friendly Version
April 19, 2013BioTime Enters into Worldwide License Agreement with UCLA to Develop Therapy for the Treatment of Stroke
ALAMEDA, Calif.--(BUSINESS WIRE)--Apr. 19, 2013-- BioTime, Inc. (NYSE MKT: BTX) today announced that it has entered into an exclusive license agreement with the University of California, Los Angeles (UCLA) for novel technology related to the treatment of stroke. The licensed technology, developed in the laboratories of Tom Carmichael, MD, PhD of UCLA’s Department of Neurology, at the David Geffen School of Medicine, uses one of BioTime’s HyStem® h... 
Printer Friendly Version
March 18, 2013BioTime Announces Fourth Quarter and Fiscal Year End 2012 Financial Results and Recent Corporate Accomplishments
ALAMEDA, Calif.--(BUSINESS WIRE)--Mar. 18, 2013-- BioTime, Inc. (NYSE MKT: BTX), today reported financial results for the fourth quarter and year ended December 31, 2012 and highlighted its fourth quarter and recent corporate accomplishments. Fourth Quarter and Recent Highlighted Corporate Accomplishments Entered into a definitive agreement with Geron Corporation in which BioTime’s subsidiary BioTime Acquisition Corporatio... 
Printer Friendly Version
March 13, 2013BioTime to Present at 25th Annual ROTH Conference
ALAMEDA, Calif.--(BUSINESS WIRE)--Mar. 13, 2013-- BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced that Dr. Michael D. West, Chief Executive Officer, will present a corporate overview of BioTime and its subsidiaries at the 25th Annual ROTH Conference. The presentation will take place on Monday, March 18, 2013 at 5:30 p.m. PDT at The Ritz-Carlton, Laguna Ni... 
Printer Friendly Version
March 12, 2013BioTime Appoints Stephen C. Farrell to Board of Directors
ALAMEDA, Calif., Mar 12, 2013 (BUSINESS WIRE) --BioTime, Inc. (NYSE MKT: BTX) today announced that Stephen C. Farrell has been appointed to its Board of Directors. “We are pleased to welcome an experienced executive of Steve’s caliber to BioTime’s board,” said Alfred D. Kingsley, Chairman of the Board of BioTime. “Steve adds critical and highly relevant experience as a successful leader and director of healthcare companies during periods of rapid growth... 
Printer Friendly Version
March 07, 2013BioTime and Romulus Agree to Accelerate Closing Date for Second Tranche of $5 Million Financing
A total of $17.6 million in new capital raised by BioTime and its subsidiaries since October 2012 ALAMEDA, Calif.--(BUSINESS WIRE)--Mar. 7, 2013-- BioTime, Inc. (NYSE MKT: BTX) today announced it has amended its $5 million Stock and Warrant Purchase Agreement with Romulus Films, Ltd., originally signed on January 4, 2013. Through the amendment, BioTime and Romulus have agreed to accelerate the closing date for the $3 million second tra... 
Printer Friendly Version
March 04, 2013BioTime and Subsidiary LifeMap Sciences Announce Data Mining Collaboration
LifeMap Sciences’ discovery platform will be used to evaluate approximately 100 million proprietary gene expression data points relating to human embryonic stem cells generated by BioTime scientists ALAMEDA, Calif.--(BUSINESS WIRE)--Mar. 4, 2013-- BioTime, Inc. (NYSE MKT: BTX) and its bioinformatics subsidiary LifeMap Sciences, Inc. (“LifeMap”) today announced that they have entered into a definitive collaboration agreement to utilize LifeMap... 
Printer Friendly Version
January 18, 2013BioTime CEO Dr. Michael West to Present at Scale-Up and Manufacturing of Cell-Based Therapies II Conference
ALAMEDA, Calif.--(BUSINESS WIRE)--Jan. 18, 2013-- BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced that Chief Executive Officer Michael D. West, PhD will present at the Scale-Up and Manufacturing of Cell-Based Therapies II conference in San Diego, California on Monday, January 21, 2013. Dr. West’s presentation titled “hES-Derived Clonal Embryonic Progenito... 
Printer Friendly Version
January 10, 2013BioTime Submits Protocol for Initiation of Human Clinical Trials of Renevia™ in Europe
ALAMEDA, Calif.--(BUSINESS WIRE)--Jan. 10, 2013-- BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced it has submitted a Clinical Investigation Protocol (CIP) to European regulatory authorities for approval to initiate studies for its Renevia™ stem cell delivery platform. The Principal Investigator for the studies will be Ramon Llull, MD, and the planned tria... 
Printer Friendly Version
January 07, 2013BioTime Signs Definitive Agreement With Geron Regarding Stem Cell Assets
Investor Commits to $10 Million Financing ALAMEDA, Calif.--(BUSINESS WIRE)--Jan. 7, 2013-- BioTime, Inc. (NYSE MKT: BTX) and its recently formed subsidiary BioTime Acquisition Corporation (BAC) jointly announced today that they have entered into a definitive Asset Contribution Agreement with Geron Corporation (Nasdaq: GERN) to acquire the intellectual property, including patents and patent applications, and other assets related to Gero... 
Printer Friendly Version
December 20, 2012BioTime Announces the Appointment of Jeffrey Janus as Vice President
Adds senior executive with significant experience in sales and marketing of research products ALAMEDA, Calif.--(BUSINESS WIRE)--Dec. 20, 2012-- BioTime, Inc. (NYSE MKT: BTX) today announced the appointment of Jeffrey Janus as its Vice President of Sales and Marketing. Mr. Janus’ primary focus will be to create, market, and sell research products for BioTime and its subsidiaries in the expanding field of regenerative medicine. M... 
Printer Friendly Version
December 18, 2012BioTime Reports Isolation of Seven Diverse Cartilage and Bone Cell Types From Human Embryonic Stem Cells
ALAMEDA, Calif.--(BUSINESS WIRE)--Dec. 18, 2012-- BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, and its subsidiaries OrthoCyte Corporation and LifeMap Sciences reported today a means of manufacturing seven distinct types of cartilage, bone, and tendon cells from human embryonic stem cells. The paper, scheduled to be published online (ahead of print) at 1600 GMT today i... 
Printer Friendly Version
December 04, 2012BioTime CEO Dr. Michael West Presents Product Development Update at World Stem Cell Summit 2012
ALAMEDA, Calif.--(BUSINESS WIRE)--Dec. 4, 2012-- BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, announced that Chief Executive Officer Michael D. West, Ph.D. will provide an update today on five products being developed by BioTime and its subsidiaries during a presentation at the World Stem Cell Summit 2012 in West Palm Beach, Florida in the session on “Developing Combi... 
Printer Friendly Version
November 29, 2012BioTime CEO Dr. Michael West to Present at World Stem Cell Summit 2012
ALAMEDA, Calif.--(BUSINESS WIRE)--Nov. 29, 2012-- BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced that Chief Executive Officer Michael D. West, Ph.D. will present at the World Stem Cell Summit 2012 in West Palm Beach, Florida on Tuesday, December 4, 2012. Dr. West will be presenting in the session on “Developing Combination Products: Cells, Genes, and Dev... 
Printer Friendly Version
November 26, 2012BioTime Announces Passing of Director Abraham E. Cohen
ALAMEDA, Calif.--(BUSINESS WIRE)--Nov. 26, 2012-- BioTime, Inc. (NYSE MKT: BTX) announced with sadness that Abraham (Barry) E. Cohen, a member of its Board of Directors, passed away on Thursday, November 22, 2012 at the age of 76. Mr. Cohen has been a valued member of the Board of Directors and was a member of several committees, including the Audit Committee. Mr. Cohen had a long career in the pharmaceutical industry, where he played a key ... 
Printer Friendly Version
November 15, 2012BioTime and BioTime Acquisition Corporation Announce Combined $10 Million Financing
ALAMEDA, Calif.--(BUSINESS WIRE)--Nov. 15, 2012-- BioTime, Inc. (NYSE MKT: BTX) and its recently formed subsidiary BioTime Acquisition Corporation (BAC) jointly announced today that they have entered into a non-binding letter of intent for a $10 million investment from a private investor to provide financing for the recently announced proposed acquisition of Geron Corp.’s stem cell assets by BAC. Under the terms outlined in the letter of inte... 
Printer Friendly Version
November 15, 2012BioTime Announces Non-Binding Letter of Intent with Geron Regarding Stem Cell Assets
ALAMEDA, Calif.--(BUSINESS WIRE)--Nov. 15, 2012-- BioTime, Inc. (NYSE MKT: BTX) and its recently formed subsidiary BioTime Acquisition Corporation (BAC) jointly announced today that they have entered into a non-binding letter of intent (LOI) with Geron Corporation. The LOI contains broad terms of a potential transaction through which Geron would contribute to BAC its intellectual property and other assets related to Geron’s discontinued human embryon... 
Printer Friendly Version
November 14, 2012BioTime and Subsidiary LifeMap Sciences Announce the Launch of LifeMap BioReagents™ Portal
ALAMEDA, Calif.--(BUSINESS WIRE)--Nov. 14, 2012-- BioTime, Inc. (NYSE MKT: BTX) and its subsidiary LifeMap Sciences have announced the launch of LifeMap BioReagents™ (http://bioreagents.lifemapsc.com/), a new portal offering researchers access to BioTime’s research product lines including PureStem™ human progenitor cell lines, PureStem™ packages, clinical and research grade human embryonic stem cell lines (hES), HyStem® hydrogels, culture media, and ... 
Printer Friendly Version
November 09, 2012BioTime Announces Third Quarter 2012 Financial Results and Recent Corporate Accomplishments
ALAMEDA, Calif.--(BUSINESS WIRE)--Nov. 9, 2012-- BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today reported financial results for the third quarter and year-to-date period ended September 30, 2012 and highlighted recent corporate accomplishments. Financial Results Net Loss Net loss attributable to BioTime for the third quarter of 2012 w... 
Printer Friendly Version
November 07, 2012BioTime and Subsidiary Cell Cure Neurosciences Ltd. Announce Financing
ALAMEDA, Calif. & JERUSALEM--(BUSINESS WIRE)--Nov. 7, 2012-- BioTime, Inc. (NYSE MKT: BTX) and its subsidiary Cell Cure Neurosciences Ltd. (Cell Cure) today announced that they have entered into a share purchase agreement through which BioTime agreed to purchase 87,456 Cell Cure ordinary shares in exchange for 906,735 BioTime common shares. As a result of the share purchase, BioTime will own, directly and through its wholly owned subsidiary ES Ce... 
Printer Friendly Version
October 18, 2012BioTime, Inc. Issues Open Letter to Shareholders of Geron Corporation
ALAMEDA, Calif.--(BUSINESS WIRE)--Oct. 18, 2012-- BioTime, Inc. (NYSE MKT: BTX) today issued the following letter to the shareholders of Geron Corporation (Nasdaq: GERN) regarding Geron’s stem cell assets: October 18, 2012 AN OPEN LETTER TO GERON SHAREHOLDERS Dear Geron Shareholders: As you know, during November 2011, Geron Corporation (Nasdaq: GERN) announced that it was discontinuing its stem cell resea... 
Printer Friendly Version
September 28, 2012BioTime Forms BioTime Acquisition Corporation
Subsidiary will seek to acquire assets and businesses in the stem cell and regenerative medicine fields Dr. Thomas Okarma appointed Chief Executive Officer of the new company ALAMEDA, Calif.--(BUSINESS WIRE)--Sep. 28, 2012-- BioTime, Inc. (NYSE MKT: BTX), an Alameda-based company engaged in research and development of innovative new products in the field of regenerative medicine utilizing stem cells and related technology, anno... 
Printer Friendly Version
September 19, 2012BioTime CEO Michael D. West to Present at Stem Cells USA & Regenerative Medicine Congress 2012
ALAMEDA, Calif.--(BUSINESS WIRE)--Sep. 19, 2012-- BioTime, Inc. (NYSE MKT: BTX) announced that Chief Executive Officer Michael D. West, Ph.D. will present at the Stem Cells USA & Regenerative Medicine Congress 2012 in Cambridge, MA on Thursday, September 20, 2012. Dr. West will speak on “Second Generation hES Cell-Based Therapies: Achieving Purity and Scalability in the Midst of Diversity” in the session Developments in Novel Therapeutics.... 
Printer Friendly Version
August 27, 2012BioTime Obtains Expanded License to HyStem® Technology
- BioTime now holds exclusive worldwide license for all human medical applications of the core HyStem® technology - ALAMEDA, Calif.--(BUSINESS WIRE)--Aug. 27, 2012-- BioTime, Inc. (NYSE MKT: BTX) announced that the company has amended its license from the University of Utah to expand the field of use for which BioTime is licensed to produce and market products covered by the core patents underlying HyStem® technology. Under the ... 
Printer Friendly Version
August 16, 2012BioTime and OncoCyte Corporation Publish Data on the Gene COL10A1 as a Marker and Potential Diagnostic for a Wide Array of Human Cancers
Collagen Type X determined to be a protein specifically associated with tumor vasculature Antibodies to detect the protein planned to be one component of PanC-DxTM, a blood-based screen for multiple types of solid tumors ALAMEDA, Calif.--(BUSINESS WIRE)--Aug. 16, 2012-- BioTime, Inc. (NYSE MKT: BTX) and BioTime’s subsidiary OncoCyte Corporation today announced the publication of a scientific rep... 
Printer Friendly Version
August 09, 2012BioTime Announces Second Quarter 2012 Financial Results and Recent Corporate Accomplishments
ALAMEDA, Calif.--(BUSINESS WIRE)--Aug. 9, 2012-- BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today reported financial results for the second quarter ended June 30, 2012 and highlighted recent corporate accomplishments. Financial Results Net Loss Net loss attributable to BioTime, Inc. for the second quarter of 2012 was $5.5 millio... 
Printer Friendly Version
July 17, 2012BioTime Signs Agreements with Jade Therapeutics for Ophthalmological Drug Delivery Applications of HyStem® Technology
ALAMEDA, Calif.--(BUSINESS WIRE)--Jul. 17, 2012-- BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced the signing of an exclusive sublicense agreement and a supply agreement with Jade Therapeutics, LLC, a developer of an ophthalmological therapeutic sustained-release drug delivery platform. Under the agreements, BioTime will provide Jade with clinical-grade H... 
Printer Friendly Version
July 16, 2012BioTime CEO Dr. Michael West to Present at the 2012 Agora Financial Investment Symposium
ALAMEDA, Calif.--(BUSINESS WIRE)--Jul. 16, 2012-- BioTime, Inc. (NYSE MKT:BTX) announced today that Chief Executive Officer Michael D. West, Ph.D. will present at the 2012 Agora Financial Investment Symposium on Tuesday, July 24, 2012, 4:40 p.m. PDT, at the Fairmont Hotel in Vancouver, British Columbia, Canada. Dr. West will speak on “The Stem Cell Revolution: Designing First-in-Class Therapies for Age-Related Degenerative Disease,” including an upda... 
Printer Friendly Version
May 30, 2012BioTime CEO Dr. Michael West to Present at the Jefferies 2012 Global Healthcare Conference
ALAMEDA, Calif.--(BUSINESS WIRE)--May. 30, 2012-- BioTime, Inc. (NYSE MKT: BTX) announced that its Chief Executive Officer, Michael D. West, Ph.D., will provide a corporate update at the Jefferies 2012 Global Healthcare Conference in New York City on Monday, June 4, 2012 at 3:30 p.m. ET. The presentation will be webcast and may be accessed at http://wsw.com/webcast/jeff68/btx/ or under “Investor Presentations” on BioTime's website at www.biot... 
Printer Friendly Version
May 23, 2012BioTime and Subsidiary LifeMap Sciences, Inc. Announce Release of GeneCards® Version 3.08
ALAMEDA, Calif. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--May. 23, 2012-- XenneX, a Division of LifeMap Sciences, Inc. and BioTime, Inc. (NYSE Amex:BTX), announced today the release of GeneCards®, Version 3.08, on May 20, 2012. The new release is available at www.genecards.org. The new GeneCards® release includes more than 94,500 gene entries. One of the important enhancements is the display of about 52,000 non-protein-coding RNA genes, more t... 
Printer Friendly Version
May 22, 2012BioTime and Subsidiary LifeMap Sciences, Inc. Announce Agreement to Market MalaCards - A Database of Human Diseases
ALAMEDA, Calif.--(BUSINESS WIRE)--May. 22, 2012-- BioTime, Inc. (NYSE MKT: BTX) today announced that its subsidiary LifeMap Sciences, Inc. has entered into a license agreement with Yeda Research and Development Company Ltd, the technology transfer arm of the Weizmann Institute of Science, to market a new database called MalaCards. A database of human diseases that is based on the GeneCards® platform, MalaCards contains computerized “cards” classifyin... 
Printer Friendly Version
May 21, 2012BioTime Completes Merger of XenneX, Inc. into LifeMap Sciences, Inc.
ALAMEDA, Calif.--(BUSINESS WIRE)--May. 21, 2012-- BioTime, Inc. (NYSE MKT: BTX) and its subsidiary LifeMap Sciences, Inc. today announced that they have completed the acquisition of XenneX, Inc. through a merger of XenneX into LifeMap Sciences. The definitive merger agreement was previously announced on April 20, 2012. LifeMap Sciences now holds the exclusive, worldwide licenses to market GeneCards® and PanDaTox from Yeda Research and Develop... 
Printer Friendly Version
May 14, 2012HyStem(R)-C Demonstrated Effective when Formulated with Human Heart Cells and Transplanted in an Animal Model of Heart Disease
ALAMEDA, Calif., May 14, 2012 (BUSINESS WIRE) --BioTime, Inc. (NYSE MKT: BTX) announced today the publication of a scientific paper demonstrating the effectiveness of HyStem(R)-C in the transplantation of heart muscle-derived cells in an animal model of heart disease. The paper, "Functional performance of human cardiosphere-derived cells delivered in an in situ polymerizable hyaluronan-gelatin hydrogel," is published online (ahead of print) in the ... 
Printer Friendly Version
May 10, 2012BioTime Announces First Quarter 2012 Financial Results and Recent Corporate Accomplishments
Alameda, Calif., May 10, 2012 - BioTime, Inc. (NYSE Amex: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today reported financial results for the first quarter ended March 31, 2012 and highlighted recent corporate accomplishments. Financial Results Net Loss Net loss attributable to BioTime, Inc. for the first quarter of 2012 was $5.0 million or $0.10 per share, compared to a net loss of $3.4 million or $0.07 per share for the same peri... 
Printer Friendly Version
April 23, 2012BioTime and its Subsidiary OrthoCyte Corporation Provides Update on Preclinical Development of OTX-CP07
ALAMEDA, Calif., Apr 23, 2012 (BUSINESS WIRE) --BioTime, Inc. (NYSE Amex: BTX) announced today that BioTime's CEO Michael West, Ph.D. will provide an update on the development of OTX-CP07 by BioTime's subsidiary OrthoCyte Corporation at an investor meeting in New York City. OTX-CP07 is a combination product with human embryonic cartilage progenitors manufactured from human embryonic stem cells formulated with BioTime's proprietary cell delivery device ReneviaTM. Dr. West will describe stu... 
Printer Friendly Version
April 23, 2012BioTime Provides Update on ReneviaTM Product Development
- Product development on track for CE Marking by 2013 - ALAMEDA, Calif., Apr 23, 2012 (BUSINESS WIRE) --BioTime, Inc. (NYSE Amex:BTX) announced today that William Tew, Ph.D., BioTime's Chief Commercial Officer will provide an update on the development of ReneviaTM (formerly known as HyStem(R)-Rx) at an investor meeting in New York City. In his presentation, Dr. Tew will discuss the global distribution network marketing the HyStem(R) line of rese... 
Printer Friendly Version
April 23, 2012BioTime Demonstrates Efficient Method for the Manufacture of Cartilage-Producing Cells from Human Embryonic Stem Cells
- First demonstration of a scalable source of highly purified and identified progenitor cells capable of making definitive (non-hypertrophic) cartilage - ALAMEDA, Calif., Apr 23, 2012 (BUSINESS WIRE) --BioTime, Inc. (NYSE Amex: BTX) and its wholly owned subsidiary OrthoCyte Corporation reported today a means of manufacturing cartilage from human embryonic stem cells that is suited for industrial scale-up of a product for the treatment of osteoar... 
Printer Friendly Version
April 20, 2012BioTime and Subsidiary LifeMap Sciences Announce Agreement to Acquire XenneX, Inc.
Acquisition will integrate GeneCards(R) and associated databases in a centralized resource called "LifeMap" LifeMap Sciences will use new family of online databases to promote the sale of stem cell research products and for discovery of regenerative medicine therapeutic products, based on BioTime's ACTCellerate(TM) human progenitor cell lines ALAMEDA, Calif. & CAMBRIDGE, Mass., Apr... 
Printer Friendly Version
April 18, 2012BioTime CEO Michael D. West to Present at the Future Leaders in the Biotech Industry Conference
ALAMEDA, Calif., Apr 18, 2012 (BUSINESS WIRE) --BioTime, Inc. (NYSE Amex:BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced that Chief Executive Officer Michael D. West, Ph.D. will present at the Future Leaders in the Biotech Industry conference on Friday, April 20, 2012, 9:00 a.m. EDT, at the Millennium Broadway Hotel in New York City. Dr. West will present a corporate overview of BioTim... 
Printer Friendly Version
April 16, 2012BioTime CEO Michael D. West to Present at the 8th GTC Stem Cell Summit 2012
ALAMEDA, Calif., Apr 16, 2012 (BUSINESS WIRE) --BioTime, Inc. (NYSE Amex: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced that Chief Executive Officer Michael D. West, Ph.D. will present at the 8th GTC Stem Cell Summit 2012 in Boston, Massachusetts at 3:45 p.m. EDT on Thursday, April 19, 2012. Dr. West will speak on recent trends in the stem cell industry and will provide an up... 
Printer Friendly Version
April 12, 2012BioTime Board of Directors Forms Science and Technology Committee
- Advancing product development efforts - ALAMEDA, Calif., Apr 12, 2012 (BUSINESS WIRE) --BioTime, Inc. (NYSE Amex:BTX) today announced that its Board of Directors has recently formed a Science and Technology Committee to oversee the development and commercialization of BioTime's technology and products in regenerative medicine and oncology. The three-member committee will work with officers and employees of BioTime and its subsidiaries to overs... 
Printer Friendly Version
March 21, 2012BioTime CEO Michael D. West to Present at 2012 Maxim Group Growth Conference
ALAMEDA, Calif.--(BUSINESS WIRE)--Mar. 21, 2012-- BioTime, Inc. (NYSE Amex:BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced that Chief Executive Officer, Michael D. West, Ph.D., will present a corporate overview of BioTime and its subsidiaries with an update on recent developments at the 2012 Maxim Group Growth Conference on Monday, March 26, 2012, 11:00 a.m. EDT, at the Gr... 
Printer Friendly Version
March 14, 2012 BioTime Announces Fourth Quarter and Fiscal Year End 2011 Financial Results and Recent Corporate Accomplishments
ALAMEDA, Calif.--(BUSINESS WIRE)--Mar. 14, 2012--  BioTime, Inc. (NYSE Amex: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today reported financial results for the fourth quarter and year ended December 31, 2011 and highlighted recent corporate accomplishments. "At the forefront of our corporate strategy is a plan to develop and acquire novel technologies in the stem cell field and to establish one of the broadest sets of capabilit... 
Printer Friendly Version
March 08, 2012BioTime to Present at ROTH 24th Annual Growth Stock Conference
ALAMEDA, Calif.--(BUSINESS WIRE)--Mar. 8, 2012-- BioTime, Inc. (NYSE Amex:BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced that Chief Financial Officer, Peter S. Garcia, will present a corporate overview of BioTime and its subsidiaries at the ROTH 24th Annual Growth Stock Conference. The presentation will take place on Tuesday, March 13, 2012, at 9:30 a.m. PDT at The Ritz-Carlton ... 
Printer Friendly Version
February 17, 2012BioTime CEO Michael D. West to Present at New York Stem Cell Summit
ALAMEDA, Calif.--(BUSINESS WIRE)--Feb. 17, 2012-- BioTime, Inc. (NYSE Amex: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced that Chief Executive Officer Michael D. West, Ph.D. will present at the 7th Annual New York Stem Cell Summit at Bridgewaters New York City on Tuesday, February 21, 2012 at 8:48 a.m. ET. Dr. West will provide an update and new information on the Compan... 
Printer Friendly Version
January 24, 2012BioTime Licenses Technology for Key Regulatory Gene Underlying Cancer and Stem Cell Reprogramming from The Wistar Institute
ALAMEDA, Calif.--(BUSINESS WIRE)--Jan. 24, 2012-- BioTime, Inc. (NYSE Amex:BTX) today announced that it has obtained an exclusive license from The Wistar Institute in Philadelphia, PA for technology related to a gene designated as SP100. Wistar Institute researchers have demonstrated pivotal roles for this gene in both cancer and stem cell biology. Scientists at BioTime’s subsidiaries OncoCyte Corporation and ReCyte Therapeutics plan to apply ... 
Printer Friendly Version
January 03, 2012BioTime to Produce Stem Cells for Research in Muscle Disorders
ALAMEDA, Calif.--(BUSINESS WIRE)--Jan. 3, 2012-- BioTime, Inc. (NYSE Amex: BTX) today announced that it has elected to market progenitors of muscle stem cells bearing hereditary diseases. BioTime will produce the products from five human embryonic stem (hES) cell lines from Reproductive Genetics Institute (RGI) of Chicago, Illinois. The muscle cell lines will display the genes for Duchenne muscular dystrophy, Emery-Dreifuss muscular dystrophy, spinal... 
Printer Friendly Version
December 21, 2011BioTime Signs Agreement with USCN Life Science to Source Antibody-Based Products
ALAMEDA, Calif.--(BUSINESS WIRE)--Dec. 21, 2011-- BioTime, Inc. (NYSE Amex: BTX) today announced agreements with USCN Life Science, Inc. (USCN) of Wuhan, China, granting BioTime an option to license USCN’s antibody-producing cell lines and certain related technology that may be used by BioTime and its subsidiary OncoCyte Corporation for the large-scale manufacture of the antibody components of PanC-DxTM. PanC-DxTM is a novel diagnostic technol... 
Printer Friendly Version
December 16, 2011BioTime's Subsidiary OncoCyte Corporation Announces Plans for the Novel Pan-Cancer Diagnostic Product PanC-DxTM
- A novel blood-based screening method for the early detection of many common human cancers such as those of the breast, colon, and lung - ALAMEDA, Calif., Dec 16, 2011 (BUSINESS WIRE) --BioTime, Inc. (NYSE Amex: BTX) and BioTime's subsidiary OncoCyte Corporation today announced plans for the development of PanC-DxTM, a novel diagnostic device discovered at BioTime and OncoCyte to detect the presence of various human cancers, including cancers of the br... 
Printer Friendly Version
December 12, 2011BioTime Successfully Completes HyStem®-Rx Preclinical ISO 10993 Studies
ALAMEDA, Calif.--(BUSINESS WIRE)--Dec. 12, 2011-- BioTime, Inc. (NYSE Amex: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced the successful completion of ISO 10993 biocompatibility studies for HyStem®-Rx. These tests, as prescribed by the International Organization for Standardization for permanent implantable medical devices, are required by the United States Food and Drug... 
Printer Friendly Version
November 29, 2011BioTime, Inc. Appoints Andrew C. von Eschenbach, M.D. to its Board of Directors
ALAMEDA, Calif., Nov 29, 2011 (BUSINESS WIRE) --BioTime, Inc. (NYSE Amex: BTX) and BioTime's subsidiary, OncoCyte Corporation, today announced they have each appointed Dr. Andrew von Eschenbach to their boards of directors. Dr. von Eschenbach is the President of Samaritan Health Initiatives, Inc., a health care policy consultancy, and is an Adjunct Professor at University of Texas MD Anderson Cancer Center. From September of 2005 to January 2009, Dr. ... 
Printer Friendly Version
November 14, 2011BioTime Cell Information Now Available in GeneCards(R)
- New GeneCards® release includes gene expression markers for BioTime’s ACTCellerateTM cell lines - ALAMEDA, Calif. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 14, 2011-- BioTime, Inc. (NYSE Amex: BTX) and XenneX, Inc. today announced the inclusion of cell identification data in GeneCards® 3.07 available at www.genecards.org. The new GeneCards release identifies BioTime’s ACTCellerate™ human embryonic progenitor (hEP) cell lines that... 
Printer Friendly Version
November 08, 2011BioTime Announces Third Quarter 2011 Financial Results and Recent Corporate Accomplishments
BioTime, Inc. (NYSE Amex:BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today reported financial results for the third quarter and nine months ended September 30, 2011 and highlighted recent corporate accomplishments. "The key to building the leading company in the emerging field of regenerative medicine is the identification of a strategy for the rapid development and commercialization of significant therapeutic products. Our s... 
Printer Friendly Version
October 25, 2011BioTime CEO Michael D. West to Present Keynote Address at Translational Strategies for Tissue Engineering Conference
BioTime, Inc. (NYSE Amex:BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced that Chief Executive Officer Michael D. West, Ph.D. will present a keynote address at the Translational Strategies for Tissue Engineering Conference in Boston, MA at 9:30 a.m. EDT on Tuesday, November 1, 2011. Dr. West's presentation will be titled: "Cell and Matrix: Translational Strategies in the Era of Pluripotency." He will discu... 
Printer Friendly Version
October 13, 2011BioTime Publishes Paper Describing First Complete Sequencing of the Nuclear DNA of Five Clinical-Grade Human Embryonic Stem Cell Lines
Study shows normal gene content of the cells and potential suitability for use in the manufacture of human therapeutics BioTime, Inc. (NYSE Amex:BTX) announced today the publication in the peer-reviewed journalStem Cell Research of the complete genome sequence analysis of five clinical-grade human embryonic stem cell lines. "Evaluating the Genomic and Sequence Integrity of Human ES Cell Lines: Comparison to Normal Genomes" is the first such analysis of the entire genome of huma... 
Printer Friendly Version
October 10, 2011BioTime CEO Michael D. West to Present at GTC 2011 5th Advances in Stem Cell Discovery & Development Conference
BioTime, Inc. (NYSE Amex:BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced that Chief Executive Officer Michael D. West, Ph.D. will present at the GTC 2011 5th Advances in Stem Cell Discovery & Development Conference in San Diego, California at 9:10 a.m. PDT on Thursday, October 20, 2011. Dr. West will speak on recent trends in the stem cell industry and BioTime's strategies in product development. The ... 
Printer Friendly Version
October 04, 2011BioTime Announces Appointment of Chief Financial Officer
- Peter Garcia brings 25 years of public and private life science and high-tech finance experience - BioTime, Inc. (NYSE Amex: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced the appointment of Peter Garcia to the position of Chief Financial Officer. Mr. Garcia, age 50, will lead the accounting, finance, and investor relations functions of the Company, will report directly to Michael D. West, Ph.D., President an... 
Printer Friendly Version
September 29, 2011BioTime CEO Dr. Michael West to Present at 2011 World Stem Cell Summit
BioTime, Inc. (NYSE Amex: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced that Chief Executive Officer Michael D. West, Ph.D. will present at the 2011 World Stem Cell Summit in Pasadena, California at 2:30 p.m. PDT on Monday, October 3, 2011. Dr. West will be presenting "Unleashing Regenerative Medicine to Extend the Healthy Lifespan: Technological Issues and Commercial Opportunities" which will include a... 
Printer Friendly Version
September 12, 2011BioTime CEO Michael D. West to Present at Stem Cells USA & Regenerative Medicine Congress 2011
BioTime, Inc. (NYSE Amex:BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced that Chief Executive Officer Michael D. West, Ph.D. will present at the Stem Cells USA & Regenerative Medicine Congress 2011 in Boston, MA at 9:35 a.m. EDT on Wednesday, September 14, 2011. Dr. West's presentation, "A roadmap for successful commercialization of hES and iPS cell-based therapies," will include a discussion of the n... 
Printer Friendly Version
September 06, 2011BioTime Enters into Worldwide License Agreement with Cornell University to Develop and Commercialize Vascular Cells Derived from Human Embryonic Stem Cells
Technology to be utilized in product development by BioTime's subsidiaries OncoCyte Corporation and ReCyte Therapeutics, Inc. BioTime, Inc. (NYSE Amex:BTX) today announced it has entered into an exclusive license agreement with Cornell University for the worldwide development and commercialization of technology developed at Weill Cornell Medical College for the differentiation of human embryonic stem cells into vascular endothelial cells. Published last year in Nature Biotechno... 
Printer Friendly Version
September 01, 2011BioTime CEO Michael D. West to Present at Rodman & Renshaw 13th Annual Healthcare Conference
BioTime, Inc. (NYSE Amex: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced that Chief Executive Officer Michael D. West, Ph.D. will present at the Rodman & Renshaw 13th Annual Healthcare Conference at 4:05 p.m. EDT on Tuesday, September 13, 2011. The conference will be held at The Waldorf Astoria Hotel in New York. Dr. West will provide updates on product development by BioTime and its subsidiaries Onc... 
Printer Friendly Version
August 24, 2011BioTime's Subsidiary OncoCyte Corporation Expands Cancer Programs with $10 Million Equity Financing
Capital to be utilized in advancing the development of novel cancer diagnostic and therapeutic products BioTime, Inc. (NYSE Amex:BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced its majority-owned subsidiary OncoCyte Corporation (OncoCyte) has received a new round of equity financing to fund expansion of its development of novel proprietary diagnostics and therapeutics for cancer in humans. The financing included... 
Printer Friendly Version
August 19, 2011BioTime Receives NIH Approval for Four GMP Human Embryonic Stem Cell Lines
ESI-035, ESI-049, ESI-051 and ESI-053 approved for use in federally funded research BioTime, Inc. (NYSE Amex:BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced that four human embryonic stem (hES) cell lines: ESI-035, ESI-049, ESI-051 and ESI-053, developed by a BioTime subsidiary have been approved by the National Institutes of Health (NIH) for inclusion in the NIH Human Embryonic Stem Cell Registry. This approval... 
Printer Friendly Version
August 09, 2011BioTime Announces Second Quarter 2011 Financial Results and Corporate Developments
BioTime, Inc. (NYSE Amex: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today reported financial results for the quarter ended June 30, 2011 and provided an update on corporate developments. For the quarter ended June 30, 2011, total revenue (including royalties from product sales and other revenue, revenue recognition of deferred license fees and grant income) was $756 thousand, up 11% from $680 thousand for the same period on... 
Printer Friendly Version
July 21, 2011BioTime CEO Dr. Michael West to Present at the Agora Financial Investment Symposium 2011
BioTime, Inc. (NYSE Amex:BTX) announced today that Chief Executive Officer Michael D. West, Ph.D. will present at the Agora Financial Investment Symposium 2011 in Vancouver, British Columbia, Canada on Thursday, July 28, 2011. The title of Dr. West's presentation will be "The Stem Cell Revolution: Designing First-in-Class Therapies for Age-Related Degenerative Disease." In this presentation Dr. West will describe new corporate developments at BioTime and its subsidiaries. Dr. West's pres... 
Printer Friendly Version
July 19, 2011BioTime Announces the Issuance of a Second U.S. Glycosan Hydrogel Patent
BioTime, Inc. (NYSE Amex: BTX) announced today the issuance of United States patent number 7,981,871 titled "Modified Macromolecules and Associated Methods of Synthesis and Use," covering aspects of the composition of Glycosan hydrogels. The patent and related patent family members, assigned to the University of Utah, are licensed to BioTime's subsidiary OrthoCyte Corporation for the manufacture of research products and for therapeutic uses when combined with human cells by BioTime or it... 
Printer Friendly Version
July 15, 2011BioTime Receives $335,900 SBIR Grant
HyStem® microcarrier hydrogels to be developed for stem cell research and therapeutic applications BioTime, Inc. (NYSE Amex:BTX) today announced it has been awarded a 10-month, $335,900 Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH) to develop HyStem® microcarriers for the propagation of human stem cells and as a means of cell delivery for human clinical applications. "Hundreds of millions of stem cells will be required for many of the cl... 
Printer Friendly Version
June 29, 2011BioTime Announces Appointment of Chief Commercial Officer
William P. Tew, Ph.D. will lead commercial efforts for BioTime and its subsidiaries BioTime, Inc. (NYSE Amex:BTX) today announced the appointment of its Vice President of Business Development, William P. Tew, Ph.D., to the additional position of Chief Commercial Officer. Dr. Tew will be responsible for the commercial operations of the BioTime family of companies and for near-term product development activities. Dr. Tew's commercial team will expand the depth and breadth of the BioTime c... 
Printer Friendly Version
June 09, 2011BioTime Reports First Complete Sequencing of the Nuclear Genome of Five GMP-Compliant Human Embryonic Stem Cell Lines at Jefferies 2011 Global Healthcare Conference
Complete sequencing of DNA shows normality of the cells and their suitability for clinical use BioTime, Inc. (NYSE Amex:BTX) Chief Executive Officer, Michael D. West, Ph.D., will present today at the Jefferies 2011 Global Healthcare Conference in New York City at 1:00 p.m. EDT. His presentation will disclose commercial progress in each of the Company's seven subsidiaries. Included in this update will be information on the first complete sequencing of the DNA of five human embryonic stem... 
Printer Friendly Version
June 03, 2011BioTime Receives NIH Approval for Two GMP Human Embryonic Stem Cell Lines
ESI-014 and ESI-017 approved for use in Federally funded research BioTime, Inc. (NYSE Amex:BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced that two human embryonic stem (hES) cell lines, ESI-014 and ESI-017, developed by a BioTime subsidiary have been approved by the National Institutes of Health (NIH) for inclusion in the NIH Human Embryonic Stem Cell Registry. This approval opens the door to the use of these cell ... 
Printer Friendly Version
June 02, 2011BioTime CEO Dr. Michael West to Present at the Jefferies 2011 Global Healthcare Conference
BioTime, Inc. (NYSE Amex: BTX) Chief Executive Officer, Michael D. West, Ph.D., is scheduled to speak during the Jefferies 2011 Global Healthcare Conference June 6-9, 2011 in New York City. Dr. West will present on Thursday, June 9 at 1:00 p.m. EDT. He will discuss BioTime's business in regenerative medicine and provide an update on recent progress in developing its stem cell-based products. A link to the live webcast of the company's presentation will be available in the investors sect... 
Printer Friendly Version
May 10, 2011BioTime Announces Issuance of U.S. Glycosan Hydrogel Patent
BioTime, Inc. (NYSE Amex:BTX) announced today the issuance of United States patent number 7,928,069 covering certain aspects of the composition of Glycosan hydrogels. The patent and related patent family members, assigned to the University of Utah, are licensed to BioTime's subsidiary OrthoCyte Corporation for the manufacture of research products and for therapeutic uses when combined with human cells by BioTime or its subsidiaries. The patent is of strategic value to the BioTime family ... 
Printer Friendly Version
May 05, 2011BioTime Announces First Quarter 2011 Financial Results and Corporate Developments
BioTime, Inc. (NYSE Amex:BTX), a biotechnology company that develops and markets products in the field of stem cells and regenerative medicine and blood plasma volume expander solutions, today reported financial results for the quarter ended March 31, 2011 and provided an update on corporate developments. For the quarter ended March 31, 2010, total revenue (including royalties from product sales and other revenue, revenue recognition of deferred license fees and grant income) was $825 t... 
Printer Friendly Version
May 03, 2011BioTime Initiates Clinical Development Program for HyStem®-Rx as a Cell Delivery Device for Reconstructive Surgery and Other Cell-Based Therapies
BioTime, Inc. (NYSE Amex:BTX) announced today that it has elected to seek regulatory approval of HyStem®-Rxas an implantable cell delivery vehicle that can be used to significantly improve outcomes in reconstructive surgery and potentially a wide array of other cell-based therapies. Such applications may include numerous cell transplant procedures currently being developed in which a patient's own adult stem cells are utilized. Similarly, once newer cell replacement products derived from... 
Printer Friendly Version
April 12, 2011BioTime Presents Data at FABS 2011 on the Restoration of Cell Lifespan Using iPS Cell Technology
Restoration of Replicative Lifespan in Five Human Cell Types Validates Previous Published Report of Reversal of Developmental Aging by Transcriptional Reprogramming BioTime, Inc. (NYSE Amex:BTX) and its subsidiary ReCyte Therapeutics, Inc. announced that today, BioTime CEO Dr. Michael West will present at the French-American Biotech Symposium(FABS 2011) on "New Therapeutic Approaches of Aging" held in San Francisco, CA, showing data for the first time on the restoration of cell lif... 
Printer Friendly Version
April 05, 2011BioTime and XenneX Form LifeMap Sciences, Inc. to Create Roadmap for Regenerative Medicine
Database to promote the marketing of BioTime's research products BioTime, Inc. (NYSE Amex: BTX), a biotechnology company that develops and markets products in the field of stem cells and regenerative medicine, today announced it has formed LifeMap Sciences, Inc., in collaboration with XenneX, Inc. LifeMap Sciences will develop and commercialize a database of the thousands of cell lineages branching from embryonic stem cells, and their molecular markers. LifeMap Sciences plans to make ... 
Printer Friendly Version
March 22, 2011BioTime Announces the Closing of the Merger of Glycosan BioSystems with OrthoCyte Corporation
William P. Tew, Ph.D. Becomes Vice President, Business Development of BioTime and OrthoCyte BioTime, Inc. (NYSE Amex: BTX), a biotechnology company that develops and markets products in the fields of stem cells, regenerative medicine and blood plasma volume expanders today announced it has completed the merger of Glycosan BioSystems, Inc. into BioTime's wholly-owned subsidiary OrthoCyte Corporation. The definitive merger agreement was previously announced on February 14, 2011. OrthoCyt... 
Printer Friendly Version
March 15, 2011BioTime Announces Fourth Quarter and Fiscal Year 2010 Financial Results and Corporate Developments
89% Increase in Total Revenue Year-over-Year for the Quarter 91% Increase in Total Revenues Year-over-Year for the Fiscal Year BioTime, Inc. (NYSE Amex:BTX), a biotechnology company that develops and markets products in the field of stem cells and regenerative medicine and blood plasma volume expander solutions, today reported financial results for the quarter and year ended December 31, 2010 and provided an update on corporate developments. Fourth Quarter 2010 For the quarter ended ... 
Printer Friendly Version
March 04, 2011BioTime CEO Michael West to Present at French-American Biotech Symposium, San Francisco, April 11-12, 2011
Update on ReCyte™ technology for resetting telomere length and its application in cardiovascular disease BioTime, Inc. (NYSE Amex:BTX) and its subsidiary ReCyte Therapeutics, Inc. announced today that BioTime CEO Dr. Michael West will present at the French-American Biotech Symposium on "New Therapeutic Approaches of Aging" in San Francisco, April 11-12, 2011. Dr. West will speak on "Resetting Telomere Length using Transcriptional Reprogramming and its Application in Age-Related Degenera... 
Printer Friendly Version
February 14, 2011BioTime Announces Agreement To Acquire Glycosan BioSystems
Acquisition to accelerate BioTime's development of tissue engineered therapeutic products and expand research product portfolio BioTime, Inc. (NYSE Amex:BTX), a biotechnology company that develops and markets products in the field of stem cells and regenerative medicine, today announced it has signed a definitive agreement to merge Utah-based Glycosan BioSystems, Inc. (Glycosan) with BioTime's wholly-owned subsidiary, OrthoCyte Corporation. The acquisition is expected to close by March ... 
Printer Friendly Version
January 28, 2011BioTime Acquires Assets of Cell Targeting, Inc.
--Proprietary technology "paints" cells with peptides to target them to diseased tissues-- BioTime, Inc. (NYSE Amex:BTX) today announced that it has acquired substantially all the assets of Cell Targeting, Inc. (CTI), a Cleveland, Ohio-based biotechnology company conducting research in regenerative medicine. The technology acquired from CTI uses peptides selected for their ability to adhere to diseased tissues. By coating or "painting" these peptides onto the surfaces of therapeutic cel... 
Printer Friendly Version
January 21, 2011BioTime Launches New Stem Cell Lines in Anticipation of President Obama's Removal of Restrictions on Federal Funding of Embryonic Stem Cell Research
New Cell Line Products to be Presented at Stem Cells World Conference BioTime, Inc. (OTCBB:BTIM) Chief Executive Officer Michael West, Ph.D., will deliver a presentation on January 21, 2009 at the Select Biosciences Stem Cells World Congress meeting in Palm Springs, California. Dr. West's presentation is titled "Embryomics: High Throughput Generation and Mapping of Embryonic Progenitors." This year's conference will focus on new technologies in stem cell research and developm... 
Printer Friendly Version
January 10, 2011BioTime's CEO Michael West to Present Preclinical Data on OTX-CP03 and OTX-CP07 for the Treatment of Osteoarthritis at STEM 2011 in Gurgaon, India
BioTime, Inc. (NYSE Amex:BTX) and its subsidiary OrthoCyte Corporation announced today that BioTime's CEO Dr. Michael West will present at STEM 2011 in Gurgaon, India on January 31, 2011. The conference is the 7th Annual Conference on Biotechnology sponsored by the Society for Regenerative Medicine and Tissue Engineering. Dr. West's presentation titled, "Progress in the commercialization of human embryonic stem cell technology" will disclose animal preclinical data on the ... 
Printer Friendly Version
January 03, 2011BioTime Subsidiary ReCyte Therapeutics, Inc. to Develop Therapies for Age-Related Cardiovascular and Blood Disorders
$4 Million Equity Financing Company Plans Near-Term Commercialization of iPS Cell Banking Services that Reverse the Developmental Aging of Human Cells BioTime, Inc. (NYSE Amex:BTX) today announced a $4 million equity financing by its subsidiary, Embryome Sciences, Inc. Concurrent with the financing, Embryome Sciences will be renamed ReCyte Therapeutics, Inc. and will develop therapeutic products for cardiovascular and blood diseases. The new equity financing is being led by a $2.5 mill... 
Printer Friendly Version
December 22, 2010BioTime, Inc. and the University of California System Sign Cell Transfer Agreement for Human Embryonic Stem Cell Lines
BioTime, Inc. (NYSE Amex: BTX) today announced a material transfer agreement (MTA) with the University of California (UC) system to make five research-grade human embryonic stem (hES) cell lines available to UC system researchers. These lines are genetically identical to a bank of GMP-compliant hES cell lines that will be made available to California-based researchers under a recent agreement between BioTime and the California Institute for Regenerative Medicine (CIRM). Institutions cove... 
Printer Friendly Version
December 09, 2010BioTime Asia, Limited and Shanghai Genext Medical Technology Co., Ltd. Sign Marketing Agreement for ACTCellerate™ Cell Lines
BioTime Asia, Limited, a subsidiary of BioTime, Inc. (NYSE Amex:BTX) today announced an agreement with Shanghai Genext Medical Technology Co., Ltd. to sell ACTCellerate™ cell lines to the medical and biological research communities in China, Taiwan, Hong Kong, and Macau. In addition to a wide array of human cell types, Genext will market cell culture media customized for each line. The marketing agreement includes provisions for an initial stocking inventory and annual milestones to main... 
Printer Friendly Version
December 03, 2010BioTime Plans Warrant Distribution to Shareholders
BioTime, Inc. (NYSE Amex: BTX) today announced that it plans to distribute new common share purchase warrants to the holders of BioTime common shares. Under the plan, shareholders will receive one warrant for every eight shares held. Each warrant will entitle the holder to purchase one common share for $12.00 per share. The warrants will expire four years after the date of issue. BioTime's Board of Directors has not yet set a record date for determining shareholders entitled to receive t... 
Printer Friendly Version
November 29, 2010BioTime, Inc. and the California Institute for Regenerative Medicine Sign Distribution Agreement for GMP-Compliant Human Embryonic Stem Cell Lines
BioTime, Inc. (NYSE Amex: BTX) today announced an agreement with the California Institute for Regenerative Medicine (CIRM) to make five clinical-grade human embryonic stem (hES) cell lines available to California-based researchers. CIRM is the stem cell agency created when California voters supported a $3 billion funding measure for stem cell-related research and clinical translation. Under the agreement, BioTime will initially provide research grade cell lines, and within one year, BioT... 
Printer Friendly Version
November 15, 2010BioTime Announces Third Quarter 2010 Financial Results and Recent Corporate Developments
82% Increase in Total Revenue Year-over-Year for the Quarter 92% Increase in Total Revenues Year to Date over Last Year BioTime, Inc. (NYSE Amex: BTX) today reported financial results for the quarter ended September 30, 2010 and provided an update on recent corporate developments. For the nine months ended September 30, 2010, total revenue (including royalty income, revenue recognition of deferred license fees, grant income, and sale of research products) was $2,261,375, up 92% from $... 
Printer Friendly Version
November 10, 2010BioTime's CEO Michael West to Present Keynote Address at BIT Life Sciences' 3rd Annual World Congress of Regenerative Medicine & Stem Cells 2010 in Shanghai, China
BioTime, Inc. (NYSE Amex: BTX) announced today that BioTime's CEO Dr. Michael West will present the keynote address at the BIT Life Sciences' 3rd Annual World Congress of Regenerative Medicine & Stem Cells 2010 in Shanghai, China on December 5, 2010. Dr. West's presentation will be titled "Regenerative Medicine: A Force for Change in Biotechnology." During his talk, Dr. West will present a group of new research products that the Company's subsidiary Embryome Sciences, Inc. ... 
Printer Friendly Version
November 04, 2010BioTime Announces Final Results of Warrant Exercises
BioTime, Inc. (NYSE Amex:BTX) today announced that in the last 18 months it has received cumulative total proceeds of $24,174,733 from exercises of warrants that expired November 1, 2010. A remaining 24,976 common share purchase warrants expired unexercised. BioTime now has approximately $32 million of cash on hand on a consolidated basis. BioTime plans to use the capital raised through the warrant exercises to strengthen its working capital reserves and for the expansion of its stem ce... 
Printer Friendly Version
November 03, 2010BioTime, Inc. Awarded $733,000 in Grants Under Qualifying Therapeutic Discovery Project Program
- Funding advances BioTime's therapeutic programs - ALAMEDA, Calif.--(BUSINESS WIRE)-- BioTime, Inc. (NYSE Amex: BTX) announced today that it has been awarded three grants totaling approximately $733,000 under the U.S. Government's Qualifying Therapeutic Discovery Project ("QTDP") program. The QTDP program was part of the Patient Protection and Affordable Care Act signed into law on March 23, 2010. The QTDP was created by Congress to support investment in qualified biomedical proje... 
Printer Friendly Version
October 26, 2010BioTime Expands Corporate Headquarters
- An Additional 6,000 Square Feet of Facilities for Therapeutic Product Development - ALAMEDA, Calif., Oct 26, 2010 (BUSINESS WIRE) --BioTime Inc. (NYSE Amex: BTIM) announced today it is expanding its corporate headquarters and laboratory facility in Alameda, California and has signed a new Lease Agreement effective December 1, 2010 for an initial five-year term, with an option to renew the lease for an additional five years. The new lease extends BioTi... 
Printer Friendly Version
October 22, 2010BioTime's CEO Michael West Presents 12 New ACTCellerateTM Cell Lines and New PureStemTM Products Slated for Launch in 2011 at GTCbio Stem Cell Conference Today
ALAMEDA, Calif., Oct 22, 2010 (BUSINESS WIRE) --BioTime, Inc. (NYSE Amex:BTIM) announced that the Company's CEO Dr. Michael West will present data today relating to 12 new cell lines, differentiation kits, and cell culture media at the GTCbio 4th Advances in Stem Cell Discovery and Development Conference in San Francisco, California. Dr. West's presentation titled: "Fate Space Screening of Clonal Human ES-derived Embryonic Progenitor Cell Lines" wi... 
Printer Friendly Version
October 14, 2010BioTime's CEO Michael West to Speak at GTCbio and Unveil 12 New Diverse Cell Lines to be Launched November 1, 2010
ALAMEDA, Calif., Oct 14, 2010 (BUSINESS WIRE) --BioTime, Inc. (NYSE Amex:BTIM) announced today that on October 22, 2010 BioTime's CEO Dr. Michael West will present at the GTCbio 4th Advances in Stem Cell Discovery and Development Conference in San Francisco, California. Dr. West's presentation titled: "Fate Space Screening of Clonal Human ES-derived Embryonic Progenitor Cell Lines" will include a discussion of the Company's proprietary bank of more... 
Printer Friendly Version
October 12, 2010BioTime Announces Stock Ticker Symbol Change and Extension of Warrant Expiration Date
Trading Symbol for BioTime Common Shares to Change Effective November 2, 2010 BioTime Extends Expiration Date of Warrants to November 1, 2010 ALAMEDA, Calif., Oct 12, 2010 (BUSINESS WIRE) --BioTime, Inc. (NYSE Amex:BTIM). BioTime announced today the change of its stock ticker symbol on the NYSE Amex. Additionally, BioTime announced today that it is extending the expiration date of its common share purchase warrants that expire on Octo... 
Printer Friendly Version
October 10, 2010Cell Cure Neurosciences Ltd., a Subsidiary of BioTime, Inc. and Hadasit Bio Holdings Ltd., Enters into an Exclusive License Option Agreement with Teva Pharmaceutical Industries Ltd.
To Develop and Market OpRegenTM for the Treatment of Age-Related Macular Degeneration JERUSALEM & ALAMEDA, Calif., Oct 10, 2010 (BUSINESS WIRE) --BioTime, Inc. (NYSE Amex:BTIM), Cell Cure Neurosciences Ltd., and Hadasit Bio-Holdings Ltd. (Tel Aviv Stock Exchange:HDST) jointly announced today that Cell Cure and Teva Pharmaceutical Industries Ltd. have entered into an exclusive license option agreement to develop and commercialize Cell Cure's OpRegenTM pr... 
Printer Friendly Version
October 10, 2010Cell Cure Neurosciences' Shareholders Will Invest $7.1 M in the Company's Development of Innovative Stem Cell Treatments for Neural and Retinal Diseases
JERUSALEM & ALAMEDA, Calif., Oct 10, 2010 (BUSINESS WIRE) --BioTime, Inc. (NYSE Amex:BTIM), Cell Cure Neurosciences Ltd., and Hadasit Bio-Holdings Ltd. (Tel Aviv Stock Exchange:HDST) jointly announced today that Cell Cure will receive an equity investment of $7.1 million from BioTime, Teva Pharmaceutical Industries Ltd., and Hadasit Bio-Holdings (HBL). This financial round extends previous investments by Teva and HBL in Cell Cure. BioTime already held a si... 
Printer Friendly Version
September 16, 2010BioTime CEO Dr. Michael West and CMO Dr. David Jin to Present Keynote Addresses at The Sixth Chinese Congress in Regenerative Medicine and Stem Cell Therapy in Suzhou, P.R. China
ALAMEDA, Calif., Sep 16, 2010 (BUSINESS WIRE) --BioTime, Inc. (NYSE Amex: BTIM) announced that Chief Executive Officer Michael West, Ph.D. will deliver a keynote presentation this week at the Sixth Chinese Congress in Regenerative Medicine and Stem Cell Therapy being held September 16-19, 2010 in Suzhou, P.R. China. This Congress is the largest of its type in China with over 2,000 participants from various stem cell-related disciplines. Dr. West's pre... 
Printer Friendly Version
September 13, 2010BioTime CEO Dr. Michael West to Present at Stem Cells USA & Regenerative Medicine Congress 2010
Ten New ACTCellerate Cell Lines to be Launched October 1, 2010 ALAMEDA, Calif., Sep 13, 2010 (BUSINESS WIRE) --BioTime, Inc. (NYSE Amex:BTIM) announced that Chief Executive Officer Michael West, Ph.D. will give a presentation today at the Stem Cells USA & Regenerative Medicine Congress 2010 being held September 13-15, 2010 in Philadelphia, PA. Dr. West will give a presentation during a panel session discussing tools and technologies relating to manu... 
Printer Friendly Version
September 08, 2010BioTime Announces Executive Management Changes
ALAMEDA, Calif., Sep 08, 2010 (BUSINESS WIRE) --BioTime, Inc. (NYSE Amex:BTIM) announced today that its Chief Financial Officer, Steven A. Seinberg, has resigned his position effective September 17, 2010. Mr. Seinberg, who is an attorney, will be returning to the practice of law at a private firm. Mr. Seinberg has agreed to assist BioTime in transition tasks on a consulting basis. Mr. Seinberg has reported to BioTime's Senior Vice President and Chief ... 
Printer Friendly Version
August 26, 2010BioTime to Launch Seven New Embryonic Progenitor Cell Lines on September 1, 2010
ALAMEDA, Calif., Aug 26, 2010 (BUSINESS WIRE) --BioTime, Inc. (NYSE Amex: BTIM) announced today that it will launch seven new human embryonic progenitor cell lines and seven novel culture media for these lines on September 1, 2010. These progenitor lines were produced from embryonic stem cells using the Company's ACTCellerateTM technology. Human embryonic progenitor cells are intermediate in the developmental process between embryonic stem cells and f... 
Printer Friendly Version
August 19, 2010BioTime Raises $9.2 Million in Warrant Discount Offer
ALAMEDA, Calif., Aug 19, 2010 (BUSINESS WIRE) --BioTime, Inc. (NYSE Amex:BTIM) announced the completion of its warrant discount offer which closed at 5:00 p.m., New York time, on August 18, 2010. The deadline for submitting warrant certificates and exercise funds under notices for guaranteed delivery is August 23, 2010 at 5:00 p.m., New York time. Based upon preliminary results, the warrant discount offer generated $9,195,422 of proceeds to BioTime fr... 
Printer Friendly Version
August 16, 2010BioTime Announces Second Quarter 2010 Financial Results and Recent Corporate Developments
57% Increase in Total Revenue for the Quarter 99% Increase in Total Revenues Year to Date over Last Year ALAMEDA, Calif., Aug 16, 2010 (BUSINESS WIRE) --BioTime, Inc. (NYSE Amex:BTIM) today reported financial results for the quarter ended June 30, 2010 and provided an update on recent corporate developments. For the three months ended June 30, 2010, total revenue (including royalty income, revenue recognition of deferred license fees, and grant income) wa... 
Printer Friendly Version
July 21, 2010BioTime Announces Addition of New Stem Cell Lines to Its Product Portfolio
ALAMEDA, Calif., Jul 21, 2010 (BUSINESS WIRE) --BioTime, Inc. (AMEX:BTIM) announced today that on August 1, 2010 the Company will be offering for sale 21 new stem cell products for research use only. These products will include the novel stem cell lines: E120 expressing the gene LGR5 useful in colon cancer drug discovery, EN16, T43, RAD20.5, RA-SKEL8, SM22, and Z1, full properties of which will be disclosed on product launch, along with differentiation kit... 
Printer Friendly Version
July 19, 2010BioTime, Inc. Provides Financial Information about Its Acquisition of ES Cell International Pte Ltd.
ALAMEDA, Calif., Jul 19, 2010 (BUSINESS WIRE) --On Friday, July 16, 2010 BioTime, Inc. (NYSE Amex: BTIM) filed an amendment to its Current Report on Form 8-K with the Securities and Exchange Commission reporting BioTime's acquisition of ES Cell International Pte Ltd, a Singapore private limited company ("ESI"). BioTime filed the amendment in the time frame provided in the SEC's rules to include audited financial statements of ESI and pro forma fina... 
Printer Friendly Version
July 09, 2010BioTime CEO Dr. Michael West to Present at the Agora Financial Investment Symposium 2010
ALAMEDA, Calif., Jul 09, 2010 (BUSINESS WIRE) --BioTime, Inc. (NYSE Amex:BTIM) Chief Executive Officer Michael West, Ph.D., will give a presentation at the Agora Financial Investment Symposium 2010, July 20-23, at the Fairmont Hotel Vancouver. Dr. West's presentation on Wednesday, July 21, is titled "Regenerative Medicine: Finding Opportunity in a Scientific Revolution." The Symposium is the 11th for Agora Financial, LLC, an independent firm p... 
Printer Friendly Version
July 06, 2010BioTime Announces Passing of Board Director Dr. Robert N. Butler
ALAMEDA, Calif., Jul 06, 2010 (BUSINESS WIRE) --BioTime, Inc. (NYSE Amex: BTIM) announced with sadness that Dr. Robert N. Butler, a member of its Board of Directors, passed away on Sunday, July 4, 2010 at the age of 83. Dr. Butler was a leading expert in geriatrics and diseases associated with the aging process, and founded the International Longevity Center-USA, a non-profit international research, policy, and education organization formed to educate ... 
Printer Friendly Version
June 18, 2010BioTime Commences Warrant Discount Offer
ALAMEDA, Calif., Jun 18, 2010 (BUSINESS WIRE) --BioTime, Inc. (NYSE Amex: BTIM) announced today that it is commencing a warrant discount offer under which it will permit holders of its common share purchase warrants expiring October 31, 2010 to exercise their warrants at a discounted price of $1.818 per share, which represents a discount of $0.182 from the regular warrant exercise price of $2.00 per share. The discount offer will expire at 5:00 p.m., New Y... 
Printer Friendly Version
June 14, 2010BioTime Announces Results of Vote at Annual Shareholders Meeting
Annual Meeting Presentation Now Available on BioTime's Website ALAMEDA, Calif., Jun 14, 2010 (BUSINESS WIRE) --BioTime, Inc. (NYSE Amex: BTIM) announced today that all of the nominees for election to the BioTime Board of Directors were re-elected by BioTime's shareholders at the 2010 Annual Meeting held on June 10. Each nominee received not less than 99.8% of the votes cast at the meeting. Our directors are Neal C. Bradsher, Arnold I. Burns, Robert N. Butler, ... 
Printer Friendly Version
June 13, 2010BioTime Set to Join Russell 3000 Index
ALAMEDA, Calif., Jun 13, 2010 (BUSINESS WIRE) --BioTime, Inc. (NYSE Amex:BTIM) announced today that it has been included on a preliminary list of additions to the Russell 3000(R) Index and Russell Global(R) Index posted by Russell Investments on June 11, 2010 at www.russell.com. These changes are expected to go into effect after the close of trading on Friday, June 25, 2010 and remain in place for one year. BioTime expects that inclusion in the Russell 300... 
Printer Friendly Version
June 10, 2010BioTime Forms New Subsidiary, OrthoCyte Corporation, to Develop Treatments for Orthopedic Conditions Using Stem Cell Technology
Arnold I. Caplan Ph.D., Founder of Osiris Therapeutics, Inc. Appointed Chief Scientific Officer ALAMEDA, Calif., Jun 10, 2010 (BUSINESS WIRE) --BioTime, Inc. (NYSE Amex: BTIM) announced today that it has organized a new subsidiary, OrthoCyte Corporation, for the purpose of developing novel therapeutics based on stem cell technology for the treatment of injuries and disorders affecting the musculoskeletal system, including therapeutics that would regener... 
Printer Friendly Version
June 08, 2010BioTime CEO Dr. Michael West to Present at the Inaugural Jefferies Global Life Sciences Conference
ALAMEDA, Calif., Jun 08, 2010 (BUSINESS WIRE) --BioTime, Inc. (AMEX: BTIM) Chief Executive Officer Michael West, Ph.D., will give a presentation this week at the Inaugural Jefferies Global Life Sciences Conference being held June 8-11, 2010 in New York City. Dr. West will give an overview of BioTime's business and technology in the stem cell and regenerative medicine sector on Wednesday, June 9 at 11:00 a.m. EDT, Track C. The presentation will be webcast l... 
Printer Friendly Version
May 27, 2010BioTime Adds Five New Stem Cell Lines to Its Product Portfolio
ALAMEDA, Calif., May 27, 2010 (BUSINESS WIRE) --BioTime, Inc. (AMEX:BTIM) announced today that on June 1, 2010 the Company will be offering for sale five new human stem cell lines for research use only. These cell lines were developed using BioTime's ACTCellerate(TM) technology. These highly purified, novel, and scalable cell lines are embryonic progenitors, meaning that they are intermediate between human embryonic stem cells and fully developed cells. Th... 
Printer Friendly Version
May 21, 2010BioTime CEO Dr. Michael West to Present at GTCbio 6th Annual Stem Cell Research & Therapeutics Conference
ALAMEDA, Calif., May 21, 2010 (BUSINESS WIRE) --BioTime, Inc. (AMEX:BTIM) Chief Executive Officer Michael West, Ph.D. will give a presentation next week at the GTCbio 6th Annual Stem Cell Research & Therapeutics Conference, which will be held May 27-28, 2010 in Boston, Massachusetts. Dr. West will speak on "Fate Space Screening of Clonal Human ES-Derived Embryonic Progenitor Cell Lines for Chondrogenesis" in the meeting's first session, whose t... 
Printer Friendly Version
May 10, 2010BioTime Announces Receipt of $8 Million from Early Exercise of Warrants
Proceeds to Accelerate Pace of Stem Cell Product Development Company to Offer Same Early Exercise Terms to Other Warrant Holders ALAMEDA, Calif., May 10, 2010 (BUSINESS WIRE) --BioTime, Inc. (NYSE Amex: BTIM), a biotechnology company that develops and markets products in the field of human stem cells and regenerative medicine, today announced that it has received an additional $8 million from two investors. These two investors have elected to exercise early an... 
Printer Friendly Version
May 05, 2010BioTime Announces First Quarter 2010 Financial Results and Recent Corporate Developments
159% Increase in Total Revenue for the Quarter ALAMEDA, Calif., May 05, 2010 (BUSINESS WIRE) --BioTime, Inc. (NYSE Amex: BTIM) today reported financial results for the first quarter ended March 31, 2010 and provided an update on recent corporate developments. For the three months ended March 31, 2010, total quarterly revenue (including royalty income, revenue recognition of deferred license fees, and grant income) was $767,127, up 159% from $296,743 for the ... 
Printer Friendly Version
May 03, 2010BioTime, Inc. Announces Completion of ES Cell International Pte Ltd Acquisition
Acquisition to Accelerate Development of Research and Therapeutic Products ALAMEDA, Calif., May 03, 2010 (BUSINESS WIRE) --BioTime, Inc. (NYSE Amex: BTIM), a biotechnology company that develops and markets products in the field of human stem cells and regenerative medicine, today announced that it has completed its acquisition of the Singapore company ES Cell International Pte Ltd ("ESI"). Established in 2000, ESI has been a worldwide leader in the deve... 
Printer Friendly Version
April 29, 2010BioTime, Inc. Provides Additional Information on Acquisition of Promissory Notes in Connection with Planned Acquisition of ES Cell International Pte Ltd.
ALAMEDA, Calif., Apr 29, 2010 (BUSINESS WIRE) --BioTime, Inc. (NYSE Amex: BTIM) announced earlier today that it plans to acquire ES Cell International Pte Ltd, a Singapore private limited company ("ESI"). In its press release earlier today, BioTime stated that it will "acquire all of ESI's approximately $35 million of debt and accrued interest. ESI has no significant liabilities other than the debt obligations that BioTime will own after the acquisition." ... 
Printer Friendly Version
April 29, 2010BioTime, Inc. Announces Agreement to Acquire ES Cell International
Acquisition to Accelerate BioTime's Development of Human Stem Cell-Based Therapeutics ALAMEDA, Calif., Apr 29, 2010 (BUSINESS WIRE) --BioTime, Inc. (NYSE Amex:BTIM), a biotechnology company that develops and markets products in the field of stem cells and regenerative medicine, today announced that it has agreed to acquire the Singapore-based company ES Cell International Pte Ltd (ESI). The acquisition is expected to close next week, at which time BioTi... 
Printer Friendly Version
March 16, 2010BioTime, Inc. Reports Peer-Reviewed Scientific Publication on the Reversal of the Developmental Aging of Normal Human Cells
Paper and Related Patent Filings Are a Strategic Step Forward in the Development of the Company's ReCyte(TM) iPS TechnologyALAMEDA, Calif., Mar 16, 2010 (BUSINESS WIRE) -- BioTime, Inc. (NYSE Amex:BTIM), a biotechnology company that develops and markets products in the field of stem cells and regenerative medicine, today announced the publication of a scientific paper titled "Spontaneous Reversal of Developmental Aging in Normal Human Cells Following Transcription... 
Printer Friendly Version
March 10, 2010BioTime Announces Fourth Quarter and Fiscal Year-End 2009 Financial Results and Recent Corporate Developments
163% Increase in Total Revenue for the Quarter28% Increase in Total 2009 RevenueALAMEDA, Calif., Mar 10, 2010 (BUSINESS WIRE) -- BioTime, Inc. (NYSE Amex:BTIM) today reported financial results for the fourth quarter and fiscal year ended December 31, 2009 and provided an update on recent corporate developments. For the three months ended December 31, 2009 total quarterly revenue (including royalty income, revenue recognition of deferred license fees, and grant in... 
Printer Friendly Version
February 05, 2010BioTime Reports Results from Independent Hextend(R) Study
-- First Report on Hextend for Initial Fluid Resuscitation at a Level I Trauma Center --ALAMEDA, Calif., Feb 05, 2010 (BUSINESS WIRE) -- BioTime, Inc. (NYSE Amex:BTIM) today reported recently-released results from an independent study evaluating the use of Hextend(R) in hemodynamically unstable trauma patients. Hextend (6% Hetastarch in Lactated Electrolyte Injection) is BioTime's commercially-available blood plasma volume expander used to treat hypovolemia (low b... 
Printer Friendly Version
January 05, 2010BioTime Commences Shipment of Stem Cell Research Products to Millipore
BioTime, Inc. (NYSE Amex:BTIM) announced today that it has initiated shipments of stem cell research products to its worldwide distributor, Millipore Corporation, according to the terms of the co-marketing agreement between the two companies that was announced on July 9, 2009. BioTime has shipped inventory of six ACTCellerate™ progenitor cell lines to Millipore and plans to begin shipments of additional cell lines and ESpan™ cell growth media in the next several weeks. Derived from human... 
Printer Friendly Version
December 04, 2009BioTime CEO Dr. Michael West to Ring The Opening Bell at the New York Stock Exchange
BioTime, Inc. (NYSE Amex:BTIM) Chief Executive Officer Michael D. West, Ph.D. will ring The Opening Bell at the New York Stock Exchange at 9:30 a.m. Eastern on Tuesday, December 8, 2009. Executives and guests of BioTime will also be at the ceremony to celebrate the company's recent listing on the NYSE Amex. Trading of BioTime's common shares and warrants commenced on the NYSE Amex on Friday, October 30, 2009 under the ticker symbols "BTIM" for the common shares and "BTIM.WS" for the warr... 
Printer Friendly Version
November 24, 2009BioTime, Inc. Announces Third Quarter 2009 Financial Results and Update on Recent Developments
-- Records Increase of $9 Million in Shareholders’ Equity -- -- Receives First Installment of California-Sponsored Grant Funds -- -- Forms Two New Subsidiaries: BioTime Asia and OncoCyte Corporation -- -- Common Shares and Warrants Listed on the NYSE Amex -- BioTime, Inc. (NYSE Amex:BTIM) reported financial results for the quarter ended September 30, 2009 and an update. For the three months ended September 30, 2009, BioTime's total quarterly revenue (including royalty income, revenu... 
Printer Friendly Version
November 12, 2009BioTime CEO Dr. Michael West to Present at Stem Cells USA & Regenerative Medicine Congress 2009
BioTime, Inc. (NYSE Amex: BTIM) Chief Executive Officer Michael West, Ph.D. will give two presentations at the Stem Cells USA & Regenerative Medicine Congress 2009 to be held at The Westin Washington DC City Center Hotel in Washington, DC from November 16-18, 2009. On Tuesday, November 17, Dr. West will discuss applications of stem cell technology for diseases of the skin and bone. Dr. West will provide an update on BioTime's ACTCellerate™ technology platform in cartilage b... 
Printer Friendly Version
November 12, 2009BioTime CEO Dr. Michael West to Present at Stem Cells USA & Regenerative Medicine Congress 2009
BioTime, Inc. (NYSE Amex: BTIM) Chief Executive Officer Michael West, Ph.D. will give two presentations at the Stem Cells USA & Regenerative Medicine Congress 2009 to be held at The Westin Washington DC City Center Hotel in Washington, DC from November 16-18, 2009. On Tuesday, November 17, Dr. West will discuss applications of stem cell technology for diseases of the skin and bone. Dr. West will provide an update on BioTime's ACTCellerate™ technology platform in cartilage b... 
Printer Friendly Version
October 22, 2009Chief Medical Officer of BioTime's Subsidiary OncoCyte Corporation to Deliver Keynote Address at Fifth Chinese Congress on Stem Cell Therapy in Beijing, P.R. China
BioTime, Inc. (OTCBB:BTIM) announced today that Dr. David Jin, Chief Medical Officer of BioTime's subsidiary OncoCyte Corporation, will present the keynote address at the Fifth Chinese Congress on Stem Cell Therapy in Beijing, Peoples Republic of China. The presentation titled, "Chemokine regulation of hematopoietic stem cell mobilization and angiogenesis" will be delivered on Friday, October 23, 2009 on behalf of OncoCyte Corporation and BioTime Asia. The presentation will address the ... 
Printer Friendly Version
October 22, 2009BioTime, Inc. Announces Approval For NYSE Amex Listing
Trading will begin on Friday, October 30, 2009 BioTime, Inc. (OTCBB: BTIM), a biotechnology company that develops and markets products in the field of stem cells and regenerative medicine, today announced that its common stock and warrants have been approved for listing on the NYSE Amex. Trading is expected to commence on the NYSE Amex on Friday, October 30, 2009 under the same ticker symbols 'BTIM' (NYSE Amex: BTIM) for the common stock and "BTIMW" for the warrants. Prior to that date,... 
Printer Friendly Version
October 14, 2009BioTime to Podcast Presentation at Annual Meeting of Shareholders
BioTime, Inc. (OTCBB:BTIM), a biotechnology company that develops and markets products in the field of stem cells and regenerative medicine, today announced that Dr. Michael West, BioTime's CEO, will give a presentation at the Company's Annual Meeting of Shareholders scheduled for October 15, 2009 at its headquarters in Alameda, California. Dr. West will update investors on recent progress in its stem cell programs and business development. The presentation will be recorded and the podca... 
Printer Friendly Version
September 22, 2009BioTime, Inc. to Form Asian Subsidiary
Enters Into Agreements With Dr. Lu Daopei and Nanshan Memorial Medical Institute Limited BioTime, Inc. (OTCBB:BTIM) announced today that it will organize a new subsidiary, BioTime Asia, Limited, for the purpose of clinically developing and marketing therapeutic stem cell products in the People's Republic of China, and marketing stem cell research products in China and other countries in Asia. BioTime Asia will initially seek to develop the therapeutic products for the treatment of ophth... 
Printer Friendly Version
September 18, 2009BioTime CEO Dr. Michael West to Present Keynote Address at China-USA Scientific Forum of Stem Cell and Regenerative Medicine
Dr. Walter Funk to Present at 2009 World Stem Cell Summit BioTime, Inc. (OTCBB:BTIM) Chief Executive Officer Michael West, Ph.D. will deliver the keynote presentation on Tuesday, September 22, 2009 at the China-USA Scientific Forum of Stem Cell and Regenerative Medicine in Beijing, China. Dr. West's presentation is titled "The New Era of Regenerative Medicine—Induced Pluripotent Stem Cells and Beyond." Dr. Walter Funk, BioTime's Vice President–Stem Cell Research, will speak in place of... 
Printer Friendly Version
September 02, 2009BioTime CEO Dr. Michael West to Present at 2009 World Stem Cell Summit
BioTime, Inc. (OTCBB:BTIM) Chief Executive Officer Michael West, Ph.D. will deliver a presentation on Wednesday, September 23, 2009 at the 2009 World Stem Cell Summit meeting in Baltimore, Maryland. Dr. West's presentation is titled "Regenerative Medicine 2.0—Solving the Challenge of Purity and Identity in Stem Cell Therapies." The presentation will address the challenges the regenerative medicine (ReGEN) industry is currently facing due to cellular contamination producing undesired cell... 
Printer Friendly Version
August 24, 2009BioTime, Inc. Completes Exchange Offer for Revolving Line of Credit Notes
BioTime, Inc. (OTCBB: BTIM) announced today that it has completed an Exchange Offer to the holders of notes issued under its revolving line of credit agreement. BioTime issued 1,989,515 common shares and warrants to purchase 100,482 common shares in exchange for notes in the aggregate principal amount of $3,349,259. BioTime also paid interest in the aggregate amount of $294,351 on the notes tendered in the exchange offer. The warrants issued in the exchange offer are exercisable at a pr... 
Printer Friendly Version
August 17, 2009BioTime, Inc. Appoints Pedro Lichtinger to Its Board of Directors
BioTime, Inc. (OTCBB: BTIM) announced today that it had appointed Pedro Lichtinger to its board of directors. Pedro Lichtinger, 55, served as an executive of Pfizer, Inc. from 1995 to 2009, including as President of Pfizer's Global Primary Care Unit, Area President, Europe Pharmaceuticals, President, Global Animal Health, and Regional President Europe Animal Health. Before joining Pfizer, Mr. Lichtinger was an executive of Smith Kline Beecham, last serving as Senior Vice President Europ... 
Printer Friendly Version
August 10, 2009BioTime Appoints Walter Funk Vice President for Stem Cell Research
Experienced Biotechnology Executive to Join Team Managing BioTime’s Human Embryonic Stem Cell Research and Product Development BioTime, Inc. (OTCBB:BTIM) announced today that Walter Funk, Ph.D. has joined its management team as Vice President for Stem Cell Research. Dr. Funk will participate in the management of BioTime's team of scientists developing numerous products from human embryonic stem cells for use in research and in novel therapies for human diseases. Dr. Funk is an experien... 
Printer Friendly Version
August 05, 2009BioTime, Inc. Commences Exchange Offer for Revolving Line of Credit Notes
BioTime, Inc. (OTCBB: BTIM) announced today that it is making an Exchange Offer to the holders of approximately $3,500,000 of its Revolving Credit Notes issued under its revolving line of credit agreement. Under the terms of the Exchange Offer, each holder of a Revolving Credit Note tendered for exchange will receive (a) a number of BioTime common shares equal to the sum of the principal balance of the Revolving Credit Note divided by the applicable price per share for which the Revolvin... 
Printer Friendly Version
July 13, 2009BioTime Investors Fund Second $4,000,000 Equity Tranche
BioTime, Inc. (OTCBB:BTIM) announced that two of its shareholders have completed the funding of the second tranche of their equity investments in BioTime following the exercise of their rights to purchase additional shares and warrants under the terms of their May 2009 stock and warrant purchase agreements. Broadwood Partners, L.P. and George Karfunkel have each purchased an additional 1,100,000 BioTime common shares and 1,100,000 stock purchase warrants. BioTime received $4,000,000 from... 
Printer Friendly Version
July 09, 2009BioTime Announces Stem Cell Co-marketing Agreement with Millipore
Millipore to Distribute BioTime’s Novel ACTCellerate™ Human Progenitor Cells BioTime, Inc. (OTCBB:BTIM) today announced that Millipore Corporation and BioTime's subsidiary Embryome Sciences, Inc., have entered into a co-marketing agreement whereby Millipore will become a worldwide distributor of ACTCellerate™ human progenitor cell lines. Derived from human embryonic stem cells but not fully differentiated into specific cell types, each ACTCellerate™ line provides a convenient, highly pu... 
Printer Friendly Version
July 07, 2009BioTime, Inc. Adds New Members to Its Board of Directors
Neal C. Bradsher Arnold I. Burns Abraham E. "Barry" Cohen Alfred D. Kingsley BioTime, Inc. (OTCBB: BTIM) announced today that it has expanded its Board of Directors to include four new members, Neal C. Bradsher, Arnold I. Burns, Abraham E. Cohen, and Alfred D. Kingsley. Mr. Kingsley will serve as Chairman of the Board. These new directors bring to BioTime a wealth of experience in corporate finance, corporate governance, and the pharmaceutical industry.  Neal C. Bradsher is... 
Printer Friendly Version
May 14, 2009BioTime Raises $4,000,000 in Equity Financing
May Receive an Additional $4,000,000 Within 60 Days An Additional $8,800,000 Possible by October 2010 BioTime, Inc. (OTCBB:BTIM) announced that it has raised $4,000,000 of equity capital through the sale of 2,200,000 common shares and 2,200,000 stock purchase warrants to two private investors. The warrants entitle the investors to purchase additional common shares at an exercise price of $2.00 per share and expire on October 31, 2010. In addition, the investors have an option to purc... 
Printer Friendly Version
May 07, 2009BioTime CEO Dr. Michael West to Present at World Stem Cells & Regenerative Medicine Congress 2009 and Discuss New Cell Lines with Cartilage-Forming Potential
BioTime, Inc. (OTCBB: BTIM) Chief Executive Officer Michael West, Ph.D. will deliver a presentation on May 14, 2009 at the World Stem Cells and Regenerative Medicine Congress meeting in London. Dr. West's presentation is titled "Opportunities and Challenges of Commercializing Stem Cell Research." This year's conference will focus on a broad array of topics related to stem cell research, including the biology, medicine, applications, regulation, and business of Stem Cells. Dr. ... 
Printer Friendly Version
April 30, 2009BioTime Awarded a $4.7 Million Research Grant from the California Institute for Regenerative Medicine
Grant to Fund Expansion of BioTime’s ACTCellerate™ Human Embryonic Stem Cell Product Development BioTime, Inc., (OTCBB:BTIM) announced today that the California Institute for Regenerative Medicine (CIRM) has approved a grant to the Company of $4.7 million to fund research related to its ACTCellerate™ embryonic stem cell technology. The overall objective of this grant is to generate tools useful in applying ACTCellerate™ technology to the manufacture of patient-specific therapeutic produ... 
Printer Friendly Version
March 30, 2009BioTime Announces 2008 Year-End Results
On March 23, 2009 BioTime, Inc. (OTCBB: BTIM) reported financial results for the fiscal year ended December 31, 2008. Total revenue for the year ended December 31, 2008 was $1,503,792 compared to $1,046,121 for the year ended December 31, 2007. BioTime received $1,203,453 in royalties from Hextend®sales by Hospira, Inc. for the year ended December 31, 2008, compared to $776,679 in 2007. This 55% increase in royalties is attributable to an increase in Hextend sales, which was largely due... 
Printer Friendly Version
January 21, 2009BioTime Launches New Stem Cell Lines in Anticipation of President Obama's Removal of Restrictions on Federal Funding of Embryonic Stem Cell Research
New Cell Line Products to be Presented at Stem Cells World Conference BioTime, Inc. (OTCBB:BTIM) Chief Executive Officer Michael West, Ph.D., will deliver a presentation on January 21, 2009 at the Select Biosciences Stem Cells World Congress meeting in Palm Springs, California. Dr. West's presentation is titled "Embryomics: High Throughput Generation and Mapping of Embryonic Progenitors." This year's conference will focus on new technologies in stem cell research and developm... 
Printer Friendly Version
November 21, 2008BioTime Inc. Announces Third Quarter 2008 Financial Results
-- Reports Growth in Third Quarter Revenue -- On November 19, 2008 BioTime, Inc. (OTCBB:BTIM) reported financial results for the quarter ended September 30, 2008. For the three months ended September 30, 2008, BioTime's total quarterly revenue, including both royalty income and revenue recognition of deferred license fees, increased 85% to $426,931 from $231,159 for the same period last year. BioTime reported a net loss of $1,077,194, or $0.05 per basic and diluted share, for the thre... 
Printer Friendly Version
November 20, 2008BioTime CEO Dr. Michael West Announces the Launch of New Products and Discusses the State of the Stem Cell Industry under the Obama Administration at the Wisconsin Academy of Sciences, Arts, and Letters
BioTime, Inc. (OTCBB:BTIM) Chief Executive Officer Michael West, Ph.D. delivered the keynote presentation on Wednesday, November 19, at a meeting in Madison, Wisconsin commemorating the 10th anniversary of the publication describing the first derivation and culturing of human embryonic stem cells. Dr. West's presentation is titled "Opportunities and Challenges of Commercializing Stem Cell Research." The Wisconsin Academy, along with University of Wisconsin-Madison and the Wisconsin Alumn... 
Printer Friendly Version
November 14, 2008BioTime CEO Dr. Michael West Presents Keynote Address at Event Commemorating the 10th Anniversary of the First Derivation of Human Embryonic Stem Cells
BioTime, Inc. (OTCBB:BTIM) Chief Executive Officer Michael West, Ph.D. will deliver a keynote presentation on Wednesday, November 19, at a meeting in Madison, Wisconsin commemorating the 10th anniversary of the publication describing the derivation and culturing of human embryonic stem cells for the first time. Dr. West's presentation is titled "Opportunities and Challenges of Commercializing Stem Cell Research." The Wisconsin Academy, along with University of Wisconsin-Madiso... 
Printer Friendly Version
October 27, 2008BioTime CEO Dr. Michael West Presents at GTCbio Advances in Stem Cell Discoveries Meeting and Announces Launch of New Neural Crest Cell Lines
BioTime, Inc. (OTCBB:BTIM) Chief Executive Officer Michael West, Ph.D. will deliver a presentation this morning at the GTCbio Advances in Stem Cell Discoveries meeting in San Francisco. Dr. West's presentation is titled "Embryomics: Implications for Regenerative Medicine." This year's conference will focus on cutting-edge information on developments in all areas of stem cell research, including the biology, medicine, applications, regulation, and business of Stem Cells. D... 
Printer Friendly Version
October 13, 2008BioTime Announces Collaboration With the International Longevity Center on Regenerative Medicine
BioTime, Inc. (OTCBB:BTIM) and the International Longevity Center-USA today announced a collaboration aimed at research, education and advocacy for regenerative medicine and its application in aging. Founded by President and CEO, Robert N. Butler, M.D. in 1990, the International Longevity Center is a non-profit international research, policy, and education organization formed to educate individuals on how to live longer and better, and advise society on how to maximize the bene... 
Printer Friendly Version
September 18, 2008BioTime CEO Dr. Michael West Presents at Tecan Symposium 2008
BioTime, Inc. (OTCBB:BTIM) Chief Executive Officer Michael West, Ph.D. gave a presentation this week at the Tecan Symposium 2008 being held September 16-18 in Zurich, Switzerland. Dr. West's presentation was on "Embryomics: Implications for Regenerative Medicine" in the opening session titled "Advances and Opportunities in Stem Cells." This is the second annual symposium sponsored by Tecan, a provider of advanced automation and detection solutions for the world'... 
Printer Friendly Version
September 11, 2008BioTime, Inc. Conference Call Will Discuss Its Recent Acquisition of Stem Cell Technology Licenses
BioTime, Inc. (OTCBB:BTIM) announced that it will host a conference call on which its Chief Executive Officer, Dr. Michael D. West, will discuss the opportunities presented by the recent additions to the company's stem cell technology portfolio. BioTime, and its wholly owned subsidiary, Embryome Sciences, Inc., have acquired licenses for a portfolio of stem cell technology patents and patent applications. These licenses include technology that allows the rapid isolation of novel highly p... 
Printer Friendly Version
August 21, 2008BioTime, Inc.'s Subsidiary, Embryome Sciences, Inc., Licenses Virus-Free iPS and Embryonic Stem Cell Differentiation Technology
Embryome Sciences, Inc., a wholly owned subsidiary of BioTime, Inc. (OTCBB:BTIM), announced today the license of a portfolio of patents and patent applications from Advanced Cell Technology, Inc. ("ACT") relating to induced pluripotent stem cells ("iPS") and embryonic stem cell differentiation technology. The license is for the commercialization of products in human therapeutic and diagnostic product markets. The technology licensed by Embryome Sciences covers methods for the transforma... 
Printer Friendly Version
August 15, 2008BioTime Inc. Announces Second Quarter 2008 Financial Results
-- Reports Growth in Second Quarter Royalty Revenue -- -- Expects Continued Growth in Royalty Revenue for Third Quarter -- On August 14, 2008 BioTime, Inc. (OTCBB:BTIM) reported financial results for the quarter ended June 30, 2008. For the three months ended June 30, 2008, BioTime's total quarterly revenue, including both royalty income and revenue recognition of deferred license fees, increased 95% to $410,563 versus $210,741 for the same period last year. BioTime reported a net lo... 
Printer Friendly Version
August 06, 2008Dr. Robert N. Butler Appointed to Board of Directors of BioTime, Inc.
BioTime, Inc. (OTCBB:BTIM) announced today that Robert N. Butler, M.D., has been elected to BioTime's Board of Directors. Dr. Butler is the founder, Chief Executive Officer, and President of the International Longevity Center-USA, a non-profit international research, policy, and education organization formed to educate individuals on how to live longer and better, and advise society on how to maximize the benefits of today's age boom. Dr. Butler received his B.A. degree from Columbia Col... 
Printer Friendly Version
July 16, 2008Embryome Sciences, Inc. Acquires Exclusive License for ACTCellerate Technology
Embryome Sciences, Inc., a wholly owned subsidiary of BioTime, Inc., (OTCBB:BTIM) has acquired from Advanced Cell Technology, Inc. ("ACT") an exclusive license to use "ACTCellerate™"embryonic stem cell technology and a bank of over 140 diverse progenitor cell lines derived using that technology. ACTCellerate™ is a recently discovered technology that allows the rapid isolation of novel highly purified embryonic progenitor cells. Embryonic progenitors are cells intermediate betw... 
Printer Friendly Version
June 27, 2008BioTime, Inc. and Embryome Sciences, Inc. Launch Embryome.com and the International Embryome Initiative
BioTime, Inc., (OTCBB:BTIM) and its wholly-owned subsidiary Embryome Sciences, Inc. announced today the launch of Embryome.com and the International Embryome Initiative, an international collaboration with scientists around the world to create the first systematic map of all the cell types derived from human embryonic stem cells. In a paper published today titled "The International Embryome Initiative: A Collaborative Database for Navigating the Complexities of Human Embryonic Stem ... 
Printer Friendly Version
June 25, 2008BioTime, Inc. and Embryome Sciences, Inc. Sign Agreement With International Stem Cell Corporation to Provide Unique Human Stem Cell Lines for Research Use
BioTime, Inc., (OTCBB:BTIM) and BioTime's wholly-owned subsidiary Embryome Sciences, Inc., have signed a manufacturing and distribution agreement with International Stem Cell Corporation (OTCBB:ISCO) through its wholly-owned subsidiary Lifeline Cell Technology (Lifeline) to jointly produce and distribute hundreds of new standardized human and animal stem cell lines, along with corresponding data and reagents. The mutual goal is to provide the "picks and shovels" for scientists ... 
Printer Friendly Version
May 19, 2008BioTime Inc. Announces First Quarter 2008 Financial Results
--Reports Growth in First Quarter Royalty Revenue-- --Expects Continued Growth in Royalty Revenue for Second Quarter-- On May 15, 2008BioTime, Inc. (OTCBB:BTIM) reported financial results for the first quarter ended March 31, 2008. For the three months ended March 31, 2008, BioTime's total quarterly revenue, including both royalty income and revenue recognition of deferred license fees, increased 55% to $381,018 versus $245,698 for the same period last year. BioTime reported a net lo... 
Printer Friendly Version
May 15, 2008BioTime CEO Dr. Michael West Presents at European Stem Cells & Regenerative Medicine Congress 2008
BioTime, Inc. (OTCBB:BTIM) Chief Executive Officer Michael West, PhD gave a presentation at theEuropean Stem Cells & Regenerative Medicine Congress 2008 being held May 13-15 in London, United Kingdom. This year's conference theme is "Transform – Translating stem cell research from bench to business." The title of Dr. West's presentation was "Mapping the human embryome: multiplex strategies for the purification and characterization of human embryonic progenit... 
Printer Friendly Version
May 06, 2008BioTime CEO Dr. Michael West Presents at 2008 Seoul Digital Forum
Embryonic Stem Cell Research Discussed in Biotechnology ``Visionaries' Panel BioTime, Inc. (OTCBB:BTIM) Chief Executive Officer Michael West, PhD today gave a presentation at the 2008 Seoul Digital Forum in Seoul, South Korea. This year's conference, May 6-8, is titled"IMAGINATION – Explore T.I.M.E. [Technology, Information, Media & Entertainment], Space and Beyond." Dr. West was one of the featured speakers on the Biotechnology Visionaries panel, which exp... 
Printer Friendly Version
April 16, 2008BioTime Opens New GMP Laboratory for Production of Embryonic Stem Cell Technology Products
BioTime, Inc. (OTCBB:BTIM) announced today that it has opened an 11,000 square foot equipped and operational tissue culture facility in Alameda, California. The facility is Good Manufacturing Practice (GMP) capable and has previously been certified as Class 1000 and Class 10,000 laboratory space, and includes cell culture and manufacturing equipment previously validated for use in GMP manufacture of cell based products. BioTime plans to move its headquarters from its current location in... 
Printer Friendly Version
April 15, 2008BioTime Announces 2007 Year-End Results
BioTime, Inc. (OTCBB:BTIM) today announced financial results for the fiscal year ended December 31, 2007. Total revenue for the year ended December 31, 2007 was $1,046,121 compared to $1,162,015 for the year ended December 31, 2006, as BioTime received $776,679 in royalties from Hextend®sales by Hospira, Inc. for the year ended December 31, 2007, compared to $933,478 in 2006. Royalty revenues were greater during 2006 due to greater sales of Hextend to the U.S. Armed Forces during the se... 
Printer Friendly Version
April 03, 2008BioTime, Inc. Signs Letter of Intent With International Stem Cell Corporation for Joint Production and Distribution of Stem Cell Products
BioTime, Inc. (OTCBB:BTIM) and its wholly-owned subsidiary Embryome Sciences, Inc., have signed a letter of intent with International Stem Cell Corporation (OTCBB:ISCO) and its wholly-owned subsidiary Lifeline Cell Technology (Lifeline) to jointly produce and distribute a wide array of research products from human embryonic stem cell technology. Human embryonic stem (hES) cells are powerful in that they possess the potential to become all of the thousands of cell types in the human body... 
Printer Friendly Version
March 11, 2008BioTime Receives Funds From The Life Extension Foundation for Application in Regenerative Medicine and Aging
BioTime, Inc. (OTCBB:BTIM) today announced that The Life Extension Foundation has joined a group of lenders providing a revolving line of credit to BioTime. "We at Life Extension Foundation are pleased to help finance BioTime's entry into the filed of regenerative medicine. We believe that one of the most important applications of embryonic stem cell technology is the slowing and reversing of aging and age-related disease. BioTime has, in Dr. Michael West, a leader in stem cell technolo... 
Printer Friendly Version
January 09, 2008BioTime Licenses Human Embryonic Stem Cell Technology from the Wisconsin Alumni Research Foundation
BioTime, Inc. (OTCBB:BTIM) announced it has signed a licensing agreement with the Wisconsin Alumni Research Foundation (WARF) to 173 patents and patent applications filed internationally relating to human embryonic stem cell technology created by James Thomson at the University of Wisconsin-Madison. BioTime develops blood plasma volume expanders and has recently entered the field of regenerative medicine through its wholly owned subsidiary, Embryome Sciences, Inc., through which it plan... 
Printer Friendly Version
January 07, 2008BioTime CEO Dr. Michael D. West to Lecture on Regenerative Medicine and Age Related Degenerative Disease
BioTime, Inc. (OTCBB:BTIM) announced today that Dr. Michael D. West will present a lecture entitled "Regenerative Medicine: Applications in Age Related Degenerative Disease" at the GTCbio New Applications For Aging Research Conference at the Hilton Harbor Island Hotel, 1960 Harbor Island Drive, in San Diego, California. Dr. West's presentation is scheduled to start at 3:40 p.m. on Monday, January 7, 2008. Dr. West's lecture will address how embryonic stem cells may be a source ... 
Printer Friendly Version
December 18, 2007BioTime, Inc. Announces Plan to Map the Human Embryome
EMERYVILLE, Calif., Dec 18, 2007 (BUSINESS WIRE) -- BioTime, Inc. (OTCBB:BTIM) announced its plan to build a relational database for its Embryome Sciences subsidiary that will display information useful in identifying the hundreds of cell types that can be made from human and mouse embryonic stem cells. BioTime believes that this database will be the first of its kind in the stem cell field. "Human embryonic stem cells have enormous potential in medicine due to their ability to become all... 
Printer Friendly Version
December 12, 2007BioTime, Inc. Announces the Formation of Embryome Sciences, Inc. for the Development and Commercialization of Stem Cell Technology
EMERYVILLE, Calif.--(BUSINESS WIRE)--Dec. 12, 2007--BioTime, Inc. (OTCBB:BTIM) today announced that it has organized a new subsidiary, Embryome Sciences, Inc. The mission of the new company is to participate in the emerging field of regenerative medicine known as "embryomics". "Human embryonic stem cells are capable of becoming all of the thousands of different cell types in the body," said Michael West, Ph.D., Chief Executive Officer. "And since embryonic stem cells can now be... 
Printer Friendly Version
November 15, 2007BioTime Announces Results for Third Quarter 2007
EMERYVILLE, Calif.--(BUSINESS WIRE)--Nov. 15, 2007--BioTime, Inc. (OTCBB:BTIM) today announced financial results for the third quarter ended September 30, 2007. Revenues for the three months ended September 30, 2007 consist primarily of royalties on sales of Hextend(R) made by Hospira, Inc. during the period beginning April 1, 2007 and ending June 30, 2007. Royalty revenues recognized for that three-month period were $183,093, a decrease of 27% from royalty revenues of $250,017 receiv... 
Printer Friendly Version
November 06, 2007BioTime, Inc. to Present Plans for Regenerative Medicine at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
EMERYVILLE, Calif., Nov 06, 2007 (BUSINESS WIRE) -- BioTime, Inc. (OTCBB:BTIM) today announced that Michael D. West, Ph.D., Chief Executive Officer, will present an update of the Company's product development programs at 10:35 a.m. EDT on Tuesday, November 6, 2007, at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference, which is being held November 5-7, 2007 at the New York Palace Hotel in New York. The update will include information about BioTime's new initiative in ... 
Printer Friendly Version
November 02, 2007BioTime Announces Joint Hypothermic Medicine Study With Argonne National Laboratory
EMERYVILLE, Calif.--(BUSINESS WIRE)--Nov. 2, 2007--BioTime, Inc. (OTCBB:BTIM) and Argonne National Laboratory today announced that they intend to engage in a cooperative research program in the field of therapeutic hypothermia. BioTime and Argonne have each developed complementary technologies in the field with potential applications in stroke, heart attack, and trauma patients. Lowering the temperature of the body and/or of individual organs is a protective measure against isch... 
Printer Friendly Version
October 31, 2007BioTime, Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
EMERYVILLE, Calif.--(BUSINESS WIRE)--Oct. 31, 2007--BioTime, Inc. (OTCBB:BTIM) today announced that Michael D. West, Ph.D., Chief Executive Officer, will present an update of the company's product development programs at 10:35 a.m. EDT on Tuesday, November 6, 2007, at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference, which is being held November 5-7, 2007 at the New York Palace Hotel in New York. The update will include information about BioTime's new init... 
Printer Friendly Version
October 23, 2007BioTime Names Robert W. Peabody Senior Vice President and Chief Operating Officer
EMERYVILLE, Calif.--(BUSINESS WIRE)--Oct. 23, 2007--BioTime, Inc. (OTCBB:BTIM) today announced that Robert W. Peabody, CPA, has joined BioTime as Senior Vice President and Chief Operating Officer. Mr. Peabody will head BioTime's efforts to obtain research funding grants from private and public sources, including the California Institute for Regenerative Medicine ("CIRM"), to help finance BioTime's entry into the field of regenerative medicine and stem cell research. Prior to joi... 
Printer Friendly Version
October 17, 2007BioTime Announces New Line of Credit
EMERYVILLE, Calif., Oct 17, 2007 (BUSINESS WIRE) -- BioTime, Inc. (OTCBB:BTIM) today announced that it has entered into an amendment of its Revolving Line of Credit Agreement (the "Credit Agreement") that increases the amount of the line of credit to $1,000,000 and extends the maturity date to April 30, 2008. Loans under the line of credit will bear interest at 12% per annum. BioTime will use the line of credit for working capital purposes. The line of credit is collateralized by a securit... 
Printer Friendly Version
October 11, 2007BioTime Names Dr. Michael D. West as CEO and Announces Entry Into Stem Cell Research and Regenerative Medicine
EMERYVILLE, Calif.--(BUSINESS WIRE)--Oct. 11, 2007--BioTime, Inc. (OTCBB:BTIM) today announced that Michael D. West, Ph.D. has become BioTime's new Chief Executive Officer. Dr. West will help spearhead BioTime's entry into the field of regenerative medicine by developing advanced human stem cell products and technology for diagnostic, therapeutic and research use. Dr. West, who has served on the BioTime Board of Directors since 2002, has played a pioneering role in organizing th... 
Printer Friendly Version
August 15, 2007BioTime Announces Results for Second Quarter 2007
EMERYVILLE, Calif.--(BUSINESS WIRE)--Aug. 15, 2007--BioTime, Inc. (OTCBB: BTIM) today announced financial results for the second quarter ended June 30, 2007. Revenues for the three months ended June 30, 2007 consist primarily of royalties on sales of Hextend(R) made by Hospira during the period beginning January 1, 2007 and ending March 31, 2007. Royalty revenues recognized for that three-month period were $163,676, a 64% increase from the $99,957 of royalty revenue during the same pe... 
Printer Friendly Version
June 13, 2007BioTime To Seek New Marketing Partners For PentaLyte(R)
EMERYVILLE, Calif.--(BUSINESS WIRE)--June 13, 2007--BioTime, Inc. (OTCBB:BTIM) announced today that Hospira, Inc. has declined an opportunity to commercialize PentaLyte(R) under the terms offered by BioTime. PentaLyte(R) is BioTime's proprietary pentastarch-based plasma volume expander in a balanced formulation. Hospira will continue to manufacture and sell Hextend(R) in the United States under its License Agreement with BioTime and retains its right to obtain regulatory approval and ... 
Printer Friendly Version
May 16, 2007BioTime Announces Results for First Quarter 2007
EMERYVILLE, Calif.--(BUSINESS WIRE)--May 16, 2007--BioTime, Inc. (OTCBB:BTIM) today announced financial results for the first quarter ended March 31, 2007. Royalty revenues from Hextend(R) sales remained relatively unchanged at $199,264 for the first quarter of 2007, compared with $205,940 during the same period last year. BioTime recognizes royalty revenues in the quarter in which sales reports are received, rather than the quarter in which the sales took place. Therefore, reve... 
Printer Friendly Version
April 19, 2007BioTime Announces 2006 Year-End Results
-- 49% Increase in Royalty Revenue -- 52% Increase in License Revenue -- 29% Increase in Total Revenues EMERYVILLE, Calif.--(BUSINESS WIRE)--April 19, 2007--BioTime, Inc. (OTCBB: BTIM) today announced financial results for the fiscal year ended December 31, 2006. BioTime's royalties from Hextend(R) sales by Hospira, Inc. increased 49% to $933,478 for the year ended December 31, 2006, from $626,135 in 2005, as the number of 500mL units of Hextend sold inc... 
Printer Friendly Version
December 07, 2006BioTime Announces a Phase II Clinical Trial of Hextend(R) in Japan
EMERYVILLE, Calif.--(BUSINESS WIRE)--Dec. 7, 2006--BioTime, Inc. (OTCBB:BTIM) announced today that a Phase II clinical trial for Hextend(R) is being conducted in Japan by Summit Pharmaceuticals International Corporation under their license agreement with BioTime. Summit is co-developing Hextend for the Japanese market with Maruishi Pharmaceutical Co., Ltd. and both Maruishi and Summit have the right to co-market Hextend if regulatory approval is obtained. Summit expects Phase III clin... 
Printer Friendly Version
November 15, 2006BioTime Announces Results for Third Quarter 2006
94% Increase in Royalties on Hextend Sales Record Royalties on Hextend to be Recognized in Q4 EMERYVILLE, Calif.--(BUSINESS WIRE)--Nov. 15, 2006--BioTime, Inc. (OTCBB:BTIM) today announced financial results for the third quarter ended September 30, 2006. Revenues for the three months ended September 30, 2006 consist primarily of royalties on sales of Hextend(R) made by Hospira, Inc. during the period beginning April 1, 2006 and ending June 30, 2006. Royalty revenues recog... 
Printer Friendly Version
August 16, 2006BioTime Announces Results for Second Quarter 2006
EMERYVILLE, Calif.--(BUSINESS WIRE)--Aug. 16, 2006--BioTime, Inc. (OTCBB:BTIM): -- Receives payment of $500,000 for China and Taiwan licenses -- 94% Increase in Royalties on Hextend Sales to be Recognized in Q3 BioTime, Inc. (OTCBB:BTIM) today announced financial results for the second quarter ended June 30, 2006. Revenues for the three months ended June 30, 2006 consist primarily of royalties on sales made by Hospira during the period beginning January ... 
Printer Friendly Version
June 19, 2006BioTime Announces Second Quarter Hextend Revenue
EMERYVILLE, Calif.--(BUSINESS WIRE)--June 19, 2006--BioTime, Inc. (OTCBB:BTIM) today announced royalty revenue to be recognized in the second quarter ended June 30, 2006. BioTime received $99,957 in royalties from Hospira based on Hextend sales during the three months ended March 31, 2006. BioTime recognizes royalty revenues during the fiscal quarter in which the payments are received rather than when the sales that generated the royalties occurred. Accordingly, this revenue will be r... 
Printer Friendly Version
May 16, 2006BioTime Announces Results for First Quarter 2006
EMERYVILLE, Calif.--(BUSINESS WIRE)--May 16, 2006--BioTime, Inc. (OTCBB:BTIM) today announced financial results for the first quarter ended March 31, 2006. Royalty revenues from Hextend(R) product sales in the United States and Canada by Hospira increased 25% to $205,940 for the first quarter of 2006, from $165,321 during the same period last year. The Company recognizes royalty revenues in the quarter in which the sales report is received, rather than the quarter in which the s... 
Printer Friendly Version
April 18, 2006BioTime Announces Fourth Quarter and Fiscal Year-End Results
EMERYVILLE, Calif.--(BUSINESS WIRE)--April 18, 2006--BioTime, Inc. (OTCBB:BTIM): -- 23% Increase in Royalty Revenue Recorded on Hextend Sales for the Quarter -- 31% Increase in Total 2005 Revenues -- 44% Increase in License Revenue Recorded for the Year BioTime, Inc. (OTCBB:BTIM) today announced financial results for the fourth quarter and fiscal year ended December 31, 2005. BioTime's royalties from Hextend(R) sales by Hospira, Inc. increa... 
Printer Friendly Version
April 14, 2006Company Profile for BioTime, Inc.
--(BUSINESS WIRE)--BioTime, headquartered in Emeryville, California, develops blood plasma volume expanders, blood replacement solutions for hypothermic (low temperature) surgery, organ preservation solutions and technology for use in surgery, emergency trauma treatment, and other applications. Company: BioTime, Inc. Headquarters Address: 6121 Hollis Street Emeryville, CA 94608 Main Telephone: 510-350-2940 Ticker: ... 
Printer Friendly Version
April 10, 2006BioTime Announces License Agreement for China and Taiwan
EMERYVILLE, Calif.--(BUSINESS WIRE)--April 10, 2006--BioTime, Inc. (OTCBB:BTIM) announced today that it has entered into a license agreement with Summit Pharmaceuticals International Corporation ("Summit") to develop Hextend(R) and PentaLyte(R) in the People's Republic of China and Taiwan. Summit has sublicensed to a pharmaceutical company the right to use our patents, trademarks and other proprietary information to manufacture and market Hextend(R) and PentaLyte(R) in those countries... 
Printer Friendly Version
December 22, 2005BioTime Raises $1,787,145 in Rights Offer
EMERYVILLE, Calif.--(BUSINESS WIRE)--Dec. 22, 2005--BioTime, Inc. (OTCBB:BTIM) announced the completion of its subscription rights offer which expired at 5:00 p.m. New York time on December 21, 2005. The deadline for submitting subscription certificates and subscription funds under notices for guaranteed delivery is December 27, 2005 at 5:00 p.m. New York time. BioTime will receive $1,787,145 through the rights offer. Based upon preliminary results, BioTime received subscripti... 
Printer Friendly Version
December 20, 2005BioTime Announces Sublicense Arrangement for Japan With Maruishi Pharmaceutical Co., Ltd.
EMERYVILLE, Calif.--(BUSINESS WIRE)--Dec. 20, 2005--BioTime, Inc. (OTCBB:BTIM) announced today that it has entered into an addendum to its agreement with Summit Pharmaceuticals International Corporation to develop Hextend(R) and PentaLyte(R) for the Japanese market. The addendum grants Summit the licenses required to permit Summit to implement an agreement with Maruishi Pharmaceutical Co., Ltd., to seek regulatory approval and to manufacture and market Hextend(R) in Japan. Summit will... 
Printer Friendly Version
November 29, 2005BioTime Amends Terms of Subscription Rights Offer
EMERYVILLE, Calif.--(BUSINESS WIRE)--Nov. 29, 2005--BioTime, Inc. (OTCBB:BTIM) today announced that it has amended the terms of its subscription rights offer by reducing the subscription price and by increasing the number of units that shareholders may purchase through the exercise of their subscription rights. Under the amended terms of the rights offer, holders of rights will be entitled to purchase one unit for every four rights owned at a subscription price of $0.40 per unit. The ... 
Printer Friendly Version
November 15, 2005BioTime Announces Results for Third Quarter 2005
EMERYVILLE, Calif.--(BUSINESS WIRE)--Nov. 15, 2005--BioTime, Inc. (OTCBB:BTIM): -- 41% Increase in Total Revenue -- Receives Payment of $247,000 under Joint Overseas Development Agreement BioTime, Inc. (OTCBB:BTIM) today announced financial results for the third quarter ended September 30, 2005. BioTime's total quarterly revenue increased 41% to $240,432 for the third quarter of 2005, from $170,381 for the same period last year. BioTime's third qu... 
Printer Friendly Version
October 27, 2005BioTime Commences Rights Offer
EMERYVILLE, Calif., Oct 27, 2005 (BUSINESS WIRE) -- BioTime, Inc. (OTCBB:BTIM) announced today that it commenced its rights offer under which it will distribute subscription rights ("Rights") to the holders of its common shares entitling each holder to subscribe for and purchase one "Unit" for every five Rights held. Each Unit will consist of one new common share and one warrant to purchase an additional common share. The subscription price for the Units is $0.50 per Unit. Each full warran... 
Printer Friendly Version
September 01, 2005BioTime Plans Rights Offering Backed by Standby Guaranty
EMERYVILLE, Calif., Sep 01, 2005 (BUSINESS WIRE) -- BioTime, Inc. (OTCBB:BTIM) announced today that it plans to distribute subscription rights ("Rights") to the holders of its common shares entitling each holder to subscribe for and purchase one "Unit" for every five Rights held. Each Unit will consist of one new common share and one warrant to purchase an additional common share. The subscription price for the Units is $0.50 per Unit. Each warrant will entitle the holder to purchase one c... 
Printer Friendly Version
August 16, 2005BioTime Announces Results for Second Quarter 2005
EMERYVILLE, Calif.--(BUSINESS WIRE)--Aug. 16, 2005--BioTime, Inc. (OTCBB:BTIM): -- 28% Increase in Total Revenue -- 71% Increase in Recognized License Revenue -- NIH Grant to Continue HetaCool(R) Development Awarded BioTime, Inc. (OTCBB:BTIM) today announced financial results for the second quarter ended June 30, 2005. BioTime's total quarterly revenue increased 28% to $249,274 for the second quarter of 2005, from $195,337 for the same period last ye... 
Printer Friendly Version
July 14, 2005BioTime Announces New Trading Symbols
EMERYVILLE, Calif.--(BUSINESS WIRE)--July 14, 2005--In BW5762 issued July 14, 2005: First graph, first sentence of the release should read: BioTime, Inc. (AMEX:BTX)(OTCBB:BTIM) today announced that after July 14, 2005 its common shares will be traded under the symbol BTIM and its publicly traded warrants will be traded under the symbol BTIMW. (sted BioTime, Inc. (AMEX:BTX)(OTCBB:BTIM) today announced that after June 14, 2005 its common shares will be traded under the symbol BTIM and its p... 
Printer Friendly Version
July 12, 2005BioTime Announces New Patent in China
EMERYVILLE, Calif.--(BUSINESS WIRE)--July 12, 2005--BioTime, Inc. (Amex: BTX) is pleased to announce the issuance of its second Chinese patent directed to BioTime's Hextend(R) and PentaLyte(R) solution technology. BioTime's second Chinese Patent No. ZL 00806029.0 issued on May 11, 2005 with broad claims covering the use of Hextend and PentaLyte in the treatment of hypovolemia. This new Chinese patent will be in force until January 24, 2020 and therefore provides important complementary pr... 
Printer Friendly Version
July 07, 2005BioTime Announces Delisting From AMEX; Common Stock and Warrants to Be Quoted on OTC Bulletin Board
EMERYVILLE, Calif.--(BUSINESS WIRE)--July 7, 2005--As previously reported, during April 2005 BioTime, Inc. (AMEX:BTX) received a notice from the staff of the American Stock Exchange indicating that BioTime did not meet certain of the Exchange's continued listing standards as set forth in Section 1003(a)(iii) of the AMEX Company Guide in that the Company has shareholders' equity of less than $6,000,000 and has incurred losses during the last five fiscal years. Accordingly, the staff of the... 
Printer Friendly Version
June 20, 2005BioTime Moves to New Headquarters
EMERYVILLE, Calif.--(BUSINESS WIRE)--June 20, 2005--BioTime, Inc. (Amex:BTX) has opened its new executive office and laboratory facility at the Heritage Square campus in Emeryville, California. BioTime will occupy 5,244 square feet of space in this multi-use complex under a five-year lease, with a five-year extension option. "After months of planning, we are very pleased to announce our move into this state-of-the-art facility," said Judith Segall, BioTime Vice President of Operatio... 
Printer Friendly Version
May 17, 2005BioTime Announces Results for First Quarter 2005
BERKELEY, Calif.--(BUSINESS WIRE)--May 17, 2005--BioTime, Inc. (Amex: BTX): -- 43% Increase in Royalty Revenue Recognized on Hextend Sales -- 74% Increase in Recognized License Revenue -- 46% Increase in Total Revenue BioTime, Inc. (Amex: BTX) today announced financial results for the first quarter ended March 31, 2005. BioTime's total quarterly revenue increased 46% to $191,083 for the first quarter of 2005, from $130,700 for the same period last ye... 
Printer Friendly Version
April 27, 2005BioTime Announces Appeal of AMEX Determination
BERKELEY, Calif.--(BUSINESS WIRE)--April 27, 2005--BioTime, Inc. (AMEX:BTX) announced that on April 21, 2005, it received notice from the staff of the American Stock Exchange indicating that BioTime does not meet certain of the Exchange's continued listing standards as set forth in Section 1003(a)(iii) of the AMEX Company Guide in that BioTime has shareholders' equity of less than $6,000,000 and has incurred losses during the last five fiscal years. Accordingly, the staff of the Exchange ... 
Printer Friendly Version
April 08, 2005BioTime Begins PentaLyte Phase II Clinical Trial
BERKELEY, Calif.--(BUSINESS WIRE)--April 8, 2005--BioTime, Inc. (AMEX:BTX) announced today that the first surgery has been completed in its Phase II clinical trial of PentaLyte(R) at Duke University. PentaLyte is BioTime's proprietary pentastarch-based synthetic plasma expander and is being tested in cardiac surgery in a prospective, randomized, double-blind controlled study. PentaLyte is similar to BioTime's Hextend(R) and is designed for use when shorter acting volume expansion is desir... 
Printer Friendly Version
April 01, 2005BioTime Announces Fourth Quarter and Fiscal Year-End Results
BERKELEY, Calif.--(BUSINESS WIRE)--April 1, 2005--BioTime, Inc. (Amex:BTX): -- 57% Increase in Royalty Revenue Recorded on Hextend Sales for the Year -- Total 2004 Revenues Increase 24% -- 48% Increase in Royalty Revenue Recorded on Hextend Sales for the Quarter -- Sales of Hextend Begin in South Korea BioTime, Inc. (Amex: BTX) today announced financial results for the fourth quarter and fiscal year ended December 31, 2004. BioTime ... 
Printer Friendly Version
November 16, 2004BioTime Announces Third Quarter Results
* Total Revenues Increase by 55% During the Third Quarter * 52% Increase in Royalty Revenue Recorded on Hextend Sales for the Third Quarter * Company Continues to Make Progress in Efforts for International Expansion of Hextend BERKELEY, Calif., Nov. 16 /PRNewswire-FirstCall/ -- BioTime, Inc. (Amex: BTX - ) today announced financial results for the third quarter ended September 30, 2004. Royalty revenues from Hextend® product sales by Hospira, Inc. increased 52% to $145,20... 
Printer Friendly Version
November 02, 2004Valeta A. Gregg, Ph.D., J.D. Joins BioTime, Inc. Board Of Directors
BERKELEY, Calif., Nov. 2 /PRNewswire-FirstCall/ -- BioTime, Inc. (Amex: BTX - ) announced today that Valeta A. Gregg, Ph.D., J.D., has been elected to BioTime's Board of Directors. Dr. Gregg currently serves as Vice President & Assistant General Counsel, Patents, for Regeneron Pharmaceuticals, Inc. and will be replacing Jeffrey B. Nickel, Ph.D. on BioTime's Board. Dr. Nickel stepped down in order to focus on his new duties as BioTime's Vice President of Business Development and Marketing.... 
Printer Friendly Version
August 13, 2004BioTime Announces Increased Revenues For Second Quarter 2004
BIOTIME ANNOUNCES INCREASED REVENUES FOR SECOND QUARTER 2004 Total Revenues More Than Double during Second Quarter 118% Increase in Royalty Revenue Recorded on Hextend Sales for Second Quarter Regulatory Approval of Hextend in South Korea Received in July BERKELEY, CA, August 13, 2004 BioTime, Inc. (AMEX: BTX) today announced financial results for the second quarter ended June 30, 2004. Royalty revenues from Hextend® product sales by Hospira, Inc. increased 118%... 
Printer Friendly Version
July 07, 2004BioTime Announces Regulatory Approval of Hextend(R) in South Korea; Receives Second License Fee From CJ Corp.
BIOTIME ANNOUNCES REGULATORY APPROVAL OF HEXTEND (R) IN sOUTH KOREA; RECEIVES SECOND LICENSE FEE FROM CJ CORP. BERKELEY, Calif., July 7 -- BioTime, Inc. (Amex: BTX) today announced that its South Korean licensing partner CJ Corp. has received regulatory approval from the Korea Food and Drug Administration (KFDA) for Hextend(R), the Company's physiologically balanced blood plasma volume expander. BioTime also announced that it has received the second of two license fee ... 
Printer Friendly Version
June 23, 2004BioTime Mourns Passing of Founder
BIOTIME CREATES OFFICE OF THE PRESIDENT BERKELEY, Calif.--June 26, 2003--BioTime, Inc. (AMEX:BTX) announced the formation of an interim Office of the President to perform the duties of the Chief Executive Officer of the Company until such time as a new CEO is appointed. Dr. Paul Segall, BioTime's Chairman and Chief Executive Officer, passed away suddenly on June 23, 2003. The Office of the President will be comprised of three of BioTime's founding executive officers,... 
Printer Friendly Version
June 01, 2004BioTime Appoints Jeffrey Nickel, Ph.D. Vice President of Business Development and Marketing
BIOTIME APPOINTS JEFFREY NICKEL, PH.D. VICE PRESIDENT OF BUSINESS DEVELOPMENT AND MARKETING BERKELEY, Calif.--June 1, 2004--BioTime, Inc. (AMEX:BTX) announced the appointment of Jeffrey B. Nickel, Ph.D. to the position of Vice President of Business Development and Marketing, effective today. Dr. Nickel has served on the Board of Directors since 1997. His more than three decades of service to the chemical, pharmaceutical, and biotechnology industries has resulted in the success... 
Printer Friendly Version
May 13, 2004BioTime Announces Strong Royalty Revenue Increase for First Quarter 2004
BIOTIME ANNOUNCES STRONG ROYALTY REVENUE INCREASES FOR FIRST QUARTER 2004 BERKELEY, Calif.--May 13, 2004--BioTime, Inc. (AMEX:BTX): -- 20% Increase in Royalty Revenue Recognized on Hextend(R) Sales for First Quarter -- 35% Increase in Total Revenue for First Quarter -- 118% Increase in Hextend Royalties on Hextend Sales during First Quarter -- Abbott Laboratories Assigns Hextend License to Hospital Products Spin... 
Printer Friendly Version
April 21, 2004BioTime Awarded NIH Grant to Aid HetaCool Development
BIOTIME AWARDED NIH GRANT TO AID HETACOOL DEVELOPMENT BERKELEY, CA, April 21, 2004 -- BioTime, Inc. (AMEX:BTX) announced that it has been awarded a research grant by the National Heart, Lung, and Blood Institute division of the National Institutes of Health (NIH) for use in the development of its HetaCool® blood plasma volume expander following peer review. The grant will be used to fund a project entitled “Resuscitating Blood-Substituted Hypothermic Dogs” at the Texas Heart Insti... 
Printer Friendly Version
February 11, 2004BioTime Announces Repayment Of Debentures; Eliminates All Long-Term Debt
B>BIOTIME ANNOUNCES REPAYMENT OF DEBENTURES; ELIMINATES ALL LONG-TERM DEBT BERKELEY, CA, February 11, 2004 -- BioTime, Inc. (AMEX:BTX) announced that it is issuing a total of 1,071,427 units, consisting of 1,071,427 common shares and 535,712 warrants, in exchange for $1,500,000 of its Series 2001-A Debentures, and that it has paid off the remaining $1,850,000 of debentures using a portion of the proceeds from its recently completed subscription rights offer. After repayment of th... 
Printer Friendly Version
January 22, 2004BioTime Completes Rights Offer, Announces That Rights Offer Was Heavily Oversubscribed
BIOTIME COMPLETES RIGHTS OFFER ANNOUNCES THAT RIGHTS OFFER WAS HEAVILY OVERSUBSCRIBED BERKELEY, Calif.--Jan. 22, 2004--BioTime, Inc. (AMEX:BTX) announced the successful completion of its subscription rights offer which expired at 5:00 p.m. New York time on January 21, 2004. The deadline for submitting subscription certificates and subscription funds under notices for guaranteed delivery is January 26, 2004 at 5:00 p.m. New York time. BioTime will receive $3,584,424 through the r... 
Printer Friendly Version
January 13, 2004BioTime Rights Offer Extended to January 21, 2004
BIOTIME RIGHTS OFFER EXTENDED TO JANUARY 21, 2004 BERKELEY, Calif.--Jan. 13, 2004--BioTime, Inc. (AMEX:BTX) announced that it has extended the expiration of its subscription rights offer from January 15, 2004 to 5:00 p.m. New York City time on January 21, 2004. BioTime does not expect that the rights offer will be further extended. Properly completed and executed subscription certificates accompanied by the subscription price or a properly completed notice of guaranteed delivery must... 
Printer Friendly Version
January 06, 2004BioTime Further Extends Expiration Date of Subscription Rights Offer
BIOTIME FURTHER EXTENDS EXPIRATION DATE OF SUBSCRIPTION RIGHTS OFFER BERKELEY, Calif.--Jan. 6, 2004--BioTime, Inc. (AMEX:BTX) announced that it has extended the expiration of its subscription rights offer from January 8, 2004 to 5:00 p.m. New York City time on January 15, 2004. Properly completed and executed subscription certificates accompanied by the subscription price or a properly completed notice of guaranteed delivery must be received by the subscription agent, American Stock T... 
Printer Friendly Version
December 29, 2003BioTime Extends Expiration Date of Subscription Rights Offer
BIOTIME EXTENDS EXPIRATION DATE OF SUBSCRIPTION RIGHTS OFFER BERKELEY, Calif.--Dec. 29, 2003--BioTime, Inc. (AMEX:BTX) announced that it has extended the expiration of its subscription rights offer from December 31, 2003 to 5:00 p.m. New York City time on January 8, 2004. Properly completed and executed subscription certificates accompanied by the subscription price or a properly completed notice of guaranteed delivery must be received by the subscription agent, American Stock Transfer &... 
Printer Friendly Version
December 11, 2003BioTime Commences Rights Offer
BIOTIME COMMENCES RIGHTS OFFER BERKELEY, Calif.--Dec. 11, 2003--BioTime, Inc. (AMEX:BTX) announced today that it commenced its rights offer under which it will distribute subscription rights ("Rights") to the holders of its common shares entitling each holder to subscribe for and purchase one "Unit" for every eight Rights held. Each Unit will consist of one new common share and one-half of a warrant to purchase an additional common share. The subscription price for the Units is $1.40 ... 
Printer Friendly Version
October 02, 2003BioTime Plans Rights Offering Backed by Standby Guaranty
BIOTIME PLANS RIGHTS OFFERING BACKED BY STANDBY GUARANTY BERKELEY, Calif.--Oct. 2, 2003--BioTime, Inc. (AMEX:BTX) announced today that it plans to distribute subscription rights ("Rights") to the holders of its common shares entitling each holder to subscribe for and purchase one "Unit" for every eight Rights held. Each Unit will consist of one new common share and one-half of a warrant to purchase an additional common share. The subscription price for the Units is $1.40 per Unit. ... 
Printer Friendly Version
June 04, 2003BioTime Meets With Its Industry Partners in Asia
BIOTIME MEETS WITH ITS INDUSTRY PARTNERS IN ASIA BERKELEY, CA, June 4, 2003 – BioTime, Inc. (AMEX:BTX) announced today that CJ Corp, Global Damon Pharma and BioTime held a ceremony at the CJ Corp headquarters in Seoul, in celebration of the signing of BioTime's agreement with CJ to license Hextend® and PentaLyte® in Korea. Dr. D. K. Kim, of Global Damon Pharma, was the consultant in the agreement. Following the ceremony, the companies met to discuss issues relating to th... 
Printer Friendly Version
April 14, 2003CJ Corp. and BioTime Sign a License Agreement for Korea
CJ CORP. AND BIOTIME SIGN A LICENSE AGREEMENT FOR KOREA SEOUL, KOREA AND BERKELEY, CA, April 14, 2003 – CJ Corp. and BioTime, Inc. (AMEX:BTX) announced today that they have entered into an Exclusive License Agreement under which BioTime granted to CJ an exclusive license to manufacture and sell BioTime's proprietary blood plasma volume expanders, Hextend® and PentaLyte® in the Republic of Korea for human therapeutic uses. Hextend is BioTime's proprietary physiologically balan... 
Printer Friendly Version
December 31, 2002Asia-Based Multinationals to Help with BioTime's Overseas Expansion
ASIA-BASED MULTINATIONALS TO HELP WITH BIOTIME'S OVERSEAS EXPANSION BERKELEY, Calif.--Dec. 31, 2002--BioTime, Inc. (AMEX:BTX - News) announced today that the company is preparing for Hextend®'s product launch in Canada in early 2003 and continuing to work to expand its markets internationally. The growing acceptance of Hextend as the plasma volume expander of choice in United States hospitals, and by our military, has enabled BioTime to attract the services of the Summit Pharmaceutic... 
Printer Friendly Version
October 01, 2002Dr. Michael D. West Nominated to Join BioTime's Board of Directors
BERKELEY, Calif., Oct. 1 /PRNewswire-FirstCall/ -- BioTime, Inc. (Amex: BTX) announced today that Dr. Michael D. West has accepted the nomination to become a member of the BioTime Board of Directors. Dr. West is the President and Chief Executive Officer of Advanced Cell Technology, Inc. of Worcester, Massachusetts, a company focused on the medical applications of nuclear transfer (cloning) and embryonic stem cell technologies. Dr. West founded Geron Corporation in 1990 where he serve... 
Printer Friendly Version
August 13, 2002BioTime Raises Over $2 Million in a Private Placement as Quarterly Revenues Grow
BERKELEY, Calif.--Aug. 13, 2002--BioTime, Inc. (AMEX:BTX) announced today that it has raised $2,075,119 in a private placement of 1,852,785 common shares through Ladenburg Thalmann & Co. Inc. Ladenburg Thalmann, established in 1876, is one of the oldest members of the New York Stock Exchange. BioTime also announced rising royalty revenues. For the three months ended June 30, 2002, BioTime recognized $60,812 in royalty revenues, a 103% increase from the same period last year... 
Printer Friendly Version
July 09, 2002Hextend Approved for Sale in Canada
HEXTEND APPROVED FOR SALE IN CANADA BERKELEY, Calif.--July 9, 2002--BioTime, Inc. (AMEX:BTX) announced today that Hextend(R) has been approved for sale in Canada. Hextend is BioTime's proprietary hetastarch-based plasma volume expander with lactate, multiple electrolytes, and physiological amounts of glucose. Hextend will be marketed in Canada by Abbott Laboratories, Limited, Canada, an affiliate of Abbott International. Dr. Paul Segall, BioTime's chairman and chief executive offi... 
Printer Friendly Version